lly fasb org gaap restructuringsettlementandimpairmentprovisionshttp fasb org gaap fasb org gaap gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummemberus gaap customerconcentrationriskmemberus gaap salesrevenuenetmemberlly minimummemberus gaap customerconcentrationriskmemberus gaap salesrevenuenetmemberlly minimummemberus gaap customerconcentrationriskmemberus gaap salesrevenuenetmemberlly gaap customerconcentrationriskmemberus gaap salesrevenuenetmemberlly threelargestwholesalesmembersrt gaap customerconcentrationriskmemberus gaap salesrevenuenetmemberlly threelargestwholesalesmembersrt gaap customerconcentrationriskmemberus gaap salesrevenuenetmemberlly threelargestwholesalesmembersrt gaap accountsreceivablemembersrt minimummemberus gaap customerconcentrationriskmemberlly gaap accountsreceivablemembersrt minimummemberus gaap customerconcentrationriskmemberlly gaap accountsreceivablememberus gaap customerconcentrationriskmemberlly threelargestwholesalesmembersrt gaap accountsreceivablememberus gaap customerconcentrationriskmemberlly threelargestwholesalesmembersrt gaap salesreturnsandallowancesmembercountry gaap salesreturnsandallowancesmembercountry gaap salesreturnsandallowancesmembercountry uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly jardiancemembercountry jardiancemembercountry jardiancemembercountry jardiancememberus gaap jardiancememberus gaap jardiancememberus gaap humalogmembercountry humalogmembercountry humalogmembercountry gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly otherdiabetesmembercountry otherdiabetesmembercountry otherdiabetesmembercountry otherdiabetesmemberus gaap otherdiabetesmemberus gaap otherdiabetesmemberus gaap uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly alimtamembercountry alimtamembercountry alimtamembercountry alimtamemberus gaap alimtamemberus gaap alimtamemberus gaap erbituxmembercountry erbituxmembercountry erbituxmembercountry gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly tyvytmembercountry tyvytmembercountry tyvytmembercountry tyvytmemberus gaap tyvytmemberus gaap tyvytmemberus gaap uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly oncologymembercountry oncologymembercountry oncologymembercountry oncologymemberus gaap oncologymemberus gaap oncologymemberus gaap taltzmembercountry taltzmembercountry taltzmembercountry gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly otherimmunologymembercountry otherimmunologymembercountry otherimmunologymembercountry otherimmunologymemberus gaap otherimmunologymemberus gaap otherimmunologymemberus gaap immunologymembercountry immunologymembercountry immunologymembercountry gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly zyprexamembercountry zyprexamembercountry zyprexamembercountry zyprexamemberus gaap zyprexamemberus gaap zyprexamemberus gaap uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly uslly uslly uslly gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly neurosciencemembercountry neurosciencemembercountry neurosciencemembercountry neurosciencememberus gaap neurosciencememberus gaap neurosciencememberus gaap gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly forteomembercountry forteomembercountry forteomembercountry gaap nonusmemberlly gaap nonusmemberlly gaap nonusmemberlly cialismembercountry cialismembercountry cialismembercountry cialismemberus gaap cialismemberus gaap cialismemberus gaap otherproductmembercountry otherproductmembercountry otherproductmembercountry otherproductmemberus gaap otherproductmemberus gaap otherproductmemberus gaap otherproducttotalmembercountry otherproducttotalmembercountry otherproducttotalmembercountry otherproducttotalmemberus gaap otherproducttotalmemberus gaap otherproducttotalmemberus gaap gaap gaap gaap dermirainc dermirainc milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativememberlly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativememberlly trajentabimemberlly trajentabimemberlly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativememberlly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativememberlly gaap royaltyagreementtermsmemberlly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativememberlly milestonepaymentsdevelopmentandregulatorycapitalizeddeferredcumulativememberlly olumiantmemberlly rochememberlly lebrikizumabmemberlly rochememberlly milestonepaymentssalesbasedmemberlly lebrikizumabmemberlly milestonepaymentssalesbasedmemberlly gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap assetbackedsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap assetbackedsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap otherdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap otherdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberlly gaap portionatotherthanfairvaluefairvaluedisclosurememberlly gaap estimateoffairvaluefairvaluedisclosurememberlly otherequitysecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly otherequitysecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly otherequitysecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly gaap carryingreportedamountfairvaluedisclosurememberlly gaap portionatotherthanfairvaluefairvaluedisclosurememberlly gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly gaap carryingreportedamountfairvaluedisclosurememberlly gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap corporatedebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap assetbackedsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap assetbackedsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap portionatotherthanfairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap otherdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap otherdebtsecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberlly gaap portionatotherthanfairvaluefairvaluedisclosurememberlly gaap estimateoffairvaluefairvaluedisclosurememberlly otherequitysecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly otherequitysecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly otherequitysecuritiesmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly gaap carryingreportedamountfairvaluedisclosurememberlly gaap portionatotherthanfairvaluefairvaluedisclosurememberlly gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberlly gaap carryingreportedamountfairvaluedisclosurememberlly gaap commercialpapermemberus gaap gaap commercialpapermemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap commercialpapermemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap commercialpapermemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap commercialpapermemberus gaap gaap commercialpapermemberus gaap gaap commercialpapermemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap commercialpapermemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap commercialpapermemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap commercialpapermemberus gaap swapswissfrancstou gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberlly gaap designatedashedginginstrumentmemberlly gaap designatedashedginginstrumentmemberlly gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap interestratecontractmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap foreignexchangecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap foreignexchangecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap nondesignatedmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap interestratecontractmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap designatedashedginginstrumentmemberus gaap crosscurrencyinterestratecontractmemberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap nondesignatedmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap nondesignatedmemberus gaap gaap gaap gaap gaap gaap gaap minimummemberus gaap gaap buildingmembersrt minimummemberus gaap maximummemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap seniornotesmemberlly gaap seniornotesmemberlly gaap gaap gaap gaap gaap seniornotesmemberlly gaap seniornotesmemberlly gaap gaap gaap seniornotesmemberlly gaap seniornotesmemberlly gaap seniornotesmemberlly gaap seniornotesmemberlly gaap gaap gaap gaap gaap gaap gaap gaap gaap seniornotesmemberlly gaap seniornotesmemberlly gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly foreigncurrencydenominateddebtmemberlly gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap designatedunusablememberus gaap designatedunusablememberus gaap designatedunusablememberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap fixedincomefundsmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap pensionplansdefinedbenefitmemberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap fixedincomefundsmemberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap othercontractmemberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap fixedincomefundsmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomefundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap pensionplansdefinedbenefitmemberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanrealestatememberus gaap gaap pensionplansdefinedbenefitmemberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap fixedincomefundsmemberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap fixedincomefundsmemberus gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap othercontractmemberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap definedbenefitplanrealestatememberus gaap gaap definedbenefitpostretirementhealthcoveragememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap fairvaluemeasuredatnetassetvaluepersharememberlly gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap gaap definedbenefitpostretirementhealthcoveragememberus gaap productliabilitymemberlly productliabilitymemberlly gaap employeelitigationmembercountry employeelitigationmembercountry employeelitigationmembercountry employeelitigationmembercountry gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap accumulateddefinedbenefitplansadjustmentnetpriorserviceincludingportionattributabletononcontrollinginterestmemberus gaap gaap accumulateddefinedbenefitplansadjustmentnetpriorserviceincludingportionattributabletononcontrollinginterestmemberus gaap gaap accumulateddefinedbenefitplansadjustmentnetpriorserviceincludingportionattributabletononcontrollinginterestmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberlly gaap reclassificationoutofaccumulatedothercomprehensiveincomememberlly gaap reclassificationoutofaccumulatedothercomprehensiveincomememberlly gaap gaap gaap statessecurities exchange commissionwashington annual report pursuant section security exchange act of the fiscal year ended december file number lilly and company exact name of registrant specified charter indiana state or jurisdiction of employerincorporation or organization identification lilly corporate center indianapolis indiana address and zip code of principal executive office registrant telephone number including area code security registered pursuant to section of the exchange act title of classtrading symbol name of each exchange registeredcommon stock no par value llynew york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock exchangesecurities registered pursuant to section of the exchange act noneindicate check mark the registrant well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is required to file report pursuant to section or of the exchange act yes no indicate by check mark whether the registrant filed report required to filed by section or of the exchange act the preceding month or shorter period the registrant required to file such report and ha subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report if security registered pursuant to section of the act indicate by check mark whether the financial statement of the registrant included in the filing reflect the correction of an error to previously issued financial statement indicate by check mark whether any of error correction are restatement that required recovery analysis of incentive based compensation received by any of the registrant executive officer during the relevant recovery period pursuant to indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no aggregate market value of the common equity held by non affiliate computed by reference to the price which the common equity wa last sold of the last business day of the registrant recently completed second fiscal quarter approximately number of share of common stock outstanding of february of the registrant proxy statement for the annual meeting of shareholder been incorporated by reference part iii of this report eli lilly and companyform kfor the year ended december table of contentspagepart iitem risk unresolved staff legal mine safety iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity reserved management discussion and analysis of result of operation and financial quantitative and qualitative disclosure market financial statement and supplementary change in and disagreement with accountant on accounting and financial control and other disclosure regarding foreign jurisdiction that prevent iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and related stockholder certain relationship and related transaction and director principal accountant fee and exhibit and financial statement form looking statementsthis annual report on form and other publicly available document include forward looking statement within the meaning of section of the security act of and section of the security exchange act of exchange act and are subject to the safe harbor created thereby under the private security litigation reform act of in particular information appearing under business risk factor and management discussion and analysis of result of operation and financial condition includes forward looking statement forward looking statement include all statement that not relate solely to historical or current fact and generally be identified by the use of word such may believe expect project estimate intend anticipate plan continue or similar expression or future or conditional verb forward looking statement inherently involve many risk and uncertainty that could cause actual result to differ materially those expressed in forward looking statement in any forward looking statement express an expectation or belief to future result or event is based on management current plan and expectation expressed in good faith and believed to have reasonable basis however we can give no assurance that any such expectation or belief will result or will be achieved or accomplished investor therefore not place undue reliance on forward looking statement the following include not all of the factor that could cause actual result or event to differ materially from those anticipated the significant cost and uncertainty in the pharmaceutical research and development process including with respect to the timing and process of obtaining regulatory approval the impact and outcome of acquisition and business development transaction and related integration cost the expiration of intellectual property protection for certain of our product and competition from generic and or biosimilar product our ability to protect and enforce patent and other intellectual property change in patent law or regulation related to data package exclusivity competitive development affecting current product and our pipeline market uptake of recently launched product information technology system inadequacy breach or operating failure unauthorized access disclosure misappropriation or compromise of confidential information or other data stored in our information technology system network and facility or those of third party with we share our data the impact of global macroeconomic condition trade disruption dispute unrest war regional dependency or other cost uncertainty and risk related to engaging in business globally unexpected safety or efficacy concern associated with our product litigation investigation or other similar proceeding involving past current or future product or commercial activity we are largely self insured issue with product supply and regulatory approval stemming from manufacturing difficulty disruption or shortage including result of unpredictability and variability in demand labor shortage third party performance quality or regulatory action related to our facility dependence on certain product for significant percentage of our total revenue and an increasingly consolidated supply chain reliance on third party relationship and outsourcing arrangement the impact of public health outbreak epidemic or pandemic such the covid pandemic regulatory change or other development regulatory action regarding operation and product continued pricing pressure and the impact of action of governmental and private payer affecting pricing of reimbursement for and access to pharmaceutical devaluation in foreign currency exchange rate or change in interest rate and inflation change in tax law tax rate or event that differ from our assumption related to tax position asset impairment and restructuring charge change in accounting and reporting standard promulgated by the financial accounting standard board and the security and exchange commission sec regulatory compliance problem or government investigation and actual or perceived deviation from environmental social or governance related requirement or expectation investor should also carefully read the factor described under item risk factor in this annual report on form for description of certain risk that could among other thing cause our actual result to differ from those expressed in forward looking statement investor should understand that it is not possible to predict or identify all such factor and should not consider the risk described and under item risk factor to be complete statement of all potential risk and uncertainty all forward looking statement speak of the date of this annual report and are expressly qualified in entirety by the risk factor and cautionary statement included in this annual report except is required by law we expressly disclaim any obligation to publicly release any revision to forward looking statement to reflect event the date of this annual report iitem businesseli lilly and company referred to the company lilly we or wa incorporated in in indiana to succeed to the drug manufacturing business founded in indianapolis indiana in by colonel eli lilly we discover develop manufacture and market product in single business segment human pharmaceutical product our purpose is to unite caring with discovery to create medicine that make life better for people around the world most of the product that we sell today discovered or developed by our scientist and our long term success depends on our ability to continually discover or acquire develop and commercialize innovative medicine we manufacture and distribute our product facility in the united state including puerto rico and other country our product are sold in approximately country productsour product include diabetes product including basaglar in collaboration with boehringer ingelheim long acting human insulin analog for the treatment of diabetes humalog humalog mix humalog humalog humalog mix insulin lispro insulin lispro protamine and insulin lispro mix human insulin analog for the treatment of diabetes humulin humulin humulin humulin and humulin human insulin of recombinant dna origin for the treatment of diabetes jardiance in collaboration with boehringer ingelheim for the treatment of type diabetes to reduce the risk of cardiovascular death in adult patient with type diabetes and established cardiovascular disease and to reduce the risk of cardiovascular death and hospitalization for heart failure in adult mounjaro glucose dependent insulinotropic polypeptide and glucagon like peptide receptor agonist for the treatment of adult with type diabetes in combination with diet and exercise to improve glycemic control trulicity for the treatment of type diabetes in adult and pediatric patient year of age and older and to reduce the risk of major adverse cardiovascular event in adult patient with type diabetes and established cardiovascular disease or multiple cardiovascular risk factor oncology product including alimta for the first line treatment in combination with two other agent of advanced non small cell lung cancer nsclc for patient with non squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberration for the first line treatment in combination with another agent of advanced non squamous nsclc for the second line treatment of advanced non squamous nsclc monotherapy for the maintenance treatment of advanced non squamous nsclc in patient whose disease ha not progressed immediately following chemotherapy treatment and in combination with another agent for the treatment of malignant pleural mesothelioma cyramza for use monotherapy or in combination with another agent second line treatment of advanced or metastatic gastric cancer or gastro esophageal junction adenocarcinoma in combination with another agent second line treatment of metastatic nsclc in combination with another agent second line treatment of metastatic colorectal cancer monotherapy second line treatment of hepatocellular carcinoma and in combination with another agent first line treatment of adult patient with metastatic nsclc with activating epidermal growth factor receptor mutation erbitux indicated monotherapy and in combination with another agent for the treatment of certain type of colorectal cancer and monotherapy in combination with chemotherapy or in combination with radiation therapy for the treatment of certain type of head and neck cancer jaypircatm for the treatment of adult patient with relapsed or refractory mantle cell lymphoma mcl after at least two line of systemic therapy including btk inhibitor retevmo for the treatment of metastatic nsclc with rearranged during transfection ret gene fusion in adult patient for the treatment of advanced metastatic medullary thyroid cancer with ret mutation require systemic therapy in adult and pediatric patient for the treatment of advanced or metastatic thyroid cancer with ret gene fusion in adult and pediatric patient who require systemic therapy and are radioactive iodine refractory and for the treatment of adult patient with locally advanced or metastatic solid tumor with ret gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment option tyvyt in collaboration with innovent biologics inc for the treatment of relapsed or refractory classic hodgkin lymphoma for the first line treatment of non squamous nsclc in combination with alimta and another agent for the first line treatment of squamous nsclc in combination with two other agent for the first line treatment of hepatocellular carcinoma in combination with another agent for the first line treatment of esophageal squamous cell carcinoma in combination with certain other agent and for the first line treatment of gastric cancer in combination with two other agent each in china verzenio for use monotherapy or in combination with endocrine therapy for the treatment of hr metastatic breast cancer and in combination with endocrine therapy for treatment of hr node positive early breast cancer at high risk of recurrence and ki score at least percent determined by food and drug administration fda approved test immunology product including olumiant in collaboration with incyte corporation for the treatment of adult with moderately to severely active rheumatoid arthritis moderate to severe atopic dermatitis and severe alopecia areata and for the treatment of hospitalized adult with covid who require supplemental oxygen mechanical ventilation or extracorporeal membrane oxygenation taltz for the treatment of adult and pediatric patient aged year or older with moderate to severe plaque psoriasis adult with active psoriatic arthritis adult with ankylosing spondylitis and adult with active non radiographic axial spondyloarthritis neuroscience product including cymbalta for the treatment of major depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder fibromyalgia and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis emgality for migraine prevention and the treatment of episodic cluster headache in adult zyprexa for the treatment of schizophrenia acute mixed or manic episode associated with bipolar disorder and bipolar maintenance other product and therapy including bamlanivimab and etesevimab administered together for the treatment of mild to moderate covid in adult and pediatric patient from birth to year old with positive result of direct sars cov viral testing and who are at high risk for progression to severe covid including hospitalization or death emergency use authorization eua granted in in may the fda announced that bamlanivimab and etesevimab are not currently authorized for emergency use for any region bebtelovimab for the treatment of mild to moderate covid in adult and pediatric patient year of age and older and weighing at least kilogram with positive result of direct sars cov viral testing and who are at high risk for progression to severe covid including hospitalization or death and for whom alternative covid treatment option approved or authorized by the fda are not accessible or clinically appropriate eua granted in in november the fda announced that bebtelovimab is not currently authorized for emergency use for any region cialis for the treatment of erectile dysfunction and benign prostatic hyperplasia forteo for the treatment of osteoporosis in postmenopausal woman and men at high risk for fracture and for glucocorticoid induced osteoporosis in men and postmenopausal woman and distributionwe sell most of our product worldwide we adapt our marketing method and product emphasis in various country to meet local customer need and comply with local regulation we promote our major product in the through sale representative who engage with physician and other healthcare professional we also educate healthcare provider about our product in various other way including promoting in online channel distributing literature and sample of certain product to physician and exhibiting at medical meeting in addition we advertise certain product directly to consumer in the and we maintain website and other medium channel with information about our major product we supplement our employee sale force with contract sale organization to leverage our resource and reach additional patient in need we maintain special business group to service wholesaler pharmacy benefit manager managed care organization group purchasing organization government and long term care institution hospital and certain retail pharmacy we enter into arrangement with organization providing for discount or rebate on our product in the most of our product are distributed through wholesaler that serve pharmacy physician and other healthcare professional and hospital in and three wholesale distributor in the mckesson corporation amerisourcebergen corporation and cardinal health inc each accounted for significant percentage of our consolidated revenue no other customer accounted for percent of our consolidated revenue in any of these year for additional information see item financial statement and supplementary data note revenue outside the the product we market and distribution of our product vary from country to country outside the we promote our product to healthcare provider through sale representative and other channel in most country in which we operate we maintain our own sale organization but in some country we market our product through third party some of which we have engaged through distribution and promotion arrangement marketing collaborationscertain of our product are marketed in arrangement with other pharmaceutical company for example we and boehringer ingelheim have global agreement to develop and commercialize portfolio of diabetes product including trajenta jentadueto jardiance glyxambi synjardy trijardy xr and basaglar for additional information see item financial statement and supplementary data note collaboration and other arrangement competitionour product compete globally with many other pharmaceutical product in highly competitive market important competitive factor include effectiveness safety and ease of use formulary placement price payer coverage and reimbursement rate and demonstrated cost effectiveness regulatory approval marketing effectiveness and research and development of new product process modality and us most new product or us that we introduce must compete with other branded biosimilar or generic product already on the market or that are later developed by competitor competitor introduce new product us or delivery system with therapeutic or cost advantage including by developing new modality our product become subject to decreased sale volume progressive price reduction or both we believe our long term competitive success depends on discovering and developing either alone or in collaboration with others or acquiring innovative cost effective product that provide improved outcome for patient and deliver value to payer and continuously improving the productivity of our operation in highly competitive environment can be no assurance that our effort will result in commercially successful product and it is possible that our product will be or will become uncompetitive from time to time result of product or us developed by our competitor pharmaceuticalsone of the biggest competitive challenge we face is from generic pharmaceutical in the europe japan and other jurisdiction the regulatory approval process for pharmaceutical other than biological product biologics exempts generic from costly and time consuming clinical trial to demonstrate their safety and efficacy allowing generic manufacturer to rely on the safety and efficacy of the innovator product result generic manufacturer generally invest far fewer resource than we do for our branded product in research and development and can price their product significantly lower than our branded product accordingly when branded non biologic pharmaceutical loses it market exclusivity it normally face intense price competition from generic form of the product which can result in the loss of significant portion of the product revenue in short period of time moreover government in some country leverage generic entrant to drive price concession through the utilization of volume based procurement bidding and other measure public and private payer typically encourage the use of generic alternative to brand name drug in their healthcare program law in the generally allow and in many case require pharmacist to substitute generic drug that have been rated under government procedure to be essentially equivalent to brand name drug where substitution is mandatory it must be made unless the prescribing physician expressly forbids it in certain country outside the intellectual property protection is weak and we must compete with generic or counterfeit version of our product relatively shortly after launch biosimilarsa number of our product and potential new medicine in our clinical stage pipeline are biologics in the the fda regulates biologics under the federal food drug and cosmetic act the public health service act and implementing regulation competition for lilly biologics may be affected by the approval of follow on biologics also known biosimilars biosimilar is subsequent version of an approved innovator biologic that due to it analytical and clinical similarity to the innovator biologic may be approved based on an abbreviated data package that relies in part on the full testing required of the innovator biologic approval by the fda ultimately depends on many factor including showing that the biosimilar is highly similar to the original product and ha no clinically meaningful difference from the original product in term of safety purity and potency globally most government have developed abbreviated regulatory pathway to approve biosimilars follow ons to innovator developed biologics including the biologics price competition and innovation act of the bpcia in the number of biosimilars have been licensed under the bpcia well in europe and japan the patent and regulatory exclusivity for the existing innovator biologic generally must expire in given market biosimilars may enter that market in addition the extent to which biosimilar approved will be substituted for the innovator biologic in way that is similar to traditional generic substitution for non biologic product is not yet entirely clear and will depend on number of regulatory and marketplace factor that are still developing in the currently only biosimilar product that is determined to be interchangeable by the fda will be considered substitutable for the original biologic product without the intervention of the healthcare provider who prescribed the original biologic product the fda requirement for interchangeability are evolving but the fda ha issued several interchangeable designation for biosimilar product including for competitive insulin product and is expected to continue in the future regulatory interpretation of important aspect of the law regulating biosimilars continues to evolve and therefore the impact of these law on our business remains subject to substantial uncertainty biosimilars may present both competitive challenge and opportunity competitor have developed biosimilars that compete with our product we have developed and may continue to develop our own biosimilars private sector dynamicsin the private sector consolidation and integration among healthcare organization significantly affect the competitive marketplace for pharmaceutical health plan managed care organization pharmacy benefit manager wholesaler and other supply chain stakeholder have been consolidating into fewer larger entity thus enhancing their market power and importance private third party insurer well government typically maintain formulary that specify coverage the condition under which drug are included on plan formulary and reimbursement the associated of pocket cost to the consumer to control cost by negotiating discount or rebate in exchange for formulary inclusion and placement placement can lead to reduced usage of drug for the relevant patient population due to coverage restriction such prior authorization and formulary exclusion or due to reimbursement limitation that result in higher consumer out of pocket cost such non preferred co pay tier increased co insurance level and higher deductible consequently pharmaceutical company face increased pressure in negotiation and compete fiercely for formulary placement not only on the basis of product attribute such efficacy safety profile or patient ease of use but also by providing rebate or other concession payer and pharmaceutical company continue to negotiate formulary placement and rebate value based agreement where rebate may be based on achievement or not of specified outcome are another tool that ha become increasingly prevalent cost is an increasingly important factor in formulary decision particularly in treatment area in which the payer ha taken the position that multiple branded product are therapeutically comparable these pressure have negatively affected and could continue to negatively affect our consolidated result of operation in addition to formulary placement change in insurance design continue to drive greater consumer cost sharing through high deductible plan and higher co insurance or co pay for additional information on pricing and reimbursement for our pharmaceutical product see regulation and private payer action affecting pharmaceutical pricing reimbursement and access patent trademark and other intellectual property rightsoverviewintellectual property protection is critical to our ability to successfully commercialize our life science innovation and invest in the search for new medicine and us we own have applied for or are licensed under large number of patent in the and many other country relating to product product us formulation and manufacturing process in addition discussed for some product we have effective intellectual property protection in the form of data protection under pharmaceutical regulatory law the patent protection anticipated to be of most relevance to pharmaceutical is provided by national patent claiming the active ingredient the compound patent for our product particularly those in major market such the major european country and japan these patent may be issued based upon the filing of international patent application usually filed under the patent cooperation treaty pct patent application covering compound are generally filed during the discovery phase of the drug discovery process which is described in the research and development section below in general national patent in each relevant country are available for period of year from the filing date of the pct application which is often year prior to the launch of commercial product further patent term adjustment and restoration may extend the original patent term patent term adjustment is statutory right available to all patent applicant to provide relief in the event that patent grant is delayed during examination by the patent and trademark office uspto patent term restoration is statutory right provided to patent holder that claim invention subject to review by the fda to compensate for portion of the time invested in clinical trial and the fda review process single patent for pharmaceutical product may be eligible for patent term restoration patent term restoration is determined by formula that can not be calculated product approval due to the uncertainty of the duration of clinical trial and the time it take the fda to review an application there is five year cap on any restoration and no patent expiration date may be extended beyond year from fda approval some country outside the similarly offer form of patent term restoration for patent claiming invention subject to local review by regulatory agency for example supplementary protection certificate are available to extend the life of european patent to an additional five year subject to year cap from european medicine agency ema approval also in japan south korea australia and other jurisdiction patent term can be extended up to five year depending on the length of regulatory review and other factor of effective patent protection for pharmaceutical especially for non biologic product typically result in the loss of effective market exclusivity for the product often leading to severe and rapid decline in revenue for the product however in some case the innovator company may retain exclusivity despite approval of the generic biosimilar or other follow on version of new medicine beyond the expiration of the compound patent through manufacturing trade secret later expiring patent on manufacturing process method of use or formulation or data protection that may be available under pharmaceutical regulatory law change to the law and regulation governing these protection could result in earlier loss of effective market exclusivity the primary form of data protection are follows regulatory authority in major market generally grant data package protection for period of year following new drug approval in recognition of the substantial investment required to complete clinical trial data package protection prohibits other manufacturer from submitting regulatory application for marketing approval in reliance on the innovator company regulatory submission data for the drug the base period of data package protection depends on the country for example the period is generally five year in the year for new biologics described below effectively year in europe and eight year in japan the period begin on the date of product approval and run concurrently with the patent term for any relevant patent under the bpcia the fda ha the authority to approve biosimilars competitor seeking approval of biosimilar must file an application to show it molecule is highly similar to an approved innovator biologic and include certain amount of safety and efficacy data that the fda will consider on case by case basis under the data protection provision of this law the fda can not approve biosimilar application until year after initial marketing approval of the innovator biologic subject to certain condition in the the fda ha the authority to grant additional data protection for approved drug where the sponsor conduct specified testing in pediatric or adolescent population within specified time period if granted this pediatric exclusivity provides an additional six month of exclusivity which is added to the term of data protection and for product other than biologics to the term of any relevant patent to the extent these protection have not already expired while the term of the pediatric exclusivity begin upon the expiration of the relevant patent pediatric exclusivity is regulatory exclusivity bar to generic or biosimilar approval not patent right under the orphan drug law specific use of drug or biologic can receive orphan designation if it is intended to treat disease or condition affecting fewer than people in the or affecting more than people but not reasonably expected to recover it development and marketing cost through sale among other benefit orphan designation entitles the particular use of the drug to seven year of market exclusivity meaning that the fda can not with limited exception approve another marketing application for the drug for the same indication until expiration of the seven year period unlike pediatric exclusivity the orphan exclusivity period is independent of and run in parallel with any applicable patent outside the major market the adequacy and effectiveness of intellectual property protection for pharmaceutical varies widely and in number of these market we are unable to patent our product or to enforce the patent that we receive for our product under the trade related aspect of intellectual property trip agreement administered by the world trade organization more than country have agreed to provide non discriminatory protection for most pharmaceutical invention and to assure that adequate and effective right are available to patent owner certain developing country limit protection for biopharmaceutical product under their interpretation of flexibility allowed under the trip agreement thus some type of patent such those on new us of compound or new form of molecule are not available in certain developing country further many developing country and some developed country do not provide effective data package protection even though it is specified in the trip agreement our intellectual property portfoliowe consider intellectual property protection for certain product process us and formulation particularly with respect to those product discussed below to be important to our operation in addition to the patent and data protection identified below we may hold patent on manufacturing process formulation device or us that extend exclusivity beyond the date shown below for approved product date include where applicable pending or granted patent term extension most relevant patent protection or data protection and associated expiry date for our major or recently launched patent protected marketed product are follows cyramza is protected by compound patent and biologics data protection emgality is protected by compound patent and biologics data protection jardiance and the related combination product glyxambi is protected by compound patent jaypirca is protected by compound patent and by data protection mounjaro is protected by compound patent and by data protection olumiant is protected by compound patent retevmo is protected by compound patent and by data protection reyvow is protected by compound patent taltz is protected by compound patent and by biologics data protection trulicity is protected by compound patent and by biologics data protection verzenio is protected by compound patent outside the important patent protection or data protection includes baqsimi is protected by data protection in japan cyramza is protected by compound patent and by data protection in major european country and by compound patent and by data protection in japan emgality is protected by compound patent and by data protection in major european country and by compound patent and by data protection in japan jardiance is protected by compound patent in major european country and japan mounjaro is protected by compound patent in major european country and japan olumiant is protected by compound patent and by data protection in major european country and by compound patent and by data protection in japan retevmo is protected by compound patent and by data protection in major european country and by compound patent and by data protection in japan reyvow is protected by data protection in major european country and compound patent and by data protection in japan taltz is protected by compound patent and data protection in major european country and compound patent and data protection in japan trulicity is protected by compound patent and by data protection in major european country and by compound patent and by data protection in japan verzenio is protected by compound patent and data protection in major european country and by compound patent and data protection in japan the following product candidate are the most relevant currently under regulatory review upon approval we expect relevant compound patent and data protection to apply donanemab ha been submitted for regulatory review in the for the treatment of early alzheimer disease in january the fda issued complete response letter for our accelerated approval submission phase iii trial are ongoing lebrikizumab ha been submitted for regulatory review in the and europe for the treatment of atopic dermatitis mirikizumab ha been submitted for regulatory review in the europe and japan for the treatment of ulcerative colitis we sell all of our major product under trademark consisting of our product name logo and unique product appearance the appearance of our trulicity autoinjector that we consider in the aggregate to be important to our operation trademark protection varies throughout the world with protection continuing in some country long the mark is used and in other country long it is registered registration are normally for fixed but renewable term trademark protection typically extends beyond the patent and data protection for product patent license and collaborationsmost of our major product are not subject to significant license and collaboration agreement for information on our license and collaboration agreement see item financial statement and supplementary data note collaboration and other arrangement patent challenge in the the drug price competition and patent term restoration act of commonly known the hatch waxman act authorizes the fda to approve generic version of innovative pharmaceutical other than biologics which are discussed below in more detail when the generic manufacturer ha not conducted safety and efficacy study but file an abbreviated new drug application anda in an anda the generic manufacturer must demonstrate only pharmaceutical equivalence and bioequivalence the generic version and the new drug application nda approved drug not safety and efficacy establishing pharmaceutical equivalence and bioequivalence is generally straightforward and inexpensive for the generic company absent patent challenge the fda can not approve an anda until after certain of the innovator patent expire however after the innovator ha marketed it product for four year generic manufacturer may file an anda alleging that one or more of the patent listed in the innovator nda are invalid or not infringed this allegation is commonly known paragraph iv certification if the innovator responds by filing suit the generic manufacturer the fda is prohibited from approving the generic company application for month period which can be shortened or extended by the trial court judge hearing the patent challenge if one or more of the nda listed patent are challenged the first filer of paragraph iv certification may be entitled to day period of market exclusivity over all other generic manufacturer generic manufacturer use paragraph iv certification extensively to challenge patent on innovative pharmaceutical in addition generic company have shown willingness to launch at risk after receiving anda approval but before final resolution of their patent challenge under the bpcia the fda can not approve an application for biosimilar product until data protection expires year after initial marketing approval of the innovator biologic and an application may not be submitted until four year following the date the innovator biologic wa first approved however the bpcia provide mechanism for prospective biosimilar competitor to challenge the validity of an innovator patent early four year after initial marketing approval of the innovator biologic the patent litigation scheme under the bpcia and the bpcia is complex and continues to be interpreted and implemented by the fda well by court court have held that biosimilar applicant are not required to engage in the bpcia patent litigation scheme and patent holder retain the right to bring suit under normal patent law procedure if biosimilar applicant attempt to commercialize product prior to patent expiration further in the the increased likelihood of generic and biosimilar challenge to innovator intellectual property ha increased the risk of loss of innovator market exclusivity see also competition biosimilars in addition there is procedure in patent law known inter partes review ipr which allows any member of the public to file petition with the uspto seeking the review of any issued patent for validity iprs are conducted before administrative patent judge in the uspto using lower standard of proof than used in federal district court in addition the challenged patent are not accorded the presumption of validity are in federal district court generic drug company and even some investment firm have engaged in the ipr process in attempt to invalidate our patent the use of ipr proceeding after the institution of litigation pursuant to the bpcia or hatch waxman act is currently topic of debate among legislator we have also observed and may continue to observe change at the patent trial and appeal board ptab including with respect to the ptab policy to discretionarily deny an otherwise meritorious petition for ipr in light of concurrent district court proceeding see item risk factor risk related to our business our long term success depends on intellectual property protection if our intellectual property right are invalidated circumvented or weakened our business will be adversely affected the the legal doctrine and process by which pharmaceutical patent can be challenged vary widely in recent year we have experienced an increase in patent challenge from generic manufacturer in many country outside the for more information on administrative challenge and litigation involving our intellectual property right see item financial statement and supplementary data note contingency government regulation of our operationsour operation are regulated extensively by numerous national state and local agency regulation of product the lengthy process of laboratory and clinical testing data analysis manufacturing development and regulatory review necessary for governmental approval of our product is extremely costly and can significantly delay product introduction and revenue generation in addition our operation are subject to complex federal state local and foreign law and regulation concerning relationship with healthcare provider and supplier the environment occupational health and safety data privacy and other matter evolving regulatory priority have intensified governmental scrutiny of our operation including with respect to current good manufacturing practice cgmp quality assurance and similar regulation compliance with the law and regulation affecting the manufacture and sale of current product and the discovery development and introduction of new product and us will continue to require substantial effort expense and capital investment of particular importance to our business is regulation by the fda in the pursuant to law and regulation that include the federal food drug and cosmetic act the fda ha jurisdiction over all of our product and device in the and administers requirement covering the testing safety effectiveness manufacturing quality control distribution labeling marketing promotion advertising dissemination of information and post marketing surveillance of those product and device following approval our product remain subject to regulation by various agency in connection with labeling import export storage recordkeeping advertising promotion and safety reporting we conduct extensive post marketing surveillance of the safety of the product we sell the fda may withdraw approval if compliance with regulatory requirement and standard is not maintained or if problem occur after product reach the market the fda also strictly regulates marketing labeling advertising and promotion of product that are placed on the market pharmaceutical product may be promoted only for approved indication and in accordance with the provision of the approved label the fda and other agency actively enforce the law and regulation prohibiting the promotion of label us outside the our product and operation are subject to similar regulatory requirement notably by the ema in europe the ministry of health labor and welfare in japan and the national medical product administration in china specific regulatory requirement vary from country to country regulatory and compliance requirement well approval process outside the may differ from those in the and may involve additional cost uncertainty and risk the fda and other regulatory agency outside the extensively regulate all aspect of manufacturing quality for pharmaceutical under their cgmp regulation we make substantial investment of capital and operating expense to implement comprehensive company wide quality system and control in our manufacturing product development and process development operation in an effort to maintain sustained compliance with cgmp and other regulation however in the event we fail to adhere to these requirement we become subject to potential government investigation regulatory and legal action product recall and seizure fine and penalty interruption of production leading to product shortage import ban or denial of import certification delay or denial in new product approval or line extension or supplemental approval of current product pending resolution of the issue and reputational harm any of which would adversely affect our business certain of our product are manufactured by third party and their failure to comply with these regulation could adversely affect including through failure to supply product to or delay in approval of new product or indication any determination by the fda or other regulatory authority of manufacturing or other deficiency could adversely affect our business and reputation we are also subject to variety of federal state local and foreign environmental health and safety and other law and regulation that may affect our research development or production effort use authorizationsthe secretary of health and human service may issue an eua to authorize unapproved medical product or unapproved us of approved medical product to be manufactured marketed and sold in the context of an actual or potential emergency that ha been designated by the government an eua terminates when the emergency determination underlying the eua terminates and euas can be revoked under other circumstance the timing of which may occur unexpectedly or be difficult to predict outside the the emergency use of medical product is subject to regulatory process and requirement that vary and differ from those in the the covid pandemic ha been designated national emergency in the on the basis of such determination the fda granted euas for bamlanivimab and etesevimab administered together certain covid related us of baricitinib and bebtelovimab and similar action have been taken by other regulator in certain jurisdiction outside the however the fda ha revised and may in the future further revise these euas in response to the changing condition of the covid pandemic such the prevalence of variant against which our antibody have varying degree of efficacy in may and november respectively the fda announced that bamlanivimab and etesevimab are and bebtelovimab is not currently authorized for emergency use for any region other law and regulationsthe marketing promotional and pricing practice of pharmaceutical manufacturer well the manner in which manufacturer interact with purchaser prescribers and patient are subject to various other federal and state law well analogous foreign law and regulation including the federal anti kickback statute the false claim act and state law governing kickback false claim unfair trade practice and consumer protection these law are administered by among others the department of justice the office of inspector general of the department of health and human service the federal trade commission the office of personnel management and state attorney general state federal and foreign government agency and other regulatory body are active in their oversight enforcement activity and coordination with respect to pharmaceutical company which ha resulted in intensified scrutiny litigation cost corporate criminal sanction and substantial civil settlement in the pharmaceutical industry the foreign corrupt practice act of fcpa prohibits certain individual and entity including publicly traded company from promising offering or giving anything of value to foreign official with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage the fcpa also imposes specific recordkeeping and internal control requirement on publicly traded company noted above our business is heavily regulated and therefore involves significant interaction with official outside the additionally in many country outside the healthcare provider who prescribe pharmaceutical are employed by the government and purchaser of pharmaceutical are government entity therefore our interaction with these prescribers and purchaser are subject to regulation under the fcpa in addition to the application and enforcement of the fcpa the various jurisdiction in which we operate and supply our product have law and regulation aimed at preventing and penalizing corrupt and anticompetitive behavior in recent year several jurisdiction have enhanced their law and regulation in this area increased their enforcement activity and or increased the level of cross border coordination and information sharing we are and could in the future become subject to administrative and legal proceeding and action which could include claim for civil penalty including treble damage under the false claim act criminal sanction and administrative remedy including exclusion from federal and other healthcare program it is possible that an adverse outcome in future action could have material adverse impact on our consolidated result of operation liquidity and financial position in any given period we are also subject to variety of federal state local and foreign environmental health and safety and other law and regulation that may affect our research development or production effort and private payer action affecting pharmaceutical pricing reimbursement and access there continues to be considerable public and government scrutiny of pharmaceutical pricing in addition government action to reduce federal spending on entitlement program including medicare and medicaid may affect payment for our product or service associated with the provision of our product in august the government enacted the inflation reduction act of ira among other measure the ira will require the department of health and human service to effectively set price for certain single source drug and biologics reimbursed under medicare part and part generally these government price apply nine medicine approved under an nda or thirteen medicine approved under biologics license application year following initial fda approval and will be capped at statutory ceiling price that is likely to represent significant discount from average price to wholesaler and direct purchaser it is soon to tell the government will set these price the law specifies ceiling price but not minimum or floor price one or more of our significant product may be selected which would have the effect of accelerating revenue erosion prior to patent expiry the effect of reducing price and reimbursement for certain of our product would significantly impact our business and consolidated result of operation the establishment of payment limit or other restriction by drug affordability review board and other state level actor would similarly impact other ira provision provide for rebate obligation on drug manufacturer that increase price of medicare part and part medicine at rate greater than the rate of inflation and part benefit redesign that includes replacing the part coverage gap discount program with new manufacturer discounting program manufacturer that fail to comply with the ira may be subject to various penalty including civil monetary penalty which could be significant the ira take effect progressively starting in with the first government set price effective in the ira may meaningfully influence our business strategy and those of our competitor in particular the nine year timeline to set price for medicine approved under an nda may reduce the attractiveness of investment in small molecule innovation the implication to of competitor product selected for price setting are also uncertain provision of the ira may be subject to legal challenge or other reformation and the full impact of the ira on our business and the pharmaceutical industry remains uncertain heightened governmental scrutiny over the manner in which drug manufacturer price their marketed product ha also resulted in several congressional inquiry and proposed and enacted federal and state legislation designed to among other thing bring more transparency to product pricing review the relationship between pricing and manufacturer patient program and reform government program reimbursement methodology for drug product restrictive or unfavorable pricing coverage or reimbursement determination for our medicine or product candidate by government regulatory agency court or private payer could also adversely impact our business and financial result for example in april the center for medicare medicaid service issued the monoclonal antibody directed against amyloid for the treatment of alzheimer disease national coverage determination the alzheimer monoclonal antibody ncd limiting coverage of fda approved monoclonal antibody that target amyloid for the treatment of alzheimer disease for people with medicare only if they are enrolled in qualifying clinical trial in it current form the alzheimer monoclonal antibody ncd would result in significantly reduced coverage for and negatively impact our product candidate donanemab and may negatively impact our business and financial result additional policy regulation legislation or enforcement including those proposed or pursued by the congress the current presidential administration and regulatory authority worldwide could intensify these effort and adversely impact our business and consolidated result of operation the we are required to provide rebate to the federal government and state government on their purchase of our pharmaceutical under various federal and state healthcare program including state medicaid and medicaid managed care program minimum of percent plus adjustment for price increase above the consumer price index over time and discount to private entity who treat patient in certain type of healthcare facility intended to serve low income and uninsured patient known covered entity additionally an annual fee is imposed on pharmaceutical manufacturer and importer that sell branded prescription drug to specified government program since the bipartisan budget act ha required manufacturer of brand name drug biologics and biosimilars to provide discount of percent of the cost of branded prescription drug for medicare part participant who are in the doughnut hole the coverage gap in medicare prescription drug coverage beginning in october under the ira the percent discount will be replaced by percent discount for all medicare part beneficiary that have met their deductible and incurred out of pocket drug cost below threshold and percent discount for beneficiary that have incurred out of pocket drug cost above the threshold rebate are also negotiated in the private sector we pay rebate to private payer that provide prescription drug benefit to senior covered by medicare and to private payer that provide prescription drug benefit to their customer these rebate are affected by the introduction of competitive product and generic in the same class our approach to the rebate we offer to private payer that provide prescription drug benefit to senior covered by medicare may be impacted by the regulatory amendment to the anti kickback statute discount safe harbor which have currently been stayed until at least january for discussion of risk related to how we price our product see item risk factor risk related to our business we face litigation and investigation related to our product how we price our product and how we commercialize our product we could face large number of claim in the future which could adversely affect our business and we are self insured for such matter outside the globally public and private payer are increasingly restricting access to pharmaceutical based on assessment of comparative effectiveness and value including through the establishment of formal health technology assessment process in addition third party organization including professional association academic institution and non profit entity associated with payer conduct and publish comparative effectiveness and cost benefit analysis on medicine the impact of which are uncertain in most international market we operate in an environment of government mandated cost containment program which may include price control international reference pricing to other country price discount and rebate therapeutic reference pricing to other often generic pharmaceutical choice restriction on physician prescription level and mandatory generic substitution in october the german parliament passed cost cutting reform and these reform were followed by activation of clawback mechanism in france and implementation of increased mandatory rebate in the united kingdom these change may be followed in by biopharmaceutical focused austerity measure in more country in europe and in other market reform including those that may stem from period of economic downturn or uncertainty or result of high inflation emergence or escalation of and response to war or unrest including the russia ukraine war or government budgeting priority including exacerbated by the covid pandemic may continue to result in added pressure on pricing and reimbursement for our product we can not predict the extent to which our business may be affected by these or other potential future legislative regulatory or payer development however in general we expect to see continued focus on regulating pricing resulting in additional state federal and international legislative and regulatory development that could have further negative effect on pricing and reimbursement for our product see item management discussion and analysis executive overview other matter trend affecting pharmaceutical pricing reimbursement and access for additional information regarding recent legislative administrative and other pricing initiative and their impact on our result and developmentour commitment to research and development date back more than year we invest heavily in research and development we believe it is critical to our long term competitiveness at the end of we employed approximately people in pharmaceutical research and development activity including substantial number of physician scientist holding graduate or postgraduate degree and highly skilled technical personnel our internal pharmaceutical research focus primarily on the area of obesity diabetes immunology neuroscience and oncology at the outset of the covid pandemic we also focused on researching and developing potential treatment for covid in addition to discovering and developing new medicine we seek to expand the value of existing product through new us formulation and therapeutic approach that provide additional value to patient to supplement our internal effort we collaborate with others including academic institution and research based pharmaceutical and biotechnology company we use the service of physician hospital medical school and other research organization worldwide to conduct clinical trial to establish the safety and effectiveness of our medicine we also invest in external research and technology that we believe complement and strengthen our own effort these investment can take many form including among others licensing arrangement co development agreement co promotion arrangement joint venture acquisition and equity investment pharmaceutical development is time consuming expensive and risky very of the candidate discovered by researcher ultimately become approved medicine the process from discovery to regulatory approval can take over decade candidate can fail at any stage of the process and even late stage candidate sometimes fail to receive regulatory approval or achieve commercial success the following describes in more detail the research and development process for pharmaceutical product phase of new drug development discovery phasein the discovery phase scientist identify design and synthesize promising candidate by analyzing their effect on biological target thought to play role in disease target are often unproven and only candidate that have the desired effect on the target and meet other design criterion move to the next phase of development which includes the initiation of study in animal to support regulatory and safety requirement for clinical research in human the discovery phase can take year and the probability of any one candidate becoming medicine is extremely low early development phaseearly development includes initial testing for safety and efficacy and early analysis of manufacturing requirement safety testing is initially performed in laboratory test and animal necessary in general the first human test often referred to phase are conducted in small group of subject to ass safety and evaluate the potential dosing range subsequently larger population of patient are studied phase ii to identify initial sign of efficacy while continuing to ass safety in parallel scientist work to identify safe effective and economical manufacturing process long term animal study continue to test for potential safety issue of the candidate that enter the early development phase approximately percent move to the late development phase the early development phase varies but can take several year to complete late development phaselate phase development project typically phase iii have met initial safety requirement and shown initial evidence of efficacy in earlier study result these candidate generally have higher likelihood of success and trial include larger patient population to demonstrate safety and efficacy in the disease these study are designed to demonstrate the benefit and risk of the potential new medicine and may be compared to competitive therapy placebo or both phase iii study are generally conducted globally and are designed to support regulatory filing for marketing approval the duration of phase iii testing varies by disease and may take two to four year submission phaseonce potential new medicine is submitted to regulatory agency the time to final marketing approval can vary from several month to several year depending on the disease state the strength and complexity of available data the degree of unmet need and the time required for the regulatory agency to evaluate the submission which can depend on prioritization by regulator and other factor there is no guarantee that potential medicine will receive marketing approval or that decision on marketing approval or indication will be consistent across geographic area we believe our investment in research both internally and in collaboration with others have resulted in robust pipeline of potential new medicine and new treatment indication in all stage of development we have number of new medicine candidate in clinical development or under regulatory review and we have larger number of project in the discovery phase see item management discussion and analysis executive overview late stage pipeline for more information on our late stage product candidate raw material and product supplymost of the principal material we use in our manufacturing operation are available from more than one source however we obtain certain raw or intermediate material primarily from only one source we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented in the event one of these supplier becomes unable to provide the material or product however various development have led and may in the future lead to interruption or shortage in supply until we establish new source implement alternative process bring new manufacturing facility online or pause or discontinue product sale in one or more market the majority of our revenue come from product produced predominantly in our own facility our principal active ingredient manufacturing occurs at site we own in the including puerto rico and ireland finishing operation including formulation filling assembling delivery device manufacturing and packaging take place at number of site throughout the world we utilize third party for certain active ingredient manufacturing and finishing operation we manage our supply chain including our own facility contracted arrangement and inventory in way that is intended to allow to meet substantially all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to change in supply and demand to maintain supply of our product we use variety of technique including comprehensive quality system inventory management and back up site however pharmaceutical production process are complex highly regulated and vary widely from product to product shifting or adding manufacturing capacity can be very lengthy process requiring significant capital expenditure process modification and regulatory approval accordingly development such unplanned plant shutdown manufacturing or quality assurance difficulty at one of our facility or contracted facility failure or refusal of supplier or contract manufacturer to supply contracted quantity increase in demand on supplier or difficulty in predicting or variability in demand for our product and those of our competitor have led and may in the future lead to interruption or higher cost in the supply of certain product product shortage or pause or discontinuation of product sale in one or more market further global transportation and logistics challenge cost inflation and tight labor market have caused and in the future may cause delay in and or increased cost related to distribution of our medicine the construction or acquisition of manufacturing capacity procurement activity and supplier or contract manufacturer arrangement for more information on the additional risk we face in connection with any difficulty disruption and shortage in the manufacturing distribution and sale of our product see item risk factor risk related to our business manufacturing quality or supply chain difficulty disruption or shortage could lead to product supply problem in addition cost inflation the strain on global transportation logistics and labor market including exacerbated by the covid pandemic and the emergence or escalation of and response to war or unrest including the russia ukraine war global economic downturn or uncertainty and an increase in overall demand in our industry for certain product and material have and may continue to have number of impact on our business including increased cost and disruption in the supply of our medicine for more information see item risk factor risk related to our business public health outbreak epidemic or pandemic such the covid pandemic have adversely impacted and may in the future adversely impact our business and operation and item management discussion and analysis executive overview other matter covid pandemic assuranceour success depends in great measure on customer confidence in the quality of our product and in the integrity of the data that support their safety and effectiveness product quality requires total commitment to quality in all part of our operation including research and development purchasing facility planning manufacturing distribution and dissemination of information about our medicine quality of production process involves strict control of ingredient equipment facility manufacturing method packaging material and labeling we perform test at various stage of production process and on the final product in an effort to ensure that the product meet all applicable regulatory requirement and our internal standard these test may involve chemical and physical chemical analysis microbiological testing testing in animal or combination thereof additional assurance of quality is provided by quality assurance group that audit and monitor all aspect of quality related to pharmaceutical manufacturing procedure and system in company operation and at third party supplier executive officer of the companythe following table set forth certain information regarding our current executive officer the term of office for each executive officer expires on the date of the annual meeting of the board of director to be held on may in connection with the company annual meeting of shareholder or on the date or successor is chosen and qualified no director or executive officer ha family relationship with any other director or executive officer of the company that term is defined for purpose of this disclosure requirement there is no understanding between any executive officer or director and any other person pursuant to which the executive officer wa selected and business experiencedavid president and chief executive officer ceo since previously mr rick held various leadership role with lilly including senior vice president and president lilly bio medicine mr rick ha year of service with lilly anat ashkenazi vice president and chief financial officer since previously ashkenazi held various leadership role with lilly including senior vice president controller and chief financial officer lilly research laboratory and vice president finance and chief financial officer lilly diabetes and lilly global manufacturing and quality ashkenazi ha year of service with lilly eric vice president human resource and diversity since previously mr dozier held various leadership role with lilly including senior vice president chief commercial officer for loxo lilly and vice president global ethic and compliance officer mr dozier ha year of service with lilly anat vice president general counsel and secretary since prior to joining lilly hakim wa senior vice president general counsel and secretary of wellcare health plan inc wellcare from to and executive vice president general counsel and secretary of wellcare from to prior to joining wellcare served divisional vice president and associate general counsel of intellectual property litigation at abbott laboratory from to and divisional vice president and associate general counsel of litigation from to hakim ha three year of service with lilly edgardo vice president and president manufacturing operation since previously mr hernandez held various leadership role with lilly including senior vice president global parenteral drug product delivery device and regional manufacturing and vice president fegersheim operation mr hernandez ha year of service with lilly patrik vice president and president lilly immunology lilly usa and chief customer officer since previously mr jonsson held various leadership role with lilly including senior vice president and president lilly usa and chief customer officer senior vice president and president lilly bio medicine and president and general manager lilly japan mr jonsson ha year of service with lilly michael mason vice president and president lilly diabetes since previously mr mason held various leadership role with lilly including senior vice president connected care and insulin and vice president of diabetes mr mason ha year of service with lilly johna vice president global quality since previously norton held various leadership role with lilly including vice president global quality assurance api manufacturing and product research and development norton ha year of service with lilly leigh ann vice president corporate affair and communication since prior to joining lilly pusey wa president and chief executive officer of the american insurance association from to pusey ha five year of service with lilly diogo vice president and chief information and digital officer since prior to joining lilly mr rau wa senior director of information system and technology for retail and online store of apple inc from to prior to his tenure at apple served partner at mckinsey company mr rau ha two year of service with lilly daniel skovronsky ph vice president chief scientific and medical officer and president lilly research laboratory since previously dr skovronsky held various leadership role with lilly including senior vice president chief scientific officer and president lilly research laboratory and senior vice president clinical and product development dr skovronsky ha year of service with lilly jacob van vice president ceo loxo lilly and president lilly oncology since previously mr van naarden served chief executive officer loxo oncology at lilly and chief operating officer loxo oncology at lilly mr van naarden joined lilly in when the company acquired loxo oncology inc where he wa the chief operating officer in previous role mr van naarden worked in various biotechnology investing operating and advisory capacity including position with healthcor management aisling capital and goldman sachs mr van naarden ha four year of service with lilly alonzo vice president enterprise risk management and chief ethic and compliance officer since previously mr weems held various leadership role with lilly including vice president and deputy general counsel for corporate legal function general counsel for lilly usa and general counsel for biomedicine and diabetes mr weems ha year of service with lilly anne vice president and president lilly neuroscience since previously white held various leadership role with lilly including senior vice president and president lilly oncology vice president of portfolio management chorus and next generation research and development white ha year of service with lilly ilya vice president and president lilly international since previously mr yuffa held various leadership role with lilly including senior vice president and president lilly bio medicine vice president of diabetes general manager of italy hub and vice president global ethic and compliance officer since mr yuffa ha year of service with lilly capital managementour core value integrity excellence and respect for people shape our approach to attracting retaining engaging and developing highly skilled and ethical workforce which is critical to executing our strategy we believe the strength of our workforce significantly contributes to our financial performance and enables to make life better for people around the world for instance most of the product we sell today were discovered or developed by our own scientist and our long term success depends on our ability to continually discover or acquire develop and commercialize innovative medicine we believe that fostering positive culture that value the contribution of our talented colleague help drive our success we are committed to creating safe supportive ethical and rewarding work environment through strategic focus on our human capital management process fairness and nondiscrimination in our employment practice robust training and development opportunity and competitive pay and benefit we believe our dedication to promoting diversity equity and inclusion dei within our company reflects our value and is key driver of business success and growth we regularly conduct anonymous employee survey to seek feedback from our workforce on variety of topic these result are reviewed and analyzed by our leader to identify opportunity to adjust our policy and benefit to improve our employee experience result of our effort we believe that we have highly performing cohesive workforce and that our employee relation are good at the end of we employed approximately people including approximately employee outside the our employee include approximately people engaged in research and development activity strategy and oversightin order to build diverse and inclusive team our ceo and executive committee set expectation for inclusive leadership and hold leader accountable for achieving result because dedication to human capital management is also core component of our corporate governance our board of director regularly engages with management and facilitates system of reporting designed to monitor human capital management initiative and progress part of the overarching framework that guide how we attract retain engage and develop workforce that aligns with our value and mission diversity equity and inclusionwe are committed to fairness and nondiscrimination in our employment practice and we deeply value diverse background skill and global perspective to fulfill our purpose we believe we must look at challenge from multiple viewpoint and understand the diverse experience of the patient who depend on we believe that fostering dei begin with understanding for example our employee journey research ha yielded important insight about the experience of woman black african american latinx asian and lgbtq employee at lilly the result of this research are reviewed by our senior leadership and we deploy action and activity in response to these insight to improve our workplace and corporate culture in part of our dei and community initiative lilly and the lilly foundation launched the racial justice commitment with lilly pledging volunteer hour and the lilly foundation committing million over five year to help decrease the burden of racial injustice and it effect on community of color the racial justice commitment aim to drive change across five area internal people development health equity social impact diversity partner and family sustaining job through the use of financial and people resource from through we have made progress in these effort including nearly tripling our spending with black owned business committing over million in minority led venture capital firm serving over volunteer hour to advance racial justice initiative and expanding our skill first program at lilly for individual without four year college degree since we have committed to increasing woman black african american latinx and asian representation in leadership role and we actively monitor our progress from the end of through the end of we increased the percentage of woman in management globally from percent to percent for minority group member mgm in the over the same period we increased management representation from percent to percent across all level of our workforce from the end of through the end of we have seen increased representation for mgms in the and woman globally our focus on dei is also evident at our executive committee and board of director five of current member approximately percent of our executive committee which includes our ceo are woman and three are mgms in addition of the filing of this report the company member board of director includes five woman and six member who are mgms effort in dei and workplace benefit have garnered numerous recognition including in top company for diversity by diversityinc top company for board of director by diversityinc top company for supplier diversity by diversityinc top company for esg by diversityinc america best employer for woman by forbes perfect score on the human right campaign foundation corporate equality index world most ethical company by ethisphere perfect score on disability equity index best place to work by disability in pharmaceutical innovation index zero project award for access lilly and top company for executive woman best company for multicultural woman best company for dad percent and higher inclusion index by seramount employee developmentwe believe attracting and retaining the best diverse talent begin with the hiring process we therefore require hiring manager to consider diverse pool of candidate and we strive to provide diverse panel of interviewer for open position we believe that hiring in this way help ensure that people from all background have equal opportunity to advance their career in early we launched discover month new employee onboarding program with multiple touchpoints designed to foster integration into lilly to accelerate learning in their new role and to create connection to further sense of belonging at lilly discover wa shaped in part by external benchmarking feedback from employee and learning from onboarding remotely during the covid pandemic we offer training to enable our employee to perform their duty in our highly regulated industry we also strive to cultivate culture that promotes ongoing learning by encouraging employee to seek further education and growth experience helping build rewarding career we have introduced online programming to facilitate access to our learning and development offering in addition to our in person program many training course are designed to improve accessibility for people with disability and other unique need across lilly we are continuously working to design learning experience to be more inclusive and effective in addition we have implemented development tool and resource for all employee improved our talent program and process to provide broader access to information and increased transparency regarding career development and advancement at lilly employee resource group erg are another important component of developing talent at lilly we currently have erg representing group including woman mgms lgbtq individual veteran and people with disability erg offer our diverse workforce opportunity to build relationship engage with senior leader advance our caring community and offer unique insight and perspective to improve our business we have continued our effort to create an inclusive workplace with the goal of ensuring that all employee feel safe to speak up and share their idea at work our make it safe to thrive education and awareness program is designed to help employee and leader understand how individual psychological safety can be created and enhanced and includes live and online training in late we introduced new version of make it safe to thrive for leader that continues to focus on psychological safety and creating an inclusive environment leader are provided the opportunity to work through challenging conversation and situation currently being navigated in the workplace lilly is committed to fostering culture of diversity and respect in the workplace an environment free of discrimination harassment or retaliation of any kind in part of our annual review of the red book and related policy and procedure we revised the global conduct in the workplace procedure to continue to help ensure that we maintain respectful safe inclusive and professional workplace employee health and safetywe strive to foster healthy vibrant work environment which includes keeping our employee safe we seek to create companywide culture where best in class safety practice are consistently followed to do this we ass and continuously attempt to improve our companywide safety performance to promote the well being of employee and to help safeguard community where we operate the covid pandemic ha evolved we have continued to take various measure necessary to protect and support the health and safety of our employee globally we believe holistic approach and dedication to safety help be our best we deliver on our company purpose to improve life around the world available on our websiteour company website is www lilly com none of the information accessible on or through our website is incorporated into this annual report on form we make available through the website free of charge our company filing with the sec soon reasonably practicable after we electronically file them with or furnish them to the sec these include our annual report on form quarterly report on form current report on form proxy statement registration statement and any amendment to those document the link to our sec filing is investor lilly com financial information sec filing paper copy of the company annual report on form and quarterly report on form that are filed with the sec are available without charge upon written request to eli lilly and companyc general counsel and secretarylilly corporate centerindianapolis indiana addition the governance section of our website includes our corporate governance guideline board of director and committee information including committee charter and our article of incorporation and bylaw the link to our corporate governance information is lilly com leadership governance we routinely post important information for investor in the investor section of our website www lilly com we may use our website mean of disclosing material non public information and for complying with our disclosure obligation under regulation fd accordingly investor should monitor the investor section of our website in addition to following our press release filing with the sec public conference call presentation and webcasts we may also use social medium channel to communicate with investor and the public about our business product and other matter and those communication could be deemed to be material information the information contained on or that may be accessed through our website or social medium channel is not incorporated by reference into and is not part of this annual report on form risk factorsin addition to the other information contained in this annual report on form the following risk factor should be considered carefully in evaluating our company it is possible that our business financial condition liquidity cash flow or result of operation could be materially adversely affected by any of these risk certain of these risk could also adversely affect the company reputation additional risk and uncertainty not presently known to or that we currently believe to be immaterial could also adversely affect our business and reputation risk related to our business pharmaceutical research and development is very costly and highly uncertain we may not succeed in developing licensing or acquiring commercially successful product sufficient in number or value to replace revenue of product that have lost or will lose intellectual property protection or are displaced by competing product or therapy there are many difficulty and uncertainty inherent in pharmaceutical research and development the introduction of new product and business development activity to enhance our product pipeline there is high rate of failure inherent in new drug discovery and development to bring drug from the discovery phase to market can take over decade and often cost in excess of billion failure can occur at any point in the process including in later stage after substantial investment result most fund invested in research program will not generate financial return new product candidate that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concern inability to obtain or maintain necessary regulatory approval or payer reimbursement or coverage the application of pricing control limited scope of approved us label change change in the relevant treatment standard or the availability of new or better competitive product difficulty or excessive cost to manufacture or infringement of the patent or intellectual property right of others regulatory agency establish high hurdle for the efficacy and safety of new product and indication delay uncertainty unpredictability and inconsistency in drug approval process across market and agency can result in delay in product launch lost market opportunity potential impairment of inventory and other negative impact in addition it can be very difficult to predict revenue growth rate of or variability in demand for new product and indication we can not state with certainty when or whether our product under development will be approved or launched whether if initially granted such approval will be maintained whether we will be able to develop license or otherwise acquire additional product candidate or product or whether our product once launched will be commercially successful we must maintain continuous flow of successful new product and successful new indication or line extension for existing product both through our internal effort and our business development activity sufficient both to cover our substantial research and development cost and to replace revenue that are lost profitable product become subject to pricing control lose intellectual property exclusivity or are displaced by competing product or therapy failure to do so in the short term or long term would have material adverse effect on our business result of operation cash flow and financial position we engage in various form of business development activity to enhance our product pipeline including licensing arrangement co development agreement co promotion arrangement joint venture acquisition and equity investment there are substantial risk associated with identifying successful business development target and consummating related transaction increased focus on business combination in our industry including by the federal trade commission and competition authority in europe and other jurisdiction and heightened competition for attractive target ha and could continue to delay jeopardize or increase the cost of our business development activity in addition failure or difficulty in integrating or retaining new personnel or the operation of the business product or asset we acquire including related technology commercial operation compliance program information security manufacturing distribution and general business operation and procedure may affect our ability to realize the expected benefit of business development transaction and may result in our incurrence of substantial asset impairment or restructuring charge we also may fail to generate the expected revenue and pipeline enhancement from business development activity due to development outside our control including unsuccessful clinical trial issue related to the quality integrity or broad applicability of data regulatory impediment and commercialization challenge accordingly business transaction may not be completed in timely manner if at all may not result in successful development outcome or successful commercialization of any product and may give rise to legal proceeding or regulatory scrutiny see item business research and development phase of new drug development and item management discussion and analysis executive overview late stage pipeline for more detail about our current product pipeline we depend on product with intellectual property protection for most of our revenue cash flow and earnings the loss of effective intellectual property protection for certain of our product ha resulted and in the future is likely to continue to result in rapid and severe decline in revenue for those product in the ordinary course of their lifecycles our product lose significant patent protection and or data protection in the well in key jurisdiction outside the after specified period of time some product also lose patent protection result of successful third party challenge we have faced and remain exposed to generic competition following the expiration or loss of such intellectual property protection for example following the expiration of patent exclusivity for alimta in europe and japan in june we have faced generic competition that ha rapidly and severely eroded revenue from prior level and we expect such competition will continue to erode revenue from current level in these market in addition result of the entry of multiple generic in the following the expiration of patent and pediatric exclusivity for alimta in in the first half of we began facing and expect to continue to face generic competition that ha rapidly and severely eroded revenue from prior level and we expect will continue to erode revenue from current level certain other significant product no longer have effective exclusivity through patent protection or data protection for non biologic product loss of exclusivity whether by expiration of legal right or by termination thereof consequence of litigation typically result in the entry of one or more generic competitor leading to rapid and severe decline in revenue especially in the for biologics such humalog humulin erbitux cyramza trulicity taltz and emgality loss of exclusivity may or may not result in the near term entry of competitor version biosimilars due to many factor including development timeline manufacturing challenge and or uncertainty regarding the regulatory pathway for approval of the competitor version generic pharmaceutical company could also introduce generic product before resolution of any related patent litigation there is no assurance that the patent we are seeking will be granted or that the patent we hold will be found valid and enforceable if challenged moreover patent relating to particular product us formulation or process do not preclude other manufacturer from employing alternative process or marketing alternative product or formulation that compete with our patented product in addition competitor or other third party may assert claim that our activity infringe patent or other intellectual property right held by them or allege third party right of ownership in our existing intellectual property see item management discussion and analysis executive overview other matter patent matter and item business patent trademark and other intellectual property right for more detail our long term success depends on intellectual property protection if our intellectual property right are invalidated circumvented or weakened our business will be adversely affected our long term success depends on our ability to continually discover or acquire develop and commercialize innovative medicine without strong intellectual property protection we would be unable to generate the return necessary to support our significant investment in research and development well the other expenditure required to bring new drug and indication to the market intellectual property protection varies throughout the world and is subject to change over time depending on local law and regulation change to such law regulation and enforcement practice could reduce protection for our innovative product and indication for example potential reform to pharmaceutical legislation in the european union may threaten the predictability and length of certain pharmaceutical intellectual property incentive change proposed by the uspto to limit the number of and difference between patent obtained could also affect the scope of patent protection for our product in the also in the in addition to the process for challenging patent set forth in the bpcia which applies to biologic product the hatch waxman act provides generic company substantial incentive to seek to invalidate our patent covering pharmaceutical product result we expect that our patent on major pharmaceutical product including biologics will continue to be routinely challenged in litigation may not be upheld in addition separate ipr process currently allows competitor to seek invalidation of patent at the uspto without the protection of the bpcia or hatch waxman act the use of ipr proceeding after the institution of litigation pursuant to the bpcia or hatch waxman act is currently topic of debate among legislator and the future ability of our competitor to use ipr proceeding an alternative to hatch waxman act or bpcia litigation procedure to challenge our patent remains uncertain recently the uspto issued an interim procedure regarding the use of discretionary denial of ipr proceeding when there is parallel district court litigation however it is not clear how this interim procedure could affect the ability of our competitor to institute ipr proceeding after institution of litigation if our patent are challenged through this expedited review process even if we prevail in demonstrating the validity of our patent our win provides limited precedential value at the ptab and no precedential value in federal district court meaning the same patent can be challenged by other competitor we face many generic manufacturer challenge to our patent outside the well the entry of generic competitor typically result in rapid and severe decline in revenue in addition competitor or other third party may claim that our activity infringe patent or other intellectual property right held by them if successful such claim could result in our being unable to market product in particular territory or being required to pay significant damage for past infringement or royalty on future sale in addition intellectual property protection in certain jurisdiction outside the is weak and we face additional risk to our intellectual property right including competition with generic or counterfeit version of our product relatively shortly after launch see item business patent trademark and other intellectual property right and item financial statement and supplementary data note contingency for more detail we and our product face intense competition from multinational pharmaceutical company biotechnology company and lower cost generic and biosimilar manufacturer and such competition could have material adverse effect on our business we compete with large number of multinational pharmaceutical company biotechnology company and generic pharmaceutical company and in many case our product compete against the leading product of one or more of our competitor to compete successfully we must continue to deliver to the market innovative cost effective product that meet important medical need our product revenue can be adversely affected by the introduction by competitor of branded product that are perceived superior by the marketplace by generic or biosimilar version of our branded product and by generic or biosimilar version of other product in the same therapeutic class our branded product our revenue can also be adversely affected by treatment innovation including new modality that eliminate or minimize the need for treatment with our drug regulation of generic and biosimilar product varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agency and court particularly for biosimilars health authority guideline and legislative action could make it le burdensome for competitor product to enter the market and further incentivize uptake of biosimilars in the the fda ha issued several interchangeability designation for biosimilar product and is expected to continue doing so in the future these designation could subject to state law requirement enable pharmacy to substitute biosimilars for innovator biological product given the importance of biologic product to our clinical stage pipeline such regulation could have material adverse effect on our business see item business competition and business research and development for more detail in addition we rely on our ability to attract engage and retain highly qualified and skilled personnel in order to compete effectively to continue to commercialize our product and advance the research development and commercialization of additional modality indication and product candidate we have expanded and will likely need to further expand our workforce including in the area of manufacturing clinical trial management regulatory affair and sale and marketing both in and outside the we continue to face intense competition for qualified individual from numerous multinational pharmaceutical company biotechnology company academic and other research institution well employer near our manufacturing and other facility which ha and may continue to increase our labor cost our ability to attract and retain talent in our increasingly competitive environment may be further complicated by evolving employment trend including related to increased preference for remote or flexible work arrangement public health outbreak epidemic or pandemic such the covid pandemic political social civil or cultural unrest emergence or escalation of and response to war and unrest or the threat of or perceived potential for any of the foregoing event our failure to compete effectively for talent could negatively affect sale of our current and any future product and could result in material financial legal commercial or reputational harm to our business failure inadequacy breach of or unauthorized access to our it system or those of our third party service provider unauthorized access to our confidential information or violation of data protection law could each result in material harm to our business and reputation great deal of confidential information owned by or our business partner or other third party is stored in our information system network and facility or those of third party this includes valuable trade secret and intellectual property clinical trial information corporate strategic plan marketing plan customer information and personally identifiable information such employee and patient information collectively confidential information we also rely to large extent on the efficient and uninterrupted operation of complex information technology system infrastructure and hardware together it system some of which are within our control and some of which are within the control of third party to accumulate process store and transmit large amount of confidential information and other data we are subject to variety of continuously evolving and developing law and regulation around the world related to privacy data protection and data security maintaining the security confidentiality integrity and availability of our it system and confidential information is vital to our business our failure or the failure of our third party service provider to protect and maintain the security confidentiality integrity and availability of our or their it system and our confidential information and other data could significantly harm our reputation well result in significant cost including those related to fine litigation and obligation to comply with applicable data breach law it system are vulnerable to system inadequacy operating failure service interruption or failure security breach malicious intrusion or cyber attack from variety of source which may remain undetected for significant period of time such vulnerability inadequacy or failure are in many case more acute for it system associated with recently acquired business and we may be unable to address such vulnerability inadequacy or failure immediately after acquiring business result our newly acquired business could be more vulnerable to potential interruption breach intrusion or attack cyber attack are growing in their frequency sophistication and intensity and are becoming increasingly difficult to detect mitigate or prevent cyber attack come in many form including the deployment of harmful malware exploitation of vulnerability including those of third party software or system denial of service attack the use of social engineering and other mean to compromise the confidentiality integrity and availability of our it system confidential information and other data breach resulting in the compromise disruption degradation manipulation loss theft destruction or unauthorized disclosure or use of confidential information or the unauthorized access to disruption of or interference with our it system product and service can occur in variety of way including negligent or wrongful conduct by employee or others with permitted access to our system and information or wrongful conduct by hacker competitor certain government or nation state or other current or former company personnel our third party partner including third party provider of data hosting or cloud service well supplier distributor alliance and other third party with whom we may share data face similar risk which could affect directly or indirectly unassociated third party present further risk including by propagating misinformation related to our product business and industry the healthcare industry ha been and continues to be target for cyber attack and the number of threat ha increased over time numerous federal agency that monitor and regulate internet and cyber crime have issued guidance alert and directive warning of software vulnerability that require immediate patching malicious actor targeting healthcare related system and nation state sponsored hacking designed to steal valuable information the failure inadequacy or breach of our it system or business process the compromise disruption degradation manipulation loss theft destruction or unauthorized access to disclosure or use of confidential information or the unauthorized access to disruption of or interference with our product and service that rely on it system or business process could impair our ability to secure and maintain intellectual property right result in product manufacturing interruption or failure or in the interruption or failure of product or service that rely on it system or business process damage our operation customer relationship or reputation undermine integration activity or otherwise delay the launch of acquired product result in unfavorable clinical trial result by virtue of incorrect or unreliable data and or cause to lose trade secret or other competitive advantage unauthorized disclosure of personally identifiable information could expose to significant sanction for violation of data privacy law and around the world and could damage public trust in our company in addition it system security in jurisdiction outside the is weaker and may result in additional cost uncertainty and risk to date system inadequacy operating failure unauthorized access service interruption or failure security breach malicious intrusion cyber attack and the compromise disruption degradation manipulation loss theft destruction or unauthorized disclosure or use of confidential information have not had material impact on our consolidated result of operation we maintain cyber liability insurance however this insurance may not be sufficient to cover the financial legal business or reputational loss that may result from an interruption or breach of our it system we continue to implement measure in an effort to protect detect respond to and minimize or prevent these risk and to enhance the resiliency of our it system however these measure may not be successful and we may fail to detect or remediate security breach malicious intrusion cyber attack or other compromise of our system any of these event could result in material financial legal commercial or reputational harm to our business economic downturn or international trade and other global disruption or dispute could adversely affect our business and operating result economic slowdown could lead to decreased utilization of our product affecting our sale declining tax revenue and increased government spending on other program attributable to economic downturn increase the pressure on government to reduce healthcare spending leading to increased control of drug price or lower utilization additionally some customer including government or other entity reliant upon government funding may be unable to pay for our product fully or in timely manner also if our customer supplier or collaboration partner experience financial difficulty we could experience slower customer collection greater bad debt expense and performance default by supplier or collaboration partner similarly significant economic downturn could limit our ability to access capital market in addition significant portion of our business are conducted in europe including the united kingdom asia including china and other international geography trade and other global dispute and interruption in international relationship including related to tariff trade protection measure import or export licensing requirement the imposition of trade sanction or similar restriction by the or other government unrest or war well public health outbreak epidemic or pandemic such the covid pandemic affect our ability to do business for example tension between the and china have led to series of tariff and sanction being imposed by the on import from china mainland well other business restriction further example the financial impact of higher energy price defense spending and inflation due in part to the russia ukraine war and resulting geopolitical and economic disruption particularly following the covid pandemic ha further exacerbated financial pressure on government with single payer or government funded healthcare system leading to increased impetus for increase in rebate clawback and other reform to reimbursement system particularly in europe these and similar event have adversely affected and may continue to adversely affect our business partner and our customer for more detail see item business regulation and private payer action affecting pharmaceutical pricing reimbursement and access pharmaceutical product can develop unexpected safety or efficacy concern which could have material adverse effect on our revenue income and reputation pharmaceutical product receive regulatory approval based on data obtained in controlled clinical trial of limited duration after approval the product are used for longer period of time by much larger number of patient accordingly we and others including regulatory agency and private payer collect extensive information on the efficacy and safety of our marketed product by continuously monitoring the use of our product in the marketplace in addition we or others may conduct post marketing clinical study on efficacy and safety of our marketed product new safety or efficacy data from both market surveillance and post marketing clinical study may result in product label change or other measure that could reduce the product market acceptance and result in declining sale serious safety or efficacy issue that arise after product approval have and could in the future result in voluntary or mandatory product recall or withdrawal from the market safety issue have and could in the future result in costly product liability claim we face litigation and investigation related to our product how we price our product and how we commercialize our product we could face large number of claim in the future which could adversely affect our business and we are self insured for such matter we are subject to substantial number of claim involving various current and historical product litigation and investigation these claim relate to how we commercialize and or how we price our product including relating to our drug pricing program well contractual matter and other dispute see item financial statement and supplementary data note contingency for more information on our current product liability litigation well pricing and other litigation investigation and inquiry because of the nature of pharmaceutical product we are and could in the future become subject to large number of product liability claim for our previous current or future product or to further litigation or investigation including related to pricing or other commercial practice such matter could affect our result of operation or require to recognize substantial charge to resolve and if involving marketed product could adversely affect sale of the product and our consolidated result of operation in any given period due to very restrictive market for liability insurance we are self insured for litigation liability loss for all of our currently marketed product well for litigation or investigation related to our pricing practice or other similar matter manufacturing quality or supply chain difficulty disruption or shortage could lead to product supply problem pharmaceutical manufacturing is complex and highly regulated manufacturing or quality assurance difficulty at our facility or those of our contractor and supplier the failure or refusal of supplier or contract manufacturer to supply contracted quantity or increase in demand on supplier could result in delay and disruption in the manufacturing distribution and sale of our product and or product shortage leading to lost revenue in select case supply constraint may also lead to pause discontinuation or other product availability issue in one or more market which could have material adverse effect on our consolidated result of operation and cash flow further cost inflation and global transportation and logistics challenge well tight labor market have caused and in the future may cause delay in and or increase cost related to distribution of our medicine the construction or other acquisition of manufacturing capacity procurement activity and supplier or contract manufacturer arrangement such difficulty disruption or challenge could result from quality oversight or regulatory compliance problem natural disaster including increased instance of natural disaster or other event that may be due to climate change public health outbreak epidemic or pandemic such the covid pandemic period of global economic downturn or uncertainty emergence or escalation of and response to war or unrest including the russia ukraine war equipment mechanical data or it system vulnerability such system inadequacy inadequate control or procedure operating failure service interruption or failure security breach malicious intrusion or cyber attack from variety of source labor shortage contractual dispute with our supplier and contract manufacturer or inability to obtain single source or other raw or intermediate material regional dependency may in some case accentuate risk related to manufacturing and supply for example we and the pharmaceutical industry generally depend on china based partner for integral chemical synthesis reagent starting material and ingredient difficulty in predicting or variability in demand for our product and those of our competitor and the very long lead time necessary for the expansion and regulatory qualification of pharmaceutical manufacturing capacity have resulted and in the future may result in difficulty meeting demand for or disruption shortage and higher cost in the supply of our product for example we have experienced challenge in meeting demand for our incretin product partially due to the limited availability of competitor therapy despite our ongoing effort to meet significant expected demand by obtaining additional internal and contracted manufacturing capacity there can be no assurance that such capacity increase will be realized expected delay or challenge in operationalizing additional manufacturing capacity would limit our ability to capitalize on expected demand conversely unexpected contingency that limit demand for our incretin product would undermine our ability to realize the full benefit of significant capital expenditure that we have incurred and expect to continue to incur to augment manufacturing capacity and may also subject to contractual payment obligation the foregoing risk and uncertainty could negatively impact our consolidated result of operation and reputation see item business raw material and product supply and item management discussion and analysis financial condition and liquidity for more detail we derive significant percentage of our total revenue from relatively few product and sell our product through increasingly consolidated supply chain stakeholder which may subject to or exacerbate various risk we derived direct product and or alliance revenue of more than billion for each of trulicity verzenio taltz jardiance including glyxambi synjardy and trijardy xr humalog including insulin lispro our covid antibody and humulin that collectively accounted for percent of our total revenue in in particular trulicity accounted for percent of our total revenue in and we expect glp including mounjaro which we launched in to represent significant and growing portion of our business loss of patent protection change in prescription rate material product liability litigation unexpected side effect or safety concern significant change in demand regulatory proceeding negative publicity affecting doctor or patient confidence pressure from existing or new competitive product change in labeling pricing and access pressure or supply shortage or disruption for these product or any of our other major product could materially impact our result of operation in addition in the most of our product are distributed through wholesaler and if one of these significant wholesaler should encounter financial or other difficulty it might decrease the amount of business the wholesaler doe with or we might be unable to timely collect the amount that the wholesaler owes which could negatively impact our result of operation see item business marketing and distribution for more detail moreover the negotiating power of health plan managed care organization pharmacy benefit manager and other supply chain stakeholder ha increased due to consolidation regulatory and other market impact and they along with government increasingly employ formulary to control cost and encourage utilization of certain drug including through the use of formulary inclusion or favorable formulary placement such stakeholder have also increasingly imposed utilization management tool favoring the use of generic product these practice expand including due to potential further consolidation of private third party payer we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our product we expect that consolidation of supply chain stakeholder will continue to increase competitive and pricing pressure on pharmaceutical manufacturer for additional information on pricing and reimbursement for our pharmaceutical product see private sector dynamic and regulation and private payer action affecting pharmaceutical pricing reimbursement and access reliance on third party relationship and outsourcing arrangement could adversely affect our business we rely on third party including supplier distributor alliance and collaboration with other pharmaceutical and biotechnology company and third party service provider for selected aspect of product and clinical development manufacturing commercialization hosting of and support for it system product distribution and certain financial transactional process example we outsource the day to day management and oversight of some of our clinical trial to contract research organization and the distribution of our product through logistics provider outsourcing involves many risk including the risk that the third party may not perform to our standard or legal requirement including applicable requirement for diversity in clinical trial may not produce reliable result may not perform in timely manner may not maintain the confidentiality integrity and availability of confidential and proprietary information relating to our clinical trial subject or patient may experience disruption or fail to perform due to it system vulnerability breach cyber attack or inadequate control or procedure may be unable to satisfy their commitment to in which case we may not be able to achieve acceptable alternative sourcing or may fail to perform at all the foregoing risk may be heightened in jurisdiction outside the where we may have fewer alternative provider well face additional cost uncertainty and risk failure of third party to meet their contractual regulatory confidentiality privacy security or other obligation to our clinical trial subject and our patient could have material adverse effect on our business public health outbreak epidemic or pandemic such the covid pandemic have adversely impacted and may in the future adversely impact our business and operation actual or threatened public health outbreak epidemic or pandemic such the covid pandemic have adversely impacted and may in the future adversely impact our business and operation the pandemic ha adversely impacted and may continue to adversely impact our business and operation across market to varying and fluctuating degree including result of cost inflation and strain on global transportation manufacturing and labor market which have negatively impacted development manufacturing supply distribution and sale of our medicine including through increased cost to provide and in some case disruption in supply or shortage of our medicine fewer in person interaction among patient and healthcare provider and our employee with healthcare professional in certain market pricing pressure rebate clawback and other change in reimbursement policy and program resulting in part from the financial strain of the covid pandemic on government funded healthcare system around the world risk related to our covid therapy including heightened regulatory scrutiny of our manufacturing practice quality assurance and similar regulation restriction on administration that limit widespread and timely access to our therapy and risk related to handling return and or refund of product after delivery by concern related to expedited authorization of restricted distribution of product with le than typical safety and efficacy data and fluctuation in or elimination of demand for our covid therapy including based on the availability of superior or competitive therapy preventative measure such vaccine and antiviral medicine mutation of the virus impacting effectiveness revocation or restriction on euas reaching endemic status in different jurisdiction reduced government and payer funding for covid therapy the unpredictable nature of pandemic and other development these and other risk related to the covid pandemic and other actual or threatened public health outbreak epidemic or pandemic could affect other aspect of our business or intensify other risk inherent in our business the degree to which the covid pandemic could continue to affect and other actual or threatened public health outbreak epidemic or pandemic could affect will depend on development that are highly uncertain and beyond our knowledge or control including the duration and severity of the public health threat the action taken to reduce it transmission the introduction and spread of new variant the degree and extent of government restriction on economic activity government spending and access to healthcare and the speed with which and extent to which economic and operating condition recover should the covid pandemic or any other actual or threatened public health outbreak epidemic or pandemic well any associated or resulting cost of inflation supply chain disruption labor market impact recession depression or other negative contingency continue for prolonged period these risk could be exacerbated causing further impact on our business and operation risk related to government regulation our business is subject to increasing government price control and other public and private restriction on pricing reimbursement and access for our drug which could have material adverse effect on our result of operation reputation or business public and private payer continue to take aggressive step to control their expenditure for pharmaceutical by placing restriction on pricing and reimbursement for and patient access to our medicine these pressure have negatively affected and could continue to negatively affect our consolidated result of operation government and private payer worldwide have intensified their scrutiny of and action intended to address pricing reimbursement and access to pharmaceutical product additional policy regulation legislation or enforcement including result of the regulatory priority of the current presidential administration and regulatory authority worldwide could adversely impact our business and consolidated result of operation in particular if one or more of our significant product are selected under the ira the resulting price reduction and reimbursement could negatively impact our business and consolidated result of operation for more detail see item business regulation and private payer action affecting pharmaceutical pricing reimbursement and access further restrictive or unfavorable pricing coverage or reimbursement determination for our medicine or product candidate by government regulatory agency court or private payer such the alzheimer monoclonal antibody ncd may adversely impact our business and financial result we to experience additional pricing pressure rebate clawback and other change in reimbursement policy and program resulting from the financial strain of the covid pandemic period of global economic downturn or uncertainty and the emergence or escalation of and response to war or unrest including the russia ukraine war for more detail see item business regulation and private payer action affecting pharmaceutical pricing reimbursement and access item management discussion and analysis executive overview other matter trend affecting pharmaceutical pricing reimbursement and access and item financial statement and supplementary data note contingency change in foreign currency rate interest rate risk or inflation affect our result of operation global company we face foreign currency risk exposure from fluctuating currency exchange rate interest rate risk from our exposure to floating and variable interest rate and inflation risk from existing and expected rate of inflation in the and other jurisdiction each of which impact our result of operation in recent period significant fluctuation in currency rate and inflation have had significant negative impact on our result of operation we are net receiver of foreign currency and our result of operation may continue to be adversely impacted if the dollar remains strong compared to foreign currency further in the event of an extreme devaluation of local currency in particular market in which we operate the price of our product could become unsustainable in the relevant market inflationary pressure in recent period have also negatively impacted and may continue to negatively impact in various way including cost inflation higher labor cost and other higher expense with some of these higher expense due in part to policy action intended to curb inflation see item management discussion and analysis financial condition and liquidity and item financial statement and supplementary data note summary of significant accounting policy and implementation of new financial accounting standard for more detail we are subject to evolving and complex tax law which may result in additional liability and affect our result of operation we are subject to income tax in the and numerous other jurisdiction and in the course of our business we make judgment about the expected tax treatment of various transaction and event change in tax law regulation administrative practice principle and interpretation well event that differ from our expectation have affected and may adversely affect our effective tax rate cash flow and or result of operation significant uncertainty currently exists regarding tax proposal introduced by the current administration and congress including modification to certain aspect of the tax cut and job act of such the potential repeal or deferral of the provision requiring capitalization of research and development expense in addition tax authority in the and other jurisdiction in which we do business routinely examine our tax return and are intensifying their scrutiny and examination of profit allocation among jurisdiction which could unfavorably impact our result of operation further action taken with respect to tax related matter by association such the organisation for economic co operation and development and the european commission could influence tax law in country in which we operate modification to key element of the current or international tax framework could have significant impact on our effective tax rate result of operation and cash flow see item management discussion and analysis executive overview other matter tax matter and item financial statement and supplementary data note income tax for more detail regulatory compliance problem could be damaging to the company the marketing promotional and pricing practice of pharmaceutical manufacturer well the manner in which manufacturer interact with purchaser prescribers and patient are subject to extensive scrutiny and regulation many company including are and have been subject to investigation and claim related to these practice asserted by federal state and foreign governmental authority private payer and consumer these investigation and claim have resulted in substantial expense and other significant consequence to we are and could in the future become subject to such investigation and claim the outcome of which include criminal charge and fine penalty or other monetary or non monetary remedy including exclusion from federal and other healthcare program such investigation and claim have intensified and may continue to intensify result of the regulatory priority of each particular presidential administration and other regulatory authority worldwide in addition regulatory issue concerning compliance with cgmp quality assurance evolving standard and increased scrutiny around excipients and potential impurity such nitrosamines and regulation and standard and comparable foreign regulation and standard for our product can lead to regulatory and legal action product recall and seizure fine and penalty interruption of production leading to product shortage import ban or denial of import certification delay or denial in new product approval or line extension or supplemental approval of current product pending resolution of the issue and reputational harm any of which would adversely affect our business regulatory compliance and process in jurisdiction outside the may also be le predictable and result in additional cost uncertainty and risk see item business government regulation of our operation for more detail furthermore there is an increased focus by foreign federal state and local regulatory and legislative body regarding environmental policy relating to climate change regulating greenhouse gas emission carbon tax emission trading scheme sustainable manufacturing human right and equity matter and disclosure regarding the foregoing many of which may be ambiguous inconsistent dynamic or conflicting we expect to experience increased restriction and compliance cost legal cost and expense related to such new or changing legal or regulatory requirement moreover compliance with any such legal or regulatory requirement would require to devote substantial time and attention to these matter in addition we may still be subject to penalty or potential litigation if such law and regulation are interpreted or applied in manner inconsistent with our practice additionally we are subject to increased negative attention from the medium stockholder activist and other stakeholder on climate change social and sustainability matter the perception that we have failed to act in socially responsible manner whether or not valid result in adverse publicity that can negatively affect our business and reputation well result in increased scrutiny from legislator and regulatory authority moreover from time to time we establish and publicly announce goal and commitment including to reduce our impact on the environment our ability to achieve any stated environmental social or governance goal target or objective is subject to numerous factor and condition many of which are outside our control example of such factor include evolving regulatory requirement affecting sustainability standard or disclosure or imposing different requirement the availability of requisite financing and the availability of supplier that can meet our sustainability and other goal if we fail to achieve are perceived to have failed or been delayed in achieving or improperly report our progress toward achieving these goal and commitment it could negatively affect our reputation or investor confidence and expose to enforcement action and litigation unresolved staff commentsnone item propertiesour principal domestic and international executive office are located in indianapolis at december we owned nine production distribution and corporate administrative site in the united state including puerto rico these facility contain an aggregate of approximately million square foot of floor area dedicated to production distribution and administration major production site include indianapolis indiana carolina puerto rico and branchburg new jersey in we expect production to commence at an additional approximately million square foot facility in durham north carolina with other production facility and expansion of production facility expected to come online in future period we own production and distribution site in seven country outside the containing an aggregate of approximately million square foot of floor area major production site include facility in ireland france spain italy and china in the our research and development facility contain an aggregate of approximately million square foot of floor area primarily consisting of owned facility located in indianapolis and smaller leased site primarily in san diego california san francisco california and new york new york outside the we own small research and development facility in spain and lease small site in singapore we believe that none of our property is subject to any encumbrance easement or other restriction that would detract materially from it value or impair it use in the operation of the business the building we own are of varying age and in good condition item legal proceedingswe are party to various currently pending legal action government investigation and environmental proceeding information pertaining to legal proceeding is described in item financial statement and supplementary data note contingency and incorporated by reference herein item mine safety disclosuresnot applicable iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity securitiesinformation relating to the principal market for our common stock dividend and related stockholder matter is described in item management discussion and analysis of result of operation and financial condition and item security ownership of certain beneficial owner and management and related stockholder matter this information is incorporated herein by reference of february there were approximately holder of record of our common stock based on information provided by eq shareowner service our transfer agent our common stock is listed under the ticker symbol lly on the new york stock exchange nyse the following table summarizes the activity related to repurchase of our equity security during the fourth quarter ended december periodtotal number ofshares purchased in thousand average price paidper sharetotal number of sharespurchased part ofpublicly announcedplans or program in thousand approximate dollar valueof share that may yet bepurchased under theplans or program dollar in million october during the three month ended december we not repurchase any share under our billion share repurchase program authorized in may graphthe following graph compare the return on lilly stock with that of the standard poor stock index and our peer group for the year through the graph assumes that on the last business day of person invested each in lilly stock the stock index and the peer group collective common stock the graph measure total shareholder return which take into account both stock price and dividend it assumes that dividend paid by company are immediately reinvested in that company stock value of invested on last business day of comparison of five year cumulative total shareholder return among lilly stock index and peer group lillypeer group dec dec dec dec dec we constructed the peer group the industry index for this graph it is comprised of the following company in the pharmaceutical and biotechnology industry abbvie inc amgen inc astrazeneca plc biogen inc bristol myers squibb company gilead science inc glaxosmithkline plc johnson johnson merck co inc novartis ag novo nordisk pfizer inc roche holding ag sanofi and takeda pharmaceutical company limited the peer group used for performance benchmarking aligns with the peer group used for executive compensation purpose for reserved item management discussion and analysis of result of operation and financial condition table present dollar in million except per share data generalmanagement discussion and analysis of result of operation and financial condition is intended to assist the reader in understanding and assessing significant change and trend related to our company result of operation and financial position this discussion and analysis should be read in conjunction with item financial statement and supplementary data certain statement in this item constitute forward looking statement various risk and uncertainty including those discussed in forward looking statement and item risk factor may cause our actual result financial position and cash generated from operation to differ materially from these forward looking statement executive overviewthis section provides an overview of our financial result late stage pipeline development and other matter affecting our company and the pharmaceutical industry financial resultsthe following table summarizes our key operating result year ended december margin percent of research and development selling and acquired in process research and development ipr and development asset impairment restructuring and other special other net income expense per share increased in driven by increased volume largely offset by lower realized price and the unfavorable impact of foreign exchange rate research and development expense increased in driven primarily by higher development expense for late stage asset partially offset by lower development expense for covid antibody and the favorable impact of foreign exchange rate marketing selling and administrative expense in remained relatively flat compared to increased cost associated with launch of new product and indication were offset by the favorable impact of foreign exchange rate following highlighted item affect comparison of our and financial result ipr and development milestone note to the consolidated financial statement we recognized million of acquired ipr and development milestone that included the buy out of substantially all future obligation that were contingent upon the occurrence of certain event linked to the success of our mutant selective inhibitor and purchase of priority review voucher asset impairment restructuring and other special charge note to the consolidated financial statement we recognized charge of million primarily related to an intangible asset impairment for gene therapy due to change in estimated launch timing other net income expense note to the consolidated financial statement we recognized million of net investment loss on equity security cost of sale see note to the consolidated financial statement we recognized net inventory impairment charge related to our covid antibody of million part of our response to the covid pandemic and at the request of the united state and international government we invested in large scale manufacturing of covid antibody at risk in order to ensure rapid access to patient around the world the covid pandemic evolved during we incurred net inventory impairment charge primarily due to the combination of change to demand from and international government including change to our agreement with the government and near term expiry date of covid antibody acquired ipr and development milestone note to the consolidated financial statement we recognized million of acquired ipr and development milestone that included charge resulting from business development transaction with foghorn therapeutic inc foghorn rigel pharmaceutical inc rigel and precision bioscience inc precision asset impairment restructuring and other special charge note to the consolidated financial statement we recognized charge of million primarily related to an impairment of contract based intangible asset from our acquisition of loxo oncology inc loxo an intangible asset impairment resulting from the sale of the right to qbrexza well acquisition and integration cost associated with the acquisition of prevail therapeutic inc prevail other net income expense note to the consolidated financial statement we recognized debt extinguishment loss of million related to the repurchase of debt we recognized million of net investment gain on equity security stage pipelineour long term success depends on our ability to continually discover or acquire develop and commercialize innovative new medicine we currently have approximately new medicine candidate in clinical development or under regulatory review and larger number of project in the discovery phase the following certain new molecular entity nmes are currently in phase ii or phase iii clinical trial or have been submitted for regulatory review or have received regulatory approval in the europe or japan the following table reflects the status of certain nmes including certain other development up to the time of the filing of this annual report on form compoundindicationstatus developmentsdiabetesbasal insulin fctype and diabetesphase iiiphase iii trial initiated in and sirnacardiovascular diseasephase iiphase ii trial initiated in lp inhibitorcardiovascular diseasephase iiphase ii trial initiated in lp sirnacardiovascular diseasephase iiphase ii trial initiated in orforglipronobesityphase iiphase ii trial were recently completed type diabetesretatrutide obesityphase iiphase ii trial were recently completed type diabetesimmunologylebrikizumab atopic dermatitissubmittedsubmitted in the and europe in phase iii trial are ongoing mirikizumabulcerative colitissubmittedsubmitted in the europe and japan in crohn diseasephase iiiphase iii trial are ongoing btla mab agonistsystemic lupus erythematosusphase iiphase ii trial initiated in ligand monoclonal antibodyhidradenitis suppurativaphase iiphase ii trial is ongoing peresolimabrheumatoid arthritisphase iiphase ii trial is ongoing rezpegaldesleukin systemic lupus erythematosusphase iiphase ii trial is ongoing developmentsneurosciencedonanemabearly alzheimer diseasecomplete response lettergranted food and drug administration fda breakthrough therapy designation submitted in the in under the accelerated approval pathway in january the fda issued complete response letter for the accelerated approval submission phase iii trial are ongoing preclinical alzheimer diseasephase iiiphase iii trial is ongoing remternetugearly alzheimer diseasephase iiiphase iii trial initiated in solanezumabpreclinical alzheimer diseasephase iiiphase iii trial is ongoing gene therapy parkinson disease phase iigranted fda fast track designation phase ii trial is ongoing grn gene therapy frontotemporal dementiaphase iigranted fda fast track designation phase ii trial is ongoing glcnacase inhalzheimer diseasephase iiphase ii trial is ongoing inhibitorpainphase iiphase ii trial initiated in agonistpainphase iiphase ii trial are ongoing antagonistpainphase iiphase ii trial are ongoing oncologypirtobrutinib jaypircatm mantle cell lymphomaapproved fda granted accelerated approval in the in january phase iii trial is ongoing chronic lymphocytic leukemiaphase iiiphase iii trial are ongoing cell malignanciesphase iiphase ii trial is ongoing selpercatinib retevmo lung cancerapproved phase iii trial are ongoing thyroid cancerapproved phase iii trial is ongoing imlunestrantadjuvant breast cancerphase iiiphase iii trial initiated in er metastatic breast cancerphase iiiphase iii trial is ongoing in collaboration with almirall in europe breakthrough therapy designation is designed to expedite the development and review of potential medicine that are intended to treat serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on clinically significant endpoint fast track designation is designed to facilitate the development and expedite the review of medicine to treat serious condition and fill an unmet medical need continued approval may be contingent on verification and description of clinical benefit in confirmatory phase iii trial pipeline also contains several new indication line extension nilex product the following certain nilex product for use in the indication described are currently in phase ii or phase iii clinical trial or have been submitted for regulatory review or have received regulatory approval in the europe or japan the following table reflects the status of certain nilex product including certain other development up to the time of the filing of this annual report on form compoundindicationstatusdevelopmentsdiabetesempagliflozin jardiance chronic kidney diseasesubmittedgranted fda fast track designation submitted in the and europe in january tirzepatide mounjaro obesitysubmission initiatedgranted fda fast track designation in initiated rolling submission in the in phase iii trial are ongoing heart failure with preserved ejection fractionphase iiiphase iii trial are ongoing obstructive sleep apneaphase iiiphase iii trial initiated in granted fda fast track designation in nonalcoholic steatohepatitis phase iiphase ii trial is ongoing oncologyabemaciclib verzenio prostate cancerphase iiiphase iii trial are ongoing in collaboration with boehringer ingelheim fast track designation is designed to facilitate the development and expedite the review of medicine to treat serious condition and fill an unmet medical need there are many difficulty and uncertainty inherent in pharmaceutical research and development and the introduction of new product well high rate of failure inherent in new drug discovery and development to bring drug from the discovery phase to market can take over decade and often cost in excess of billion failure can occur at any point in the process including in later stage after substantial investment result most fund invested in research program will not generate financial return new product candidate that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concern inability to obtain or maintain necessary regulatory approval or payer reimbursement or coverage the application of pricing control limited scope of approved us label change change in the relevant treatment standard or the availability of new or better competitive product difficulty or excessive cost to manufacture or infringement of the patent or intellectual property right of others regulatory agency establish high hurdle for the efficacy and safety of new product and indication delay uncertainty unpredictability and inconsistency in drug approval process across market and agency can result in delay in product launch and lost market opportunity in addition it can be very difficult to predict revenue growth rate of or variability in demand for new product and indication we manage research and development spending across our portfolio of potential new medicine delay in or termination of any one project will not necessarily cause significant change in our total research and development spending due to the risk and uncertainty involved in the research and development process we can not reliably estimate the nature timing and cost of the effort necessary to complete the development of our research and development project can we reliably estimate the future potential revenue that will be generated from any successful research and development project each project represents only portion of the overall pipeline and none is individually material to our consolidated research and development expense while we do accumulate certain research and development cost on project level for internal reporting purpose we must make significant cost estimation and allocation some of which rely on data that are neither reproducible nor validated through accepted control mechanism therefore we do not have sufficiently reliable data to report on total research and development cost by project by preclinical versus clinical spend or by therapeutic category matterspatent matterswe depend on patent or other form of intellectual property protection for most of our revenue cash flow and earnings following the expiration of patent exclusivity for alimta in europe and japan in june we have faced generic competition that ha rapidly and severely eroded revenue from prior level and we expect such competition will continue to erode revenue from current level in these market in addition result of the entry of multiple generic in the following the expiration of patent and pediatric exclusivity in the first half of we began facing and expect to continue to face generic competition that ha rapidly and severely eroded revenue from prior level and we expect will continue to erode revenue from current level this decline in revenue will continue to impact period over period financial result comparison particularly during the first half of see note to the consolidated financial statement for description of legal proceeding currently pending regarding certain of our patent our compound patent for humalog insulin lispro have expired in the and major international market and we have also introduced lower priced version of humalog part of our insulin access and affordability solution competitor ha similar version of insulin lispro in the and in certain european market due to the impact of competition and pricing pressure in the and certain international market we expect that lower revenue for humalog due to realized price decline will continue over time trend affecting pharmaceutical pricing reimbursement and accessreforms including those that may stem from period of economic downturn or uncertainty or result of high inflation emergence or escalation of and response to war or unrest including the russia ukraine war or government budgeting priority including exacerbated by the covid pandemic may continue to result in added pressure on pricing and reimbursement for our product global concern over access to and affordability of pharmaceutical product continues to drive regulatory and legislative debate and action well worldwide cost containment effort by governmental authority such measure include the use of mandated discount price reporting requirement mandated reference price restrictive formulary change to available intellectual property protection well other effort in august the government enacted the inflation reduction act of ira among other measure the ira will require the department of health and human service to effectively set price for certain single source drug and biologics reimbursed under medicare part and part generally these government price apply nine medicine approved under new drug application or thirteen medicine approved under biologics license application year following initial fda approval and will be capped at statutory ceiling price that is likely to represent significant discount from average price to wholesaler and direct purchaser it is too soon to tell how the government will set these price the law specifies ceiling price but not minimum or floor price one or more of our significant product may be selected which would have the effect of accelerating revenue erosion prior to patent expiry the effect of reducing price and reimbursement for certain of our product would significantly impact our business and consolidated result of operation the establishment of payment limit or other restriction by drug affordability review board and other state level actor would similarly impact other ira provision provide for rebate obligation on drug manufacturer that increase price of medicare part and part medicine at rate greater than the rate of inflation and part benefit redesign that includes replacing the part coverage gap discount program with new manufacturer discounting program manufacturer that fail to comply with the ira may be subject to various penalty including civil monetary penalty which could be significant the ira take effect progressively starting in with the first government set price effective in the ira may meaningfully influence our business strategy and those of our competitor in particular the nine year timeline to set price for medicine approved under new drug application may reduce the attractiveness of investment in small molecule innovation the implication to of competitor product being selected for price setting are also uncertain provision of the ira may be subject to legal challenge or other reformation and the full impact of the ira on our business and the pharmaceutical industry remains uncertain policy regulation legislation or enforcement including those proposed and or pursued by the congress the current presidential administration and regulatory authority worldwide could adversely impact our business and consolidated result of operation consolidation and integration of private payors and pharmacy benefit manager in the ha also significantly impacted the market for pharmaceutical by increasing payor leverage in negotiating manufacturer price or rebate concession and pharmacy reimbursement rate furthermore restrictive or unfavorable pricing coverage or reimbursement determination for our medicine or product candidate by government regulatory agency court or private payer such the center for medicare medicaid service national coverage determination for monoclonal antibody for the treatment of alzheimer disease may adversely impact our business and consolidated result of operation we expect that these action may intensify and could particularly affect certain product such insulin government manage and emerge from the covid pandemic which could adversely affect our business in addition we are engaged in litigation and investigation related to our program and access to insulin that if resolved adversely to could negatively impact our business and consolidated result of operation it is not currently possible to predict the overall potential adverse impact to or the general pharmaceutical industry of continued cost containment effort worldwide in addition regulatory issue concerning compliance with current good manufacturing practice quality assurance evolving standard and increased scrutiny around excipients and potential impurity such nitrosamines and similar regulation and standard and comparable foreign regulation and standard for our product can lead to regulatory and legal action product recall and seizure fine and penalty interruption of production leading to product shortage import ban or denial of import certification delay or denial in new product approval or line extension or supplemental approval of current product pending resolution of the issue and reputational harm any of which would adversely affect our business moreover increased focus on business combination across industry and jurisdiction can lead to impediment to the completion of business combination see item business regulation and private payer action affecting pharmaceutical pricing reimbursement and access and note to the consolidated financial statement for additional information product supplywe have faced challenge and expect to continue to face challenge meeting strong demand for our incretin product including due to the limited and fluctuating availability of competitor therapy in the given very strong uptake of mounjaro following it launch in the for type diabetes in the second quarter of and demand for trulicity ha remained strong we have experienced intermittent delay in fulfilling certain order for these product outside the we have implemented certain action to minimize the impact on existing trulicity patient but we expect to continue to experience intermittent disruption in our supply of trulicity in international market we anticipate tight supply of our incretin product will persist until additional manufacturing capacity is operationalized we expect additional internal and contracted manufacturing capacity will become fully operational around the world in the next several year with significant expansion in part of our ongoing effort to meet the significant demand for our incretin medicine tax matterswe are subject to income tax and various other tax in the and in many foreign jurisdiction therefore change in both domestic and international tax law or regulation have affected and may affect our effective tax rate result of operation and cash flow in the enacted the tax cut and job act the tax act which contained provision that requires capitalization and amortization of research and development expense for tax purpose starting in previously these expense could be deducted in the year incurred the implementation of this provision increased our cash payment of income tax by approximately billion in while the implementation of this provision will continue to increase our cash payment of income tax the increase will moderately decrease from level over the five year amortization period and country around the world are actively proposing and enacting tax law change further action taken with respect to tax related matter by association such the organisation for economic co operation and development and the european commission could influence tax law in country in which we operate tax authority in the and other jurisdiction in which we do business routinely examine our tax return and are intensifying their scrutiny and examination of profit allocation among jurisdiction change to existing and foreign tax law and increased scrutiny by tax authority in the and other jurisdiction could adversely impact our future consolidated result of operation and cash flow foreign currency exchange rate and other impactsas global company we face foreign currency risk exposure from fluctuating currency exchange rate primarily the dollar against the euro japanese yen and chinese yuan while we seek to manage portion of these exposure through hedging and other risk management technique significant fluctuation in currency rate can have material impact either positive or negative on our consolidated result of operation in any given period during the year ended december revenue wa unfavorably impacted by percent due to foreign exchange rate while there is uncertainty in the future movement in foreign exchange rate fluctuation in these rate have and we currently expect in the near term future will adversely impact our consolidated result of operation and cash flow in addition cost inflation the strain on global transportation logistics and labor market including exacerbated by the covid pandemic and the emergence or escalation of and response to war or unrest including the russia ukraine war global economic downturn or uncertainty and an increase in overall demand in our industry for certain product and material have had and may continue to have number of impact on our business including increased cost and disruption in the supply of our medicine acquisitionswe invest in external research and technology that we believe complement and strengthen our own effort these investment can take many form including acquisition collaboration investment and licensing arrangement we view our business development activity way to enhance our pipeline and strengthen our business see note to the consolidated financial statement for further discussion regarding our recent acquisition covid pandemicas the covid pandemic evolves we remain focused on protecting the health safety and well being of our employee supporting the medical system and our community and affordability of and access to our medicine at the outset of the covid pandemic we also focused on researching developing and supplying covid therapy although we do not currently expect significant further revenue attributable to treatment for covid the covid pandemic ha adversely impacted and may continue to adversely impact our business and operation across market to varying and fluctuating degree including result of cost inflation and strain on the global transportation manufacturing and labor market fewer in person interaction among patient and healthcare provider and our employee with healthcare professional in certain market pricing pressure rebate clawback and other change in reimbursement policy resulting from the financial strain of the covid pandemic on government funded healthcare system and risk related to our covid therapy the degree to which the covid pandemic could continue to affect will depend on development that are highly uncertain and beyond our knowledge or control for additional information see item risk factor risk related to our business public health outbreak epidemic or pandemic such the covid pandemic have adversely impacted and may in the future adversely impact our business and operation see item risk factor for additional information on risk factor that could impact our business and operation of operationsoperating result revenuethe following table summarizes our revenue activity by region year ended december changeu revenue may not add due to rounding the following are component of the change in revenue compared with the prior year outside price foreign exchange rate percent number may not add due to rounding in the the increase in volume in wa primarily driven by trulicity verzenio jardiance mounjaro and taltz partially offset by decreased volume for alimta following the entry of multiple generic in the first half of in the the decrease in realized price wa primarily driven by humalog due to list price reduction of insulin lispro injection and unfavorable segment mix and trulicity and basaglar due to unfavorable segment mix and higher contracted rebate in addition the decrease in realized price of humalog wa partially offset by change to estimate for rebate and discount in outside the the increase in volume in wa primarily driven by verzenio trulicity jardiance tyvyt and taltz partially offset by decrease in volume due to generic competition for alimta and cymbalta and decreased utilization of covid antibody the decrease in realized price outside the wa primarily driven by the impact of government pricing in china from national reimbursement drug list nrdl formulary for certain product particularly tyvyt and verzenio and volume based procurement vbp for humalog following table summarizes our revenue activity in compared with year ended december changeproductu outside totaltotaltrulicity covid antibody humulin cyramza olumiant emgality cialis erbitux nmzyprexa tyvyt other revenue may not add due to rounding nm not meaningful jardiance revenue includes glyxambi synjardy and trijardy xr humalog revenue includes insulin lispro covid antibody include sale for bamlanivimab administered alone for bamlanivimab and etesevimab administered together and for bebtelovimab and were made pursuant to emergency use authorization euas or similar regulatory authorization olumiant revenue includes sale for baricitinib that were made pursuant to eua or similar regulatory authorization revenue of trulicity increased percent in the driven by increased demand partially offset by lower realized price due to unfavorable segment mix and higher contracted rebate revenue outside the increased percent driven by increased volume partially offset by the unfavorable impact of foreign exchange rate and to lesser extent lower realized price we experienced intermittent delay in fulfilling certain trulicity order during the second half of action to manage strong demand across our incretin portfolio including measure to minimize existing patient impact in international market also affected volume in revenue of verzenio increased percent in the primarily driven by increased demand revenue outside the increased percent driven by increased demand partially offset by lower realized price primarily due to the impact of the nrdl formulary in china and the unfavorable impact of foreign exchange rate revenue of taltz increased percent in the driven by increased demand partially offset by lower realized price revenue outside the increased percent driven by increased volume partially offset by the unfavorable impact of foreign exchange rate and lower realized price revenue of jardiance increased percent in the primarily driven by increased demand revenue outside the increased percent primarily driven by increased demand partially offset by the unfavorable impact of foreign exchange rate see note to the consolidated financial statement for information regarding our collaboration with boehringer ingelheim involving jardiance of humalog decreased percent in the primarily driven by lower realized price due to list price reduction of insulin lispro injection and unfavorable segment mix partially offset by change to estimate for rebate and discount in revenue outside the decreased percent primarily driven by lower realized price due to the impact of vbp in china and the unfavorable impact of foreign exchange rate due to the impact of competition and pricing pressure in the and certain international market we expect that lower revenue for humalog due to realized price decline will continue over time see executive overview other matter patent matter for additional information revenue of covid antibody wa billion in the during the year ended december primarily due to bebtelovimab supplied to the government covid antibody are not currently authorized for emergency use in the we do not currently expect significant further revenue attributable to the treatment of covid revenue of alimta decreased percent in the primarily driven by decreased demand due to the entry of multiple generic in the first half of revenue outside the decreased percent primarily driven by decreased demand due to generic competition following the expiration of patent exclusivity for alimta in europe and japan in june we have faced generic competition that ha rapidly and severely eroded revenue from prior level and we expect such competition will continue to erode revenue from current level in these market in addition result of the entry of multiple generic in the following the expiration of patent and pediatric exclusivity in the first half of we began facing and expect to continue to face generic competition that ha rapidly and severely eroded revenue from prior level and we expect will continue to erode revenue from current level see executive overview other matter patent matter for additional information margin cost and expensesgross margin percent of revenue wa percent in an increase of percentage point compared with primarily driven by net inventory impairment charge related to our covid antibody recognized in and the unfavorable effect of foreign exchange rate on international inventory sold in additionally in favorable product mix including the impact of lower sale of covid antibody and olumiant for the treatment of covid were offset by lower realized price and increased expense due to inflation and logistics cost research and development expense increased percent to billion in driven primarily by higher development expense for late stage asset partially offset by lower development expense for covid antibody and the favorable impact of foreign exchange rate marketing selling and administrative expense remained relatively flat at billion in increased cost associated with launch of new product and indication were offset by the favorable impact of foreign exchange rate we have undertaken compensatory action to improve retention and address wage inflation which will increase compensation cost and impact our consolidated result of operation we recognized acquired ipr and development milestone of million in that included the buy out of substantially all future obligation that were contingent upon the occurrence of certain event linked to the success of our mutant selective inhibitor and purchase of priority review voucher we recognized acquired ipr and development milestone of million in that included charge resulting from business development transaction with foghorn rigel and precision see note to the consolidated financial statement for additional information we recognized asset impairment restructuring and other special charge of million in primarily related to an intangible asset impairment for gene therapy due to change in estimated launch timing we recognized asset impairment restructuring and other special charge of million in primarily related to an impairment of contract based intangible asset from our acquisition of loxo an intangible asset impairment resulting from the sale of the right to qbrexza well acquisition and integration cost associated with the acquisition of prevail other net income expense wa expense of million in primarily driven by net investment loss on equity security other net income expense wa expense of million in primarily driven by debt extinguishment loss of million related to the repurchase of debt partially offset by net investment gain on equity security our effective tax rate wa percent in reflecting the favorable tax impact of the implementation of provision in the tax act that requires capitalization and amortization of research and development expense for tax purpose starting in partially offset by the tax impact of the mix of earnings in higher tax jurisdiction our effective tax rate wa percent in reflecting the favorable tax impact of acquired ipr and development milestone charge net investment gain on equity security and net discrete tax benefit operating result for discussion of our result of operation pertaining to and see item management discussion and analysis of result of operation and financial condition in our annual report on form for the year ended december condition and liquiditywe believe our available cash and cash equivalent together with our ability to generate operating cash flow and our access to short term and long term borrowing are sufficient to fund our existing and planned capital requirement which include working capital requirement including related to employee payroll clinical trial manufacturing material and tax capital expenditure share repurchase and dividend repayment of outstanding short term and long term borrowing contribution to our defined benefit pension and retiree health benefit plan milestone and royalty payment and potential business development activity including acquisition collaboration investment and licensing arrangement our management continuously evaluates our liquidity and capital resource including our access to external capital to ensure we can adequately and efficiently finance our capital requirement of december our material cash requirement primarily related to purchase of good and service to produce our product and conduct our operation capital expenditure dividend repayment of outstanding borrowing milestone and royalty payment the remaining obligation for the one time repatriation transition tax also known the toll tax from the tax act lease unfunded commitment to invest in venture capital fund and retirement benefit see note and to the consolidated financial statement we anticipate our cash requirement related to ordinary course purchase of good and service will be consistent with our past level relative to revenue in we committed to invest over several year more than billion in two new facility in lebanon indiana to manufacture existing and future product more than billion in new facility in concord north carolina to manufacture parenteral injectable product and device and more than million euro in new facility in limerick ireland to expand our manufacturing network for biologic active ingredient in early we committed to invest an additional million to expand manufacturing capacity at research triangle park facility in durham north carolina for additional parenteral filling device assembly and packaging capacity these investment and other capital investment that support our operation will result in higher capital expenditure for the next several year the tax act contained provision that requires to capitalize and amortize research and development expense for tax purpose starting in whereas previously we could fully deduct these expense in the year incurred the implementation of this provision increased our cash payment of income tax by approximately billion in while the implementation of this provision will continue to increase our cash payment of income tax the increase will moderately decrease from level over the five year amortization period see executive overview other matter tax matter for additional information cash and cash equivalent decreased to billion of december compared with billion at december net cash provided by operating activity wa billion in compared with billion in refer to the consolidated statement of cash flow for additional information on the significant source and us of cash for the year ended december and in addition to our cash and cash equivalent we held total investment of billion and billion of december and respectively see note to the consolidated financial statement for additional information in december we acquired all share of akouos inc akouos for purchase price that included per share in cash or an aggregate of million net of cash acquired plus one non tradable contingent value right cvr per share the cvr entitles akouos shareholder up to an additional per share in cash or an aggregate of approximately million payable subject to certain term and condition upon the achievement of certain specified milestone this acquisition wa funded through cash on hand see note to the consolidated financial statement for additional information of december total debt wa billion decrease of million compared with billion at december see note to the consolidated financial statement for additional information of december we had total of billion of unused committed bank credit facility billion of which is available to support our commercial paper program see note to the consolidated financial statement for additional information we believe that amount accessible through existing commercial paper market should be adequate to fund short term borrowing need dividend of per share and per share were paid in and respectively the quarterly dividend wa increased to per share effective for the dividend to be paid in the first quarter of resulting in an indicated annual rate for of per share capital expenditure were billion during compared to billion in in we repurchased billion of share under our billion share repurchase program authorized in may of december we had billion remaining under this program see note to the consolidated financial statement for additional information see executive overview other matter patent matter for information regarding recent loss of patent protection both domestically and abroad we continue to monitor the potential impact of the economic environment the creditworthiness of our wholesaler and other customer including foreign government backed agency and supplier the uncertain impact of healthcare legislation and various international government funding level in the normal course of business our operation are exposed to fluctuation in interest rate currency value and fair value of equity security these fluctuation impact the cost of financing investing and operating we seek to address portion of these risk through controlled program of risk management that includes the use of derivative financial instrument the objective of this risk management program is to limit the impact on earnings of fluctuation in interest and currency exchange rate all derivative activity are for purpose other than trading our primary interest rate risk exposure result from change in short term dollar interest rate in an effort to manage interest rate exposure we strive to achieve an acceptable balance between fixed and floating rate debt position and may enter into interest rate derivative to help maintain that balance of december substantially all of our total long term debt carry interest at fixed rate we have converted approximately percent of our long term fixed rate note to floating rate through the use of interest rate swap based on our overall interest rate exposure at december and including derivative and other interest rate risk sensitive instrument hypothetical percent change in interest rate applied to the fair value of the instrument of december and respectively would not have material impact on earnings cash flow or fair value of interest rate risk sensitive instrument over one year period our foreign currency risk exposure result from fluctuating currency exchange rate primarily the dollar against the euro japanese yen and chinese yuan we face foreign currency exchange exposure when we enter into transaction arising from subsidiary trade and loan payable and receivables denominated in foreign currency we also face currency exposure that arises from translating the result of our global operation to the dollar at exchange rate that have fluctuated from the beginning of the period we may enter into foreign currency forward or option derivative contract to reduce the effect of fluctuating currency exchange rate primarily the euro the japanese yen and chinese yuan our corporate risk management policy outline the minimum and maximum hedge coverage of such exposure gain and loss on these derivative contract offset in part the impact of currency fluctuation on the existing asset and liability we periodically analyze the fair value of the outstanding foreign currency derivative contract to determine their sensitivity to change in foreign exchange rate hypothetical percent change in exchange rate primarily against the dollar applied to the fair value of our outstanding foreign currency derivative contract of december and would not have material impact on earnings cash flow or financial position over one year period this sensitivity analysis doe not consider the impact that hypothetical change in exchange rate would have on the underlying foreign currency denominated transaction our fair value risk exposure relates primarily to our public equity investment and to equity investment that do not have readily determinable fair value of december and our carrying value of these investment were billion and billion respectively hypothetical percent change in fair value of the equity instrument would have impacted other net income expense by million and million of december and respectively have no off balance sheet arrangement that have material current effect or that are reasonably likely to have material future effect on our financial condition change in financial condition revenue or expense result of operation liquidity capital expenditure or capital resource we acquire and collaborate on potential product still in development and enter into research and development arrangement with third party that often require milestone and royalty payment to the third party contingent upon the occurrence of certain future event linked to the success of the asset in development milestone payment may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product approval for marketing by the appropriate regulatory agency or upon the achievement of certain sale level if required by the arrangement we may make royalty payment based upon percentage of the sale of the product in the event that regulatory approval for marketing is obtained individually these arrangement are generally not material in any one annual reporting period however if milestone for multiple product covered by these arrangement were reached in the same reporting period the aggregate expense or aggregate milestone payment made could be material to our result of operation or cash flow respectively in that period see note to the consolidated financial statement for additional information these arrangement often give the discretion to unilaterally terminate development of the product which would allow to avoid making the contingent payment however we are unlikely to cease development if the compound successfully achieves milestone objective we view these payment positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flow from sale of product we expand our manufacturing capacity in order to meet existing and expected demand of our incretin product we have entered and expect to continue to enter into various agreement for contract manufacturing and for supply of material the executed agreement could under certain circumstance require to pay up to approximately billion if we do not purchase specified amount of good or service over the duration of the agreement which generally range from to year of critical accounting estimatesin preparing our financial statement in accordance with accounting principle generally accepted in the we must often make estimate and assumption that affect the reported amount of asset liability revenue expense and related disclosure some of those judgment can be subjective and complex and consequently actual result could differ from those estimate for any given individual estimate or assumption we make it is possible that other people applying reasonable judgment to the same fact and circumstance could develop different estimate we believe that given current fact and circumstance it is unlikely that applying any such other reasonable judgment would cause material adverse effect on our consolidated result of operation financial position or liquidity for the period presented in this report our most critical accounting estimate have been discussed with our audit committee and are described below revenue recognition and sale return rebate and discount accrualsbackground and uncertaintieswe recognize revenue primarily from two different type of contract product sale to customer net product revenue and collaboration and other arrangement for product sale to customer provision for return rebate and discount are established in the same period the related product sale are recognized to determine the appropriate transaction price for our product sale at the time we recognize sale to direct customer we estimate any rebate or discount that ultimately will be due to the direct customer and other customer in the distribution chain under the term of our contract significant judgment are required in making these estimate the largest of our sale rebate and discount amount include rebate associated with sale covered by managed care medicare medicaid and chargeback program well reduction in revenue related to our patient assistance program in the in determining the appropriate accrual amount we consider our historical rebate payment for these program well patient assistance program cost by product percentage of our historical sale well any significant change in sale trend patent expiry and product launch an evaluation of the current contract for these program the percentage of our product that are sold via these program and our product pricing refer to note to the consolidated financial statement for further information on revenue recognition and sale return rebate and discount accrual revenue recognized from collaboration and other arrangement will include our share of profit from the collaboration well royalty upfront and milestone payment we receive under these type of contract financial statement impactwe believe that our accrual for sale return rebate and discount are reasonable and appropriate based on current fact and circumstance our rebate and discount liability are included in sale rebate and discount on our consolidated balance sheet our sale return liability is included in other current liability and other noncurrent liability on our consolidated balance sheet of december percent change in our consolidated sale return rebate and discount liability would result in change in revenue of approximately million the portion of our consolidated sale return rebate and discount liability resulting from sale of our product in the wa approximately percent of december and the following represents roll forward of our most significant sale return rebate and discount liability balance including managed care medicare medicaid chargeback and patient assistance program dollar in million return rebate and discount liability beginning of year reduction of net sale cash payment sale return rebate and discount liability end of year adjustment of the estimate for these return rebate and discount to actual result were le than percent of consolidated revenue for each of the year presented increase in reduction of net sale in wa primarily driven by our incretin product due to increase in our patient assistance program and in volume of rebate for managed care medicare and medicaid program liability and other contingenciesbackground and uncertaintieslitigation liability and other contingency are by their nature uncertain and based upon complex judgment and probability the factor we consider in developing our litigation liability reserve and other contingent liability amount include the merit and jurisdiction of the litigation the nature and the number of other similar current and past matter the nature of the product and the current assessment of the science subject to the litigation applicable and the likelihood of settlement and current state of settlement discussion if any in addition we accrue for certain liability claim incurred but not filed to the extent we can formulate reasonable estimate of their cost based primarily on historical claim experience and data regarding product usage we also consider the insurance coverage we have to diminish the exposure for period covered by insurance in assessing our insurance coverage we consider the policy coverage limit and exclusion the potential for denial of coverage by the insurance company the financial condition of the insurer and the possibility of and length of time for collection due to very restrictive market for litigation liability insurance we are self insured for litigation liability loss for all our currently marketed product in addition to insurance coverage we consider any third party indemnification to which we are entitled or under which we are obligated with respect to our third party indemnification right these consideration include the nature of the indemnification the financial condition of the indemnifying party and the possibility of and length of time for collection the litigation accrual and environmental liability and the related estimated insurance recoverables have been reflected on gross basis liability and asset respectively on our consolidated balance sheet acquisitionsbackground and uncertaintiesto determine whether acquisition or licensing transaction should be accounted for business combination or an asset acquisition we make certain judgment which include assessing whether the acquired set of activity and asset would meet the definition of business under the relevant accounting rule if the acquired set of activity and asset meet the definition of business asset acquired and liability assumed are required to be recorded at their respective fair value on our consolidated balance sheet of the acquisition date the excess of the purchase price over the fair value of the acquired net asset where applicable is recorded goodwill if the acquired set of activity and asset doe not meet the definition of business the transaction is recorded an acquisition of asset and therefore any acquired ipr that doe not have an alternative future use is charged to acquired ipr and development milestone on our consolidated statement of operation at the acquisition date and goodwill is not recorded see note to the consolidated financial statement for additional information the judgment made in determining estimated fair value assigned to asset acquired and liability assumed in business combination well estimated asset life can materially affect our consolidated result of operation the fair value of intangible asset including acquired ipr are determined using information available near the acquisition date based on estimate and assumption that are deemed reasonable by management significant estimate and assumption include but are not limited to probability of technical success revenue projection and discount rate depending on the fact and circumstance we may deem it necessary to engage an independent valuation expert to assist in valuing significant asset and liability the fair value of identifiable intangible asset are primarily determined using an income method described in note to the consolidated financial statement the fair value of any contingent consideration liability that result from business combination is primarily determined using discounted cash flow analysis described in note to the consolidated financial statement estimating the fair value of contingent consideration requires the use of significant estimate and judgment including but not limited to probability of technical success and the discount rate financial statement impactas of december percent change in the contingent consideration liability would result in change in income before income tax of million of indefinite lived and long lived assetsbackground and uncertaintieswe review the carrying value of long lived asset both intangible and tangible for potential impairment on periodic basis and whenever event or change in circumstance indicate the carrying value of an asset or asset group may not be recoverable we identify impairment by comparing the projected undiscounted cash flow to be generated by the asset or asset group to it carrying value if an impairment is identified loss is recorded equal to the excess of the asset net book value over it fair value and the cost basis is adjusted goodwill and indefinite lived intangible asset are reviewed for impairment at least annually or more frequently if impairment indicator are present by first assessing qualitative factor to determine whether it is more likely than not that the fair value of the intangible asset is le than it carrying amount if we conclude it is more likely than not that the fair value is le than the carrying amount quantitative test that compare the fair value of the intangible asset to it carrying value is performed to determine the amount of any impairment several method may be used to determine the estimated fair value of acquired ipr all of which require multiple assumption we utilize the income method described in note to the consolidated financial statement for acquired ipr asset the risk of failure ha been factored into the fair value measure and there can be no certainty that these asset ultimately will yield successful product discussed previously in executive overview late stage pipeline the nature of the pharmaceutical business is high risk and requires that we invest in large number of project to maintain successful portfolio of approved product such it is likely that some acquired ipr asset will become impaired in the future estimate of future cash flow based on we believe to be reasonable and supportable assumption and projection require management judgment actual result could vary materially from these estimate retirement benefit assumptionsbackground and uncertaintiesdefined benefit pension plan and retiree health benefit plan cost include assumption for the discount rate expected return on plan asset and retirement age these assumption have significant effect on the amount reported in addition to the analysis below see note to the consolidated financial statement for additional information regarding our retirement benefit annually we evaluate the discount rate and the expected return on plan asset in our defined benefit pension and retiree health benefit plan we use an actuarially determined plan specific yield curve of high quality fixed income debt instrument to determine the discount rate in evaluating the expected return on plan asset we consider many factor with primary analysis of current and projected market condition asset return and asset allocation approximately percent of which are growth investment and the view of leading financial adviser and economist we may also review our historical assumption compared with actual result well the discount rate and expected return on plan asset of other company where applicable in evaluating our expected retirement age assumption we consider the retirement age of our past employee eligible for pension and medical benefit together with our expectation of future retirement age annually we determine the fair value of the plan asset in our defined benefit pension and retiree health benefit plan approximately percent of our plan asset are in hedge fund and private equity like investment fund collectively alternative asset we value these alternative investment using significant unobservable input or using the net asset value reported by the counterparty adjusted necessary input include underlying net asset value discounted cash flow valuation comparable market valuation and adjustment for currency credit liquidity and other risk statement impactif the discount rate for the defined benefit pension and retiree health benefit plan plan were to change by quarter percentage point income before income tax would change by million if the expected return on plan asset for plan were to change by quarter percentage point income before income tax would change by million if our assumption regarding the expected age of future retiree for plan were adjusted by one year our income before income tax would be affected by million the plan including puerto rico represent approximately percent of each of the total projected benefit obligation and total plan asset at december adjustment to the fair value of plan asset are not recognized in pension and retiree health benefit expense in the year that the adjustment occur such change are deferred along with other actuarial gain and loss and are amortized into expense over the expected remaining service life of employee income taxesbackground and uncertaintieswe file tax return based upon our interpretation of tax law and regulation and we record estimate in our financial statement based upon these interpretation at the applicable tax rate in the jurisdiction in which we operate our tax return are routinely subject to examination by taxing authority which could result in future tax interest and penalty assessment inherent uncertainty also exist in estimate of many tax position due to the complexity of tax law we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authority based on the technical merit of the position the tax benefit recognized in the financial statement from such position are measured based on the largest benefit that ha greater than percent likelihood of being realized upon ultimate resolution the amount of unrecognized tax benefit is adjusted for change in fact and circumstance such change to existing tax law the issuance of regulation by taxing authority new information obtained during tax examination or resolution of tax examination we believe our estimate for uncertain tax position are both appropriate and sufficient to pay assessment that may result from examination of our tax return we recognize both accrued interest and penalty related to unrecognized tax benefit in income tax expense we have recorded valuation allowance against certain of our deferred tax asset primarily those that have been generated from net operating loss tax credit and other tax carryforwards and carrybacks in certain taxing jurisdiction in evaluating whether we would more likely than not recover these deferred tax asset we have not assumed future taxable income in the jurisdiction associated with these carryforwards where history doe not support such an assumption implementation of tax planning strategy to recover these deferred tax asset or to generate future taxable income in these jurisdiction could lead to the reversal of all or portion of these valuation allowance and reduction of income tax expense financial statement impactas of december percent change in the amount of uncertain tax position and the valuation allowance would result in change in net income of million and million respectively legal and regulatory matter information relating to certain legal proceeding can be found in note to the consolidated financial statement and is incorporated by reference item quantitative and qualitative disclosure about market riskyou can find quantitative and qualitative disclosure about market risk interest rate risk at item management discussion and analysis financial condition and liquidity that information is incorporated by reference herein financial statement and supplementary dataconsolidated statement of operationseli lilly and company and subsidiary dollar in million and share in thousand except per share data year ended december note cost expense and other cost of research and marketing selling and acquired in process research and development and development milestone note asset impairment restructuring and other special charge note other net income expense note income before income income tax note net income earnings per share basic diluted share used in calculation of earnings per share see note to consolidated financial statement statement of comprehensive income loss eli lilly and company and subsidiary dollar in million year ended december income other comprehensive income loss change in foreign currency translation gain loss change in net unrealized gain loss on security change in defined benefit pension and retiree health benefit plan note change in effective portion of cash flow other comprehensive income loss before income benefit provision for income tax related to other comprehensive income loss other comprehensive income net of tax note comprehensive income see note to consolidated financial statement balance sheetseli lilly and company and subsidiary dollar in million share in thousand december assetscash and cash equivalent note short term investment note account receivable net of allowance of and other inventory note prepaid expense and other current total current investment note goodwill note other intangible net note deferred tax asset note property and equipment net note other noncurrent total asset liability and equitycurrent liabilitiesshort term borrowing and current maturity of long term debt note account employee sale rebate and dividend income tax payable note other current total current other liabilitieslong term debt note accrued retirement benefit note long term income tax payable note deferred tax liability note other noncurrent total other commitment and contingency note eli lilly and company shareholder equity note and common stock no par valueauthorized share share and additional paid in retained employee benefit trust accumulated other comprehensive loss note cost of common stock in treasury total eli lilly and company shareholder noncontrolling total total liability and equity see note to consolidated financial statement statement of shareholder equity equity of eli lilly and company shareholderseli lilly and company and subsidiary dollar in million except per share data and share in thousand common stockadditionalpaid incapitalretainedearningsemployee benefit trustaccumulated other comprehensive losscommon stock in treasurynoncontrolling interestsharesamountsharesamountbalance at january net other comprehensive income net of cash dividend declared per share retirement of treasury share purchase of treasury issuance of stock under employee stock plan stock based other balance at december net income other comprehensive income net of cash dividend declared per share retirement of treasury share purchase of treasury issuance of stock under employee stock plan stock based other balance at december net income loss other comprehensive income net of cash dividend declared per share retirement of treasury share purchase of treasury issuance of stock under employee stock plan stock based balance at december see note to consolidated financial statement statement of cash flowseli lilly and company and subsidiary dollar in million year ended december flow from operating activitiesnet income adjustment to reconcile net income to cash flow from operating activity depreciation and debt extinguishment loss note change in deferred income tax stock based compensation net investment gain acquired in process research and development note other non cash operating activity other change in operating asset and liability net of acquisition and divestiture receivables increase decrease inventory increase decrease other asset increase decrease income tax payable increase decrease account payable and other liability increase decrease net cash provided by operating cash flow from investing activitiespurchases of property and equipment proceeds from sale and maturity of short term purchase of short term investment proceeds from sale of noncurrent purchase of noncurrent investment purchase of in process research and development cash paid for acquisition net of cash acquired note other investing activity net net cash used for investing activity cash flow from financing activitiesdividends paid net change in short term proceeds from issuance of long term debt repayment of long term debt purchase of common stock other financing activity net net cash used for financing activity effect of exchange rate change on cash and cash equivalent net increase decrease in cash and cash equivalent cash and cash equivalent at beginning of cash and cash equivalent at end of year see note to consolidated financial statement to consolidated financial statementseli lilly and company and subsidiary table present dollar in million except per share data note summary of significant accounting policy and implementation of new financial accounting standardsbasis of presentationthe accompanying consolidated financial statement include eli lilly and company and all subsidiary and have been prepared in accordance with accounting principle generally accepted in the united state gaap we consider majority voting interest well effective economic or other control over an entity when deciding whether or not to consolidate an entity we generally do not have control by mean other than voting interest where our ownership of consolidated subsidiary is le than percent the noncontrolling shareholder interest are reflected separate component of equity all intercompany balance and transaction have been eliminated the preparation of financial statement in conformity with gaap requires management to make estimate and assumption that affect the reported amount of asset liability revenue expense and related disclosure at the date of the financial statement and during the reporting period actual result could differ from those estimate we issued our financial statement by filing with the security and exchange commission sec and have evaluated subsequent event up to the time of the filing of this annual report on form certain reclassification have been made to prior period in the consolidated financial statement and accompanying note to conform with the current presentation we operate single operating segment engaged in the discovery development manufacturing marketing and sale of pharmaceutical product worldwide global research and development organization and supply chain organization are responsible for the discovery development manufacturing and supply of our product regional commercial organization market distribute and sell the product the business is also supported by global corporate staff function our determination that we operate single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purpose of evaluating performance allocating resource setting incentive compensation target and planning and forecasting for future period research and development expense and acquired in process research and development ipr and development milestonesresearch and development cost are expensed incurred research and development cost consist of expense incurred in performing research and development activity including but not limited to compensation and benefit facility and overhead expense clinical trial expense and fee paid to contract research organization acquired ipr and development milestone include the initial cost of externally developed ipr project acquired directly in transaction other than business combination that do not have an alternative future use additionally milestone payment obligation related to these transaction that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs earnings per share eps all per share amount unless otherwise noted in the footnote are presented on diluted basis we calculate basic eps based on the weighted average number of common share outstanding plus the effect of incremental share from potential participating security we calculate diluted eps based on the weighted average number of common share outstanding plus the effect of incremental share from our stock based compensation program currency translationoperations in our subsidiary outside the united state are recorded in the functional currency of each subsidiary which is determined by review of the environment where each subsidiary primarily generates and expends cash the result of operation for our subsidiary outside the are translated from functional currency into dollar using the weighted average currency rate for the period asset and liability are translated using the period end exchange rate the dollar effect that arise from translating the net asset of these subsidiary are recorded in other comprehensive income loss advertising expensescosts associated with advertising are expensed incurred and are included in marketing selling and administrative expense advertising expense comprised primarily of television radio print medium and internet advertising totaled approximately billion billion and billion in and respectively which wa le than percent of revenue each year other significant accounting policiesour other significant accounting policy are described in the remaining appropriate note to the consolidated financial statement implementation of new financial accounting standardsaccounting standard update asu government assistance establishes annual disclosure requirement for company that analogize to grant or contribution accounting model for government assistance transaction we adopted the standard of january the adoption did not impact our financial statement disclosure asu reference rate reform further modified by asu and asu provides for temporary optional expedient and exception in applying current gaap to contract hedging relationship and other transaction affected by the transition from the use of the london interbank offered rate libor to an alternative reference rate the standard is currently applicable to contract entered into before january we adopted the standard in the first quarter of the adoption did not have material impact on our consolidated financial statement note revenuethe following table summarizes our revenue recognized in our consolidated statement of operation product revenue collaboration and other revenue revenue collaboration and other revenue associated with prior period transfer of intellectual property wa million million and million during the year ended december and respectively we recognize revenue primarily from two different type of contract product sale to customer net product revenue and collaboration and other arrangement revenue recognized from collaboration and other arrangement includes our share of profit from the collaboration well royalty upfront and milestone payment we receive under these type of contract see note for additional information related to our collaboration and other arrangement collaboration and other revenue disclosed above includes the revenue from the jardiance and trajenta family of product resulting from our collaboration with boehringer ingelheim discussed in note substantially all of the remainder of collaboration and other revenue is related to contract accounted for contract with customer product revenuerevenue from sale of product is recognized at the point where the customer obtains control of the good and we satisfy our performance obligation which generally is at the time we ship the product to the customer payment term differ by jurisdiction and customer but payment term in most of our major jurisdiction typically range from to day from date of shipment revenue for our product sale ha not been adjusted for the effect of financing component we expect at contract inception that the period between when we transfer control of the product and when we receive payment will be one year or le any exception are either not material or we collect interest for payment made after the due date provision for rebate discount and return are established in the same period the related product sale are recognized we generally ship product shortly after order are received therefore we generally only have few day of order received but not yet shipped at the end of any reporting period shipping and handling activity are considered to be fulfillment activity and are not considered to be separate performance obligation we exclude from the measurement of the transaction price all tax assessed by governmental authority that are imposed on our sale of product and collected from customer most of our product are sold to wholesaler that serve pharmacy physician and other healthcare professional and hospital for the year ended december and our three largest wholesaler each accounted for between percent and percent of consolidated revenue further they each accounted for between percent and percent of account receivable of december and significant judgment must be made in determining the transaction price for our sale of product related to anticipated rebate discount and return the following describe the most significant of these judgment sale rebate and discount background and uncertainty we initially invoice our customer at contractual list price contract with direct and indirect customer may provide for various rebate and discount that may differ in each contract consequence to determine the appropriate transaction price for our product sale at the time we recognize sale to direct customer we estimate any rebate or discount that ultimately will be due to the direct customer and other customer in the distribution chain under the term of our contract significant judgment are required in making these estimate the rebate and discount amount are recorded deduction to arrive at our net product revenue sale rebate and discount that require the use of judgment in the establishment of the accrual include managed care medicare medicaid chargebacks long term care hospital patient assistance program and various other program we estimate these accrual using an expected value approach the largest of our sale rebate and discount amount include rebate associated with sale covered by managed care medicare medicaid and chargeback program well reduction in revenue related to our patient assistance program in the in determining the appropriate accrual amount we consider our historical rebate payment for these program well patient assistance program cost by product percentage of our historical sale well any significant change in sale trend patent expiry and product launch an evaluation of the current contract for these program the percentage of our product that are sold via these program and our product pricing although we accrue liability for revenue reduction related to these program at the time we record the sale the reduction related to that sale is typically paid up to six month later because of this time lag in any particular period our net product revenue may incorporate revision of accrual for several period most of our rebate outside the are contractual or legislatively mandated and are estimated and recognized in the same period the related sale in some large european country government rebate are based on the anticipated budget for pharmaceutical payment in the country an estimate of these rebate updated governmental authority revise budgeted deficit is recognized in the same period the related sale return background and uncertainty when product sale occur to determine the appropriate transaction price for our sale we estimate reserve for future product return related to those sale using an expected value approach this estimate is based on several factor including historical return rate expiration date by product on average approximately month after the initial sale of product to our customer and estimated level of inventory in the wholesale and retail channel well any other specifically identified anticipated return due to known factor such the loss of patent exclusivity product recall and discontinuation or changing competitive environment we maintain return policy that allows most customer to return most of our product for dating issue within specified period prior to and subsequent to the product expiration date following the loss of exclusivity for patent dependent product we expect to experience an elevated level of product return product inventory remaining in the wholesale and retail channel expires adjustment to the return reserve have been and may in the future be required based on revised estimate to our assumption we record the return amount deduction to arrive at our net product revenue once the product is returned it is destroyed we do not record right of return asset our return policy outside the are generally more restrictive than in the return are not allowed for reason other than failure to meet product specification in many country our reserve for future product return for product sale outside the is not material part of our process to estimate reserve for product return we regularly review the supply level of our significant product at the major wholesaler in the and in major market outside the primarily by reviewing periodic inventory report supplied by our major wholesaler and available prescription volume information for our product or alternative approach we attempt to maintain wholesaler inventory level at an average of approximately one month or le on consistent basis across our product portfolio cause of unusual wholesaler buying pattern include actual or anticipated product supply issue weather pattern anticipated change in the transportation network redundant holiday stocking and change in wholesaler business operation in the the current structure of our arrangement provides with data on inventory level at our wholesaler however our data on inventory level in the retail channel is more limited wholesaler stocking and destocking activity historically ha not caused any material change in the rate of actual product return actual product return have been le than percent of our revenue during each of the past three year and have not fluctuated significantly percentage of revenue although fluctuation are more likely in period following loss of patent exclusivity for major product in the market adjustment to revenueadjustments to increase revenue recognized result of change in estimate for our most significant sale return rebate and discount liability balance for product shipped in previous period were le than percent of revenue during each of the year ended december and collaboration and other arrangementswe recognize several type of revenue from our collaboration and other arrangement which we discus in general term immediately below and more specifically in note for each of our material collaboration and other arrangement our collaboration and other arrangement are not contract with customer but are evaluated to determine whether any aspect of the arrangement are contract with customer revenue related to product we sell pursuant to these arrangement is included in net product revenue while other source of revenue royalty and profit sharing from our partner are included in collaboration and other revenue profit sharing due from our collaboration partner which is based upon gross margin reported to by our partner is recognized collaboration and other revenue earned royalty revenue from licensee and certain of our collaboration partner which is based on sale to third party of licensed product and technology is recorded when the third party sale occurs and the performance obligation to which some or all of the royalty ha been allocated ha been satisfied or partially satisfied this royalty revenue is included in collaboration and other revenue for arrangement involving multiple good or service research and development marketing and selling manufacturing and distribution each required good or service is evaluated to determine whether it is distinct if good or service doe not qualify distinct it is combined with the other non distinct good or service within the arrangement and these combined good or service are treated single performance obligation for accounting purpose the arrangement transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation for arrangement that involve variable consideration where we have sold intellectual property we recognize revenue based on estimate of the amount of consideration we believe we will be entitled to receive from the other party subject to constraint these estimate are adjusted to reflect the actual amount to be collected when those fact and circumstance become known significant judgment must be made in determining the transaction price for our sale of intellectual property because of the risk that product in development will not receive regulatory approval we generally do not recognize any contingent payment that would be due to upon or after regulatory approval contract liabilitiesour contract liability result from arrangement where we have received payment in advance of performance under the contract and do not include sale return rebate and discount change in contract liability are generally due to either receipt of additional advance payment or our performance under the contract the following table summarizes contract liability balance liability the contract liability balance disclosed above of december and were primarily related to the remaining license period of symbolic intellectual property and obligation to perform research and development activity or supply product for defined period of time during the year ended december and revenue recognized from contract liability of the beginning of the respective year wa not material revenue expected to be recognized in the future from contract liability the related performance obligation are satisfied is not expected to be material in any one year of revenue the following table summarizes revenue by product outside to unaffiliated customer diabetes trulicity jardiance humalog humulin basaglar mounjaro other total oncology verzenio cyramza alimta erbitux tyvyt other total immunology taltz olumiant other total neuroscience emgality zyprexa cymbalta other total other covid antibody forteo cialis total revenue number may not add due to rounding jardiance revenue includes glyxambi synjardy and trijardy xr humalog revenue includes insulin lispro olumiant revenue includes sale for baricitinib that were made pursuant to emergency use authorization eua or similar regulatory authorization covid antibody include sale for bamlanivimab administered alone for bamlanivimab and etesevimab administered together and for bebtelovimab and were made pursuant to euas or similar regulatory authorization following table summarizes revenue by geographical area to unaffiliated customer other foreign revenue number may not add due to rounding revenue is attributed to the country based on the location of the customer note acquisitionswe engage in various form of business development activity to enhance our product pipeline including acquisition collaboration investment and licensing arrangement in connection with these arrangement our partner may be entitled to future royalty and or commercial milestone based on sale should product be approved for commercialization and or milestone based on the successful progress of compound through the development process in december january and february we completed the acquisition of akouos inc akouos prevail therapeutic inc prevail and dermira inc dermira respectively these transaction further discussed below in acquisition of business were accounted for business combination under the acquisition method of accounting under this method the asset acquired and liability assumed were recorded at their respective fair value of the acquisition date in our consolidated financial statement the determination of estimated fair value required management to make significant estimate and assumption the excess of the purchase price over the fair value of the acquired net asset where applicable ha been recorded goodwill the result of operation of these acquisition have been included in our consolidated financial statement from the date of acquisition we also acquired asset in development in and which are further discussed below in asset acquisition upon each acquisition the cost allocated to acquired ipr wa immediately expensed if the compound ha no alternative future use milestone payment obligation incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs we recognized acquired ipr and development milestone charge of million million and million for the year ended december and respectively acquisition of businessesakouos acquisitionoverview of transactionin december we acquired all share of akouos for purchase price that included per share in cash or an aggregate of million net of cash acquired plus one non tradable contingent value right cvr per share the cvr entitles the akouos shareholder up to an additional per share in cash or an aggregate of approximately million payable subject to certain term and condition upon the achievement of certain specified milestone under the term of the agreement we acquired potential gene therapy treatment for hearing loss and other inner ear condition the lead gene therapy in clinical development that we acquired included which encodes connexin for common form of monogenic deafness and hearing loss ak otof for hearing loss due to mutation in the otoferlin gene ak for usher type an autosomal recessive disorder characterized by progressive loss of both hearing and vision and ak antivegf for vestibular schwannoma acquired and liability assumedour access to akouos information wa limited prior to the acquisition consequence we are in the process of determining fair value and tax base of significant portion of the asset acquired and liability assumed including the identification and valuation of intangible asset and tax exposure the final determination of these amount will be completed soon possible but no later than one year from the acquisition date the final determination may result in asset and liability fair value and tax base that differ from the preliminary estimate and require change to the preliminary amount recognized the following table summarizes the preliminary amount recognized for asset acquired and liability assumed of the acquisition date estimated fair value at december acquired ipr asset and liability acquisition date fair value of consideration transferred cash acquired fair value of cvr liability cash paid net of cash acquired acquired ipr intangible primarily relate to the goodwill recognized from this acquisition is attributable primarily to future unidentified project and product and the assembled workforce for akouos and is not deductible for tax purpose see note for discussion on the estimation of the cvr liability the result of operation attributable to akouos for the year ended december were immaterial pro forma information ha not been included this acquisition did not have material impact on our consolidated statement of operation for the year ended december and prevail acquisitionoverview of transactionin january we acquired all share of prevail for purchase price that included per share in cash or an aggregate of million net of cash acquired plus one non tradable cvr per share the cvr entitles prevail stockholder up to an additional per share in cash or an aggregate of approximately million payable subject to certain term and condition upon the first regulatory approval of prevail product in one of the following country japan united kingdom germany france italy or spain to achieve the full value of the cvr such regulatory approval must occur by december if such regulatory approval occurs after december the value of the cvr will be reduced by approximately cent per month until december at which point the cvr will expire without payment under the term of the agreement we acquired potentially disease modifying based gene therapy for patient with neurodegenerative disease the acquisition established new modality for drug discovery and development extending our research effort through the creation of gene therapy program that is being anchored by prevail portfolio of asset the lead gene therapy in clinical development that we acquired were for patient with parkinson disease with mutation and neuronopathic gaucher disease and for patient with frontotemporal dementia with grn mutation both and were granted fast track designation from the food and drug administration fda acquired and liability assumedthe following table summarizes the amount recognized for asset acquired and liability assumed of the acquisition date estimated fair value at january acquired ipr tax liability other asset and liability net acquisition date fair value of consideration transferred cash acquired fair value of cvr liability cash paid net of cash acquired acquired ipr intangible primarily relate to in the third quarter of we impaired the intangible asset related to see note for additional information the goodwill recognized from this acquisition is not deductible for tax purpose see note for discussion on the estimation of the cvr liability the result of operation attributable to prevail for the year ended december and were immaterial pro forma information ha not been included this acquisition did not have material impact on our consolidated statement of operation for the year ended december and dermira acquisitionoverview of transactionin february we acquired all share of dermira for purchase price of approximately million net of cash acquired under term of the agreement we acquired lebrikizumab novel investigational monoclonal antibody being evaluated for the treatment of moderate to severe atopic dermatitis we also acquired qbrexza glycopyrronium cloth medicated cloth approved by the fda for the topical treatment of primary axillary hyperhidrosis uncontrolled excessive underarm sweating during the year ended december we sold the right to qbrexza see note for additional information asset acquired and liability assumedthe fair value recognized related to the asset acquired and liability assumed in this acquisition included goodwill of million other intangible of billion primarily related to lebrikizumab deferred income tax liability of million and long term debt of million after the acquisition we repaid million of long term debt assumed part of our acquisition of dermira revenue attributable to asset acquired in the dermira acquisition did not have material impact on our consolidated statement of operation for the year ended december and we are unable to provide the result of operation for the year ended december and attributable to dermira those operation were substantially integrated into our legacy business pro forma information ha not been included because this acquisition did not have material impact on our consolidated statement of operation for the year ended december acquisitionsthe following table summarizes our significant asset acquisition during and counterpartycompound therapy or assetacquisition monthphase of development acquired ipr expensebiomarin pharmaceutical inc priority review voucherfebruary applicable foghorn therapeutic inc pre clinical target that could lead to potential new oncology medicinesdecember rigel pharmaceutical inc receptor interacting serine threonine protein kinase inhibitor for the potential treatment of autoimmune and inflammatory diseasesmarch precision bioscience inc potential in vivo therapy for genetic disordersjanuary innovent biologics inc innovent sintilimab injection an anti pd monoclonal antibody immuno oncology medicine for geography outside of china october petra pharma corporation petra mutant selective inhibitor that could lead to potential new medicinemay disarm therapeutic inc disease modifying therapeutic program for patient with axonal degenerationoctober the phase of development presented is of the date of the arrangement and represents the phase of development of the most advanced asset acquired where applicable in we terminated our license for sintilimab injection for geography outside of china and reverted right to innovent in connection with our acquisition of petra we were required to make milestone payment to petra shareholder contingent upon the occurrence of certain future event linked to the success of the mutant selective inhibitor in we entered into agreement with substantially all petra shareholder to acquire their right to receive any future milestone payment in exchange for one time payment result of these agreement we recognized charge of million development milestone in any remaining contingent milestone payment linked to the success of the mutant selective are not expected to be material we did not recognize other significant development milestone during the year ended december and note collaboration and other arrangementswe often enter into collaborative and other similar arrangement to develop and commercialize drug candidate collaborative activity may include research and development marketing and selling including promotional activity and physician detailing manufacturing and distribution these arrangement often require milestone well royalty or profit share payment contingent upon the occurrence of certain future event linked to the success of the asset in development well expense reimbursement from or payment to the collaboration partner see note for amount of collaboration and other revenue recognized from these type of arrangement operating expense for cost incurred pursuant to these arrangement are reported in their respective expense line item net of any payment due to or reimbursement due from our collaboration partner with such reimbursement being recognized at the time the party becomes obligated to pay each collaboration is unique in nature and our more significant arrangement are discussed below ingelheim diabetes collaborationwe and boehringer ingelheim have global agreement to jointly develop and commercialize portfolio of diabetes compound currently included in the collaboration are boehringer ingelheim oral diabetes product jardiance glyxambi synjardy trijardy xr trajenta and jentadueto well our basal insulin basaglar glyxambi synjardy and trijardy xr are included in the jardiance product family jentadueto is included in the trajenta product family in connection with the regulatory approval of jardiance trajenta and basaglar in the europe and japan milestone payment made for jardiance and trajenta were capitalized intangible asset and are being amortized to cost of sale and milestone payment received for basaglar were recorded contract liability and are being amortized to collaboration and other revenue the milestone pertaining to jardiance and trajenta are being amortized through their respective term under the collaboration which depending on country or region is determined based on the latest to occur of defined number of year following launch date the expiration of the compound patent or the expiration of marketing authorization exclusivity the milestone pertaining to basaglar are being amortized through the table below summarizes the net milestone capitalized with respect to the jardiance and trajenta family of product and the net milestone deferred with respect to basaglar of december net milestone capitalized deferred basaglar this represents the amount that have been capitalized deferred from the start of this collaboration through the end of the reporting period net of amount amortized for the jardiance product family we and boehringer ingelheim share equally the ongoing development and commercialization cost in the most significant market and we record our portion of the development and commercialization cost research and development expense and marketing selling and administrative expense respectively we receive royalty on net sale of boehringer ingelheim product in the most significant market and recognize the royalty collaboration and other revenue boehringer ingelheim is entitled to potential performance payment depending on the net sale of the jardiance product family therefore our reported revenue for jardiance may be reduced by any potential performance payment we make related to this product family the royalty received by related to the jardiance product family may also be increased or decreased depending on whether net sale for this product family exceed or fall below certain threshold we pay to boehringer ingelheim royalty on net sale for basaglar in the we record our sale of basaglar to third party net product revenue with the royalty payment made to boehringer ingelheim recorded cost of sale the following table summarizes our collaboration and other revenue recognized with respect to the jardiance and trajenta family of product and net product revenue recognized with respect to basaglar olumiantwe have worldwide license and collaboration agreement with incyte corporation incyte which provides the development and commercialization right to baricitinib which is branded and trademarked olumiant and certain follow on compound for the treatment of inflammatory and autoimmune disease and covid incyte ha the right to receive tiered double digit royalty payment on worldwide net sale with rate ranging up to percent incyte ha the right to receive an additional royalty ranging up to the low teen on worldwide net sale for the treatment of covid that exceed specified aggregate worldwide net sale threshold the agreement call for payment by to incyte associated with certain development success based regulatory and sale based milestone connection with the regulatory approval of olumiant in the europe and japan well achievement of sale based milestone milestone payment of million and million were capitalized intangible asset of december and respectively and are being amortized to cost of sale through the term of the collaboration this represents the cumulative amount that have been capitalized from the start of this collaboration through the end of each reporting period of december incyte is eligible to receive up to million of additional payment from in potential sale based milestone we record our sale of olumiant including sale of baricitinib that were made pursuant to eua or similar regulatory authorization to third party net product revenue with the royalty payment made to incyte recorded cost of sale the following table summarizes our net product revenue recognized with respect to olumiant covid antibodieswe have worldwide license and collaboration agreement with abcellera biologics inc abcellera to co develop therapeutic antibody for the potential prevention and treatment of covid including bamlanivimab and bebtelovimab for which we hold development and commercialization right abcellera ha the right to receive tiered royalty payment on worldwide net sale of bamlanivimab and bebtelovimab with percentage ranging in the mid teen to mid twenty royalty payment made to abcellera are recorded cost of sale we have license and collaboration agreement with shanghai junshi bioscience co ltd junshi bioscience to co develop therapeutic antibody for the potential prevention and treatment of covid including etesevimab for which we hold development and commercialization right outside of mainland china and the special administrative region of hong kong and macau junshi bioscience received royalty payment in the mid teen on our net sale of etesevimab pursuant to euas or similar regulatory authorization we recognized billion billion and million of net product revenue associated with our sale of our covid antibody during the year ended december and respectively tyvytwe have collaboration agreement with innovent to jointly develop and commercialize sintilimab injection in china where it is branded and trademarked tyvyt we record our sale of tyvyt to third party net product revenue with payment made to innovent for it portion of the gross margin reported cost of sale we report collaboration and other revenue our portion of the gross margin for tyvyt sale made by innovent to third party the following table summarizes our revenue recognized in china with respect to tyvyt lebrikizumabwe have worldwide license agreement with hoffmann la roche ltd and genentech inc collectively roche which provides the worldwide development and commercialization right to lebrikizumab roche ha the right to receive tiered royalty payment on future worldwide net sale ranging in percentage from high single digit to high teen if the product is successfully commercialized of december roche is eligible to receive up to million of additional payment from contingent upon the achievement of success based regulatory milestone and up to billion in series of sale based milestone contingent upon the commercial success of lebrikizumab during the year ended december milestone payment to roche were not material have license agreement with almirall almirall under which almirall licensed the right to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indication including but not limited to atopic dermatitis in europe we have the right to receive tiered royalty payment on future net sale in europe ranging in percentage from low double digit to low twenty if the product is successfully commercialized of december we are eligible to receive additional payment of million from almirall contingent upon the achievement of success based regulatory milestone and up to billion in series of sale based milestone contingent upon the commercial success of lebrikizumab there were no remaining contract liability of december of december and contract liability were not material during the year ended december and collaboration and other revenue recognized wa not material note asset impairment restructuring and other special chargesthe component of the charge included in asset impairment restructuring and other special charge in our consolidated statement of operation are described below impairment gain and other special charge total asset impairment restructuring and other special charge asset impairment restructuring and other special charge recognized during the year ended december were primarily related to an intangible asset impairment for gene therapy acquired in the prevail acquisition result of change in key assumption used in the valuation due to delay in estimated launch timing during the year ended december we recognized million of intangible asset impairment result of the decision by bayer ag to discontinue the development of phase molecule related to contract based intangible asset from our acquisition of loxo oncology inc additionally we recognized million of intangible asset impairment from the sale of the right to qbrexza well acquisition and integration cost associated with the acquisition of prevail severance cost recognized during the year ended december were incurred result of action taken worldwide to reduce our cost structure inventorieswe use the last in first out lifo method for the majority of our inventory located in the continental other inventory are valued by the first in first out fifo method fifo cost approximates current replacement cost inventory measured using lifo must be valued at the lower of cost or market inventory measured using fifo must be valued at the lower of cost or net realizable value inventory at december consisted of the following product work in raw material and total approximates replacement cost increase to lifo inventory inventory valued under the lifo method comprised billion and billion of total inventory at december and respectively we recognized net inventory impairment charge related to our covid antibody of million during the year ended december in cost of sale in our consolidated statement of operation part of our response to the covid pandemic and at the request of the and international government we invested in large scale manufacturing of covid antibody at risk in order to ensure rapid access to patient around the world the covid pandemic evolved during we incurred net inventory impairment charge primarily due to the combination of change to demand from and international government including change to our agreement with the government and near term expiry date of covid antibody note financial instrumentsinvestments in equity and debt securitiesour equity investment are accounted for using three different method depending on the type of equity investment investment in company over which we have significant influence but not controlling interest are accounted for using the equity method with our share of earnings or loss reported in other net income expense for equity investment that do not have readily determinable fair value we measure these investment at cost le any impairment plus or minus change resulting from observable price change in orderly transaction for the identical or similar investment of the same issuer any change in recorded value is recorded in other net income expense our public equity investment are measured and carried at fair value any change in fair value is recognized in other net income expense we adjust our equity investment without readily determinable fair value based upon change in the equity instrument value resulting from observable price change in orderly transaction for an identical or similar investment of the same issuer downward adjustment resulting from an impairment are recorded based upon impairment consideration including the financial condition and near term prospect of the issuer general market condition and industry specific factor adjustment recorded for the year ended december and were not material the net gain loss recognized in our consolidated statement of operation for equity security were million million and billion for the year ended december and respectively the net gain loss recognized for the year ended december and on equity security sold during the respective period were not material of december we had approximately million of unfunded commitment to invest in venture capital fund which we anticipate will be paid over period of up to year we record our available for sale debt security at fair value with change in fair value reported component of accumulated other comprehensive income loss we periodically ass our investment in available for sale security for impairment loss and credit loss the amount of credit loss are determined by comparing the difference between the present value of future cash flow expected to be collected on these security and the amortized cost factor considered in assessing credit loss include the position in the capital structure vintage and amount of collateral delinquency rate current credit support and geographic concentration impairment and credit loss related to available for sale security were not material for the year ended december and the table below summarizes the contractual maturity of our investment in debt security measured at fair value of december maturity by periodtotalless than yearsfair value of debt security summary of the amount of unrealized gain and loss in accumulated other comprehensive loss and the fair value of available for sale security in an unrealized gain or loss position follows gross gain unrealized gross fair value of security in an unrealized gain fair value of security in an unrealized loss of december the available for sale security in an unrealized loss position include primarily fixed rate debt security of varying maturity which are sensitive to change in the yield curve and other market condition approximately percent of the fixed rate debt security in loss position are investment grade debt security of december we do not intend to sell and it is not more likely than not that we will be required to sell the security in loss position before the market value recover or the underlying cash flow have been received and there is no indication of material default on interest or principal payment for our debt security activity related to our available for sale security wa follows from sale realized gross gain on realized gross loss on realized gain and loss on sale of available for sale investment are computed based upon specific identification of the initial cost adjusted for any other than temporary decline in fair value that were recorded in earnings value of investmentsthe following table summarizes certain fair value information at december and for investment asset measured at fair value on recurring basis well the carrying amount and amortized cost of certain other investment fair value measurement using carryingamountcost quoted price in active market for identical asset level significantotherobservableinputs level significantunobservableinputs level fairvaluedecember equivalent short term investment government and agency security corporate debt asset backed other short term investment noncurrent investment government and agency security corporate debt mortgage backed asset backed other marketable equity equity investment without readily determinable fair value equity method investment noncurrent investment december equivalent short term investment government and agency security corporate debt mortgage backed asset backed other short term investment noncurrent investment government and agency security corporate debt mortgage backed asset backed other marketable equity equity investment without readily determinable fair value equity method investment noncurrent investment for available for sale debt security amount disclosed represent the security amortized cost we consider all highly liquid investment with maturity of three month or le from the date of purchase to be cash equivalent the cost of these investment approximates fair value fair value disclosure are not applicable for equity method investment and investment accounted for under the measurement alternative for equity investment determine our level and level fair value measurement based on market approach using quoted market value significant other observable input for identical or comparable asset or liability or discounted cash flow analysis level fair value measurement for other investment security are determined using unobservable input including the investment cost adjusted for impairment and price change from orderly transaction fair value are not readily available for certain equity investment measured under the measurement alternative fair value of debtthe following table summarizes certain fair value information at december and for our short term and long term debt fair value measurement using carryingamountquoted price in active market for identical asset level significantotherobservableinputs level significantunobservableinputs level fairvalueshort term commercial paper borrowingsdecember december long term debt including current portiondecember december risk management and related financial instrumentsfinancial instrument that potentially subject to credit risk consist principally of trade receivables and interest bearing investment wholesale distributor of life science product account for substantial portion of our trade receivables collateral is generally not required we seek to mitigate the risk associated with this concentration through our ongoing credit review procedure and insurance large portion of our cash is held by few major financial institution we monitor our exposure with these institution and do not expect any of these institution to fail to meet their obligation in accordance with documented corporate risk management policy we monitor the amount of credit exposure to any one financial institution or corporate issuer we are exposed to credit related loss in the event of nonperformance by counterparties to risk management instrument but do not expect any counterparties to fail to meet their obligation given their investment grade credit rating we have entered into account receivable factoring agreement with financial institution to sell certain of our non account receivable these transaction are accounted for sale and result in reduction in account receivable because the agreement transfer effective control over and risk related to the receivables to the buyer our factoring agreement do not allow for recourse in the event of uncollectibility and we do not retain any interest in the underlying account receivable once sold we derecognized million and million of account receivable of december and respectively under these factoring arrangement the cost of factoring such account receivable on our consolidated result of operation for the year ended december and were not material our derivative activity are initiated within the guideline of documented corporate risk management policy and are intended to offset loss and gain on the asset liability and transaction being hedged management review the correlation and effectiveness of our derivative on quarterly basis for derivative instrument that are designated and qualify fair value hedge the derivative instrument is marked to market with gain and loss recognized currently in income to offset the respective loss and gain recognized on the underlying exposure for derivative instrument that are designated and qualify cash flow hedge gain and loss are reported component of accumulated other comprehensive income loss see note and reclassified into earnings in the same period the hedged transaction affect earnings for derivative and non derivative instrument that are designated and qualify net investment hedge the foreign currency translation gain or loss due to spot rate fluctuation are reported component of accumulated other comprehensive income loss see note derivative contract that are not designated hedging instrument are recorded at fair value with the gain or loss recognized in earnings during the period of change may enter into foreign currency forward or option contract to reduce the effect of fluctuating currency exchange rate principally the euro british pound chinese yuan japanese yen and swiss franc foreign currency derivative used for hedging are put in place using the same or like currency and duration the underlying exposure forward and option contract are principally used to manage exposure arising from subsidiary trade and loan payable and receivables denominated in foreign currency these contract are recorded at fair value with the gain or loss recognized in other net income expense we may enter into foreign currency forward and option contract and currency swap fair value hedge of firm commitment forward contract generally have maturity not exceeding month at december we had outstanding foreign currency forward commitment follows all of which have settlement date within day december in million currencyamount in million currency exchange risk is also managed through the use of foreign currency debt cross currency interest rate swap and foreign currency forward contract our foreign currency denominated note had carrying amount of billion and billion of december and respectively of which billion and billion have been designated and are effective economic hedge of net investment in certain of our foreign operation of december and respectively at december we had outstanding cross currency swap with notional amount of billion swapping dollar to euro and billion swapping swiss franc to dollar which have settlement date ranging through our cross currency interest rate swap for which majority convert portion of our dollar denominated fixed rate debt to foreign denominated fixed rate debt have also been designated and are effective economic hedge of net investment at december we had outstanding foreign currency forward contract to sell million euro and to sell billion chinese yuan with settlement date ranging through which have been designated and are effective economic hedge of net investment in the normal course of business our operation are exposed to fluctuation in interest rate which can vary the cost of financing investing and operating we seek to address portion of these risk through controlled program of risk management that includes the use of derivative financial instrument the objective of controlling these risk is to limit the impact of fluctuation in interest rate on earnings our primary interest rate risk exposure result from change in short term dollar interest rate in an effort to manage interest rate exposure we strive to achieve an acceptable balance between fixed and floating rate debt and investment position and may enter into interest rate swap or collar to help maintain that balance interest rate swap or collar that convert our fixed rate debt to floating rate are designated fair value hedge of the underlying instrument interest rate swap or collar that convert floating rate debt to fixed rate are designated cash flow hedge interest expense on the debt is adjusted to include the payment made or received under the swap agreement cash proceeds from or payment to counterparties resulting from the termination of interest rate swap are classified operating activity in our consolidated statement of cash flow at december substantially all of our total long term debt is at fixed rate we have converted approximately percent of our long term fixed rate note to floating rate through the use of interest rate swap also may enter into forward starting interest rate swap which we designate cash flow hedge part of any anticipated future debt issuance in order to reduce the risk of cash flow volatility from future change in interest rate the change in fair value of these instrument is recorded part of other comprehensive income loss see note and upon completion of debt issuance and termination of the swap is amortized to interest expense over the life of the underlying debt of december the total notional amount of forward starting interest rate contract in designated cash flow hedging instrument were billion which have settlement date ranging between and the effect of risk management instrument on the consolidated statement of operationsthe following effect of risk management instrument were recognized in other net income expense value hedge effect from hedged fixed rate debt effect from interest rate cash flow hedge effective portion of loss on interest rate contract reclassified from accumulated other comprehensive cross currency interest rate net gain loss on foreign currency exchange contract not designated hedging total during the year ended december and the amortization of loss related to the portion of our risk management hedging instrument fair value hedge and cash flow hedge that wa excluded from the assessment of effectiveness wa not material the effect of risk management instrument on other comprehensive income loss the effective portion of risk management instrument that wa recognized in other comprehensive income loss is follows investment hedge foreign currency denominated note cross currency interest rate foreign currency forward contract cash flow hedge forward starting interest rate cross currency interest rate during the next month we expect to reclassify million of pretax net loss on cash flow hedge from accumulated other comprehensive income loss to other net income expense during the year ended december and the amount excluded from the assessment of hedge effectiveness recognized in other comprehensive income loss were not material value of risk management instrumentsthe following table summarizes certain fair value information at december and for risk management asset and liability measured at fair value on recurring basis fair value measurement using carryingamountquoted price in active market for identical asset level significantotherobservableinputs level significantunobservableinputs level fairvaluedecember management instrumentsinterest rate contract designated fair value hedge other noncurrent liability interest rate contract designated cash flow hedge other other noncurrent cross currency interest rate contract designated net investment hedge other cross currency interest rate contract designated cash flow hedge other noncurrent foreign exchange contract designated hedging instrument other current liability foreign exchange contract not designated hedging instrument other other current liability contingent consideration liability other current liability other noncurrent liability fair value measurement using carryingamountquoted price in active market for identical asset level significantotherobservableinputs level significantunobservableinputs level fairvaluedecember management instrumentsinterest rate contract designated fair value hedge other receivables other noncurrent other noncurrent liability interest rate contract designated cash flow hedge other noncurrent other noncurrent liability cross currency interest rate contract designated net investment hedge other noncurrent other current liability cross currency interest rate contract designated cash flow hedge other noncurrent other noncurrent liability foreign exchange contract not designated hedging instrument other other current liability contingent consideration liability other noncurrent liability risk management instrument above are disclosed on gross basis there are various right of setoff associated with certain of the risk management instrument above that are subject to enforceable master netting arrangement or similar agreement although various right of setoff and master netting arrangement or similar agreement may exist with the individual counterparties to the risk management instrument above individually these financial right are not material contingent consideration liability relate to our liability arising in connection with the cvrs issued result of both the akouos and prevail acquisition the fair value of the cvr liability were estimated using discounted cash flow analysis and level input including projection representative of market participant view of the expected cash payment associated with the agreed upon regulatory milestone based on probability of technical success timing of the potential milestone event for the compound and estimated discount rate see note for additional information related to the cvr arrangement for both akouos and prevail goodwill and other intangiblesgoodwillgoodwill result from excess consideration in business combination over the fair value of identifiable net asset acquired goodwill is not amortized but is reviewed for impairment at least annually or more frequently if impairment indicator are present by first assessing qualitative factor to determine whether it is more likely than not that the fair value is le than it carrying amount if we conclude it is more likely than not that the fair value is le than the carrying amount quantitative test that compare the fair value to it carrying value is performed to determine the amount of any impairment the change in goodwill during wa primarily related to our acquisition of akouos see note for additional information no impairment occurred with respect to the carrying value of goodwill for the year ended december and other intangiblesthe component of intangible asset other than goodwill at december were follows grossaccumulatedamortizationcarryingamount netcarryingamount grossaccumulatedamortizationcarryingamount netfinite lived intangible asset marketed product total finite lived intangible indefinite lived intangible asset acquired ipr other intangible marketed product consist of the amortized cost of the right to asset acquired in business combination and approved for marketing in significant global jurisdiction europe and japan and capitalized milestone payment for transaction other than business combination we capitalize milestone payment incurred at or after the product ha obtained regulatory approval for marketing other finite lived intangible asset consist primarily of the amortized cost of licensed platform technology that have alternative future us in research and development manufacturing technology and customer relationship from business combination acquired ipr consists of the fair value of acquired ipr project acquired in business combination adjusted for subsequent impairment if any the cost of acquired ipr project acquired directly in transaction other than business combination are capitalized other intangible asset if the project have an alternative future use otherwise they are expensed immediately see note for significant acquired ipr project that had no alternative future use several method may be used to determine the estimated fair value of other intangible acquired in business combination we utilize the income method which is level fair value measurement and applies probability weighting that considers the risk of development and commercialization to the estimated future net cash flow that are derived from projected revenue and estimated cost these projection are based on factor such relevant market size patent protection historical pricing of similar product analyst expectation and expected industry trend the estimated future net cash flow are then discounted to the present value using an appropriate discount rate this analysis is performed for each asset independently the acquired ipr asset are treated indefinite lived intangible asset until completion or abandonment of the project at which time the asset are tested for impairment and amortized over the remaining useful life or written off appropriate decrease in acquired ipr intangible in is due to the impairment of an intangible asset for gene therapy see note for additional information this decrease wa partially offset by acquired ipr asset recognized from the acquisition of akouos see note for additional information indefinite lived intangible asset are reviewed for impairment at least annually or more frequently if impairment indicator are present by first assessing qualitative factor to determine whether it is more likely than not that the fair value of the asset is le than it carrying amount if we conclude it is more likely than not that the fair value is le than the carrying amount quantitative test that compare the fair value of the intangible asset to it carrying value is performed to determine the amount of any impairment finite lived intangible asset are reviewed for impairment when an indicator of impairment is present when required comparison of fair value to the carrying amount of asset is performed to determine the amount of any impairment when determining the fair value of indefinite lived acquired ipr well the fair value of finite lived intangible asset for impairment testing purpose we utilize the income method discussed above intangible asset with finite life are capitalized and are amortized primarily to cost of sale over their estimated useful life ranging from one to year of december the remaining weighted average amortization period for finite lived intangible asset wa approximately year amortization expense related to finite lived intangible asset wa follows expense the estimated amortization expense for each of the next five year associated with our finite lived intangible asset of december is follows amortization expense property and equipmentproperty and equipment is stated on the basis of cost provision for depreciation of building and equipment are computed generally by the straight line method at rate based on their estimated useful life to year for building and three to year for equipment we review the carrying value of long lived asset for potential impairment on periodic basis and whenever event or change in circumstance indicate the carrying value of an asset may not be recoverable impairment is determined by comparing projected undiscounted cash flow to be generated by the asset to it carrying value if an impairment is identified loss is recorded equal to the excess of the asset net book value over it fair value and the cost basis is adjusted at december property and equipment consisted of the following construction in le accumulated depreciation property and equipment net depreciation expense related to property and equipment wa follows expense capitalized interest cost were not material for the year ended december and the following table summarizes long lived asset by geographical area lived asset and puerto rico other foreign long lived asset long lived asset consist of property and equipment net operating lease asset and certain other noncurrent asset leaseswe determine if an arrangement is lease at inception we have lease with term up to year primarily for corporate office research and development facility vehicle and equipment including some of which have option to extend and or early terminate the lease we determine the lease term by assuming the exercise of any renewal and or early termination option that are reasonably assured operating lease right of use asset are presented other noncurrent asset in our consolidated balance sheet and the current and long term portion of operating lease liability are included in other current liability and other noncurrent liability respectively in our consolidated balance sheet short term lease which are deemed at inception to have lease term of month or le are not recorded on the consolidated balance sheet operating lease asset represent our right to use an underlying asset for the lease term and operating lease liability represent our obligation to make lease payment arising from the lease operating lease asset and liability are recognized at commencement date based on the present value of lease payment over the lease term most of our lease do not provide an implicit rate we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payment lease expense for operating lease asset which is recognized on straight line basis over the lease term wa million million and million during the year ended december and respectively variable lease payment which represent non lease component such maintenance insurance and tax and which vary due to change in fact or circumstance occurring after the commencement date other than the passage of time are expensed in the period in which the payment obligation is incurred and were not material during the year ended december and short term lease expense wa not material during the year ended december and supplemental balance sheet information related to operating lease of december and wa follows average remaining lease yearsweighted average discount supplemental cash flow information related to operating lease during the year ended december and wa follows cash flow from operating lease right of use asset obtained in exchange for new operating lease annual minimum lease payment of our operating lease liability of december were follows after total lease le imputed total finance lease are included in property and equipment short term borrowing and current maturity of long term debt and long term debt in our consolidated balance sheet finance lease are not material to our consolidated financial statement borrowingsdebt at december consisted of the following term commercial paper borrowing long term note long term unamortized debt issuance cost fair value adjustment on hedged long term note total le current portion long term debt the weighted average effective borrowing rate on short term commercial paper borrowing at december wa percent following table summarizes long term note at december note due note due euro denominated note due swiss franc denominated note due note due note due euro denominated note due note due note due swiss franc denominated note due note due japanese yen denominated note due euro denominated note due euro denominated note due euro denominated note due japanese yen denominated note due note due note due note due note due british pound denominated note due note due note due note due note due euro denominated note due japanese yen denominated note due note due euro denominated note due note due note due euro denominated note due unamortized note discount total long term note the weighted average effective borrowing rate for each issuance of the long term note approximates the stated interest rate at december we had total of billion of unused committed bank credit facility which consisted primarily of billion credit facility that expires in december and billion day facility that expires in september both of which are available to support our commercial paper program we have not drawn against the billion and billion facility of december of the remaining committed bank credit facility the outstanding balance of december and were not material compensating balance and commitment fee are not material and there are no condition that are probable of occurring under which the line may be withdrawn in september we issued euro denominated note consisting of million of percent fixed rate note due in september with interest to be paid annually the net proceeds from the offering have been and will continue to be used to fund in whole or in part eligible project designed to advance one or more of our environmental social and governance objective september we issued euro denominated note consisting of million of percent fixed rate note due in september and million of percent fixed rate note due in september with interest to be paid annually and british pound denominated note consisting of million of percent fixed rate note due in september with interest to be paid annually we paid billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate dollar denominated note with an aggregate principal amount of billion resulting in debt extinguishment loss of million this loss wa included in other net income expense in our consolidated statement of operation for the year ended december the billion principal amount of higher interest rate dollar denominated note that were redeemed primarily included million of percent note due million of percent note due and million of percent note due we used the remaining net proceeds from the offering to prefund certain debt maturity and for general corporate purpose in may we issued billion of percent fixed rate note due in may with interest to be paid semi annually we used the net cash proceeds from the offering of million for general corporate purpose including the repayment of outstanding commercial paper in august we issued million of percent fixed rate note due in september and an additional million of our percent fixed rate note due in may with interest to be paid semi annually we used the net cash proceeds from the offering of billion for general corporate purpose including the repayment of outstanding commercial paper the aggregate amount of maturity on long term debt for the next five year are follows on long term debt we have converted approximately percent of our long term fixed rate note to floating rate through the use of interest rate swap the weighted average effective borrowing rate based on long term debt obligation and interest rate at december and including the effect of interest rate swap for hedged debt obligation were percent and percent respectively the aggregate amount of cash payment for interest on borrowing net of capitalized interest are follows payment for interest on borrowing in accordance with the requirement of derivative and hedging guidance the portion of our fixed rate debt obligation that is hedged fair value hedge is reflected in the consolidated balance sheet an amount equal to the sum of the debt carrying value plus the fair value adjustment representing change in fair value of the hedged debt attributable to movement in market interest rate subsequent to the inception of the hedge note stock based compensationour stock based compensation expense consists of performance award pa shareholder value award svas relative value award rvas and restricted stock unit rsus we recognize the fair value of stock based compensation expense over the requisite service period of the individual grantee which generally equal the vesting period we provide newly issued share of our common stock and treasury stock to satisfy the issuance of pa sva rva and rsu share stock based compensation expense and the related tax benefit were follows based compensation expense tax at december stock based compensation award may be granted under the lilly stock plan for not more than million additional share award programpas are granted to officer and management and are payable in share of our common stock the number of pa share actually issued if any varies depending on the achievement of certain pre established earnings per share target over two year period pa share are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period the fair value of pa granted for the year ended december and were and respectively the number of share ultimately issued for the pa program is dependent upon the eps achieved during the vesting period pursuant to this program approximately million share million share and million share were issued during the year ended december and respectively approximately million share are expected to be issued in of december the total remaining unrecognized compensation cost related to nonvested pa wa million which will be amortized over the weighted average remaining requisite service period of month shareholder value award programsvas are granted to officer and management and are payable in share of our common stock the number of share actually issued if any varies depending on our stock price at the end of the three year vesting period compared to pre established target stock price we measure the fair value of the sva unit on the grant date using monte carlo simulation model the model utilizes multiple input variable that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award expected volatility utilized in the model are based on implied volatility from traded option on our stock historical volatility of our stock price and other factor similarly the dividend yield is based on historical experience and our estimate of future dividend yield the risk free interest rate is derived from the treasury yield curve in effect at the time of grant the weighted average fair value of the sva unit granted during the year ended december and were and respectively determined using the following assumption dividend risk free interest pursuant to this program approximately million share million share and million share were issued during the year ended december and respectively approximately million share are expected to be issued in of december the total remaining unrecognized compensation cost related to nonvested svas wa million which will be amortized over the weighted average remaining requisite service period of month relative value award programrvas are granted to officer and management and are payable in share of our common stock the number of share actually issued if any varies depending on the growth of our stock price at the end of the three year vesting period compared to our peer we measure the fair value of the rva unit on the grant date using monte carlo simulation model the model utilizes multiple input variable that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award expected volatility utilized in the model are based on implied volatility from traded option on our stock historical volatility of our stock price and our peer stock price and other factor similarly the dividend yield is based on historical experience and our estimate of future dividend yield the risk free interest rate is derived from the treasury yield curve in effect at the time of grant the weighted average fair value of the rva unit granted during the year ended december and were and respectively determined using the following assumption dividend risk free interest approximately million share are expected to be issued in of december the total remaining unrecognized compensation cost related to nonvested rvas wa million which will be amortized over the weighted average remaining requisite service period of month stock unitsrsus are granted to certain employee and are payable in share of our common stock rsu share are accounted for at fair value based upon the closing stock price on the date of grant the corresponding expense is amortized over the vesting period typically three year the weighted average fair value of rsu award granted during the year ended december and were and respectively the number of share ultimately issued for the rsu program remains constant with the exception of forfeiture pursuant to this program million million and million share were granted and approximately million million and million share were issued during the year ended december and respectively approximately million share are expected to be issued in of december the total remaining unrecognized compensation cost related to nonvested rsus wa million which will be amortized over the weighted average remaining requisite service period of month note shareholder equityin and we repurchased billion billion and million respectively of share associated with our share repurchase program of december we had billion remaining under our billion share repurchase program that our board authorized in may we have million authorized share of preferred stock of december and no preferred stock wa issued we have an employee benefit trust that held million share of our common stock at both december and to provide source of fund to assist in meeting our obligation under various employee benefit plan the cost basis of the share held in the trust wa billion at both december and and is shown reduction of shareholder equity any dividend transaction between and the trust are eliminated stock held by the trust is not considered outstanding in the computation of eps the asset of the trust were not used to fund any of our obligation under these employee benefit plan during the year ended december and note income taxesdeferred tax are recognized for the future tax effect of temporary difference between financial and income tax reporting based on enacted tax law and rate deferred tax related to global intangible low taxed income gilti are also recognized for the future tax effect of temporary difference we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position based on it technical merit will be sustained upon examination by the taxing authority the tax benefit recognized in the financial statement from such position are measured based on the largest benefit that ha greater than percent likelihood of being realized upon ultimate resolution following is the composition of income tax expense federal total current tax deferred federal foreign state total deferred tax benefit income tax the and current tax expense includes million million and million of tax benefit respectively from utilization of net operating loss and other tax carryforwards component of our deferred tax asset and liability of december were follows tax asset purchase of intangible asset compensation and tax credit tax loss and other tax carryforwards and sale rebate and correlative tax foreign tax operating lease capitalized research and total gross deferred tax valuation allowance total deferred tax deferred tax liability earnings of foreign subsidiary intangible inventory prepaid employee benefit property and equipment financial instrument operating lease asset total deferred tax liability deferred tax asset net the deferred tax asset and related valuation allowance amount for federal international and state net operating loss and tax credit shown above have been reduced for difference between financial reporting and tax return filing at december based on filed tax return we have tax credit carryforwards and carrybacks of million available to reduce future income tax million if unused will expire by and million if unused will expire between and the remaining portion of the tax credit carryforwards is related to federal tax credit of million international tax credit of million and state tax credit of million all of which are fully reserved at december based on filed tax return we had net operating loss and other carryforwards for international and federal income tax purpose of billion million will expire by billion will expire between and and million of the carryforwards will never expire net operating loss and other carryforwards for international and federal income tax purpose are partially reserved deferred tax asset related to state net operating loss and other carryforwards of million are fully reserved of december at december and prepaid expense and other current asset included prepaid tax of billion and billion respectively domestic and puerto rican company contributed approximately percent percent and percent for the year ended december and respectively to consolidated income before income tax we have subsidiary operating in puerto rico under tax incentive grant effective through the end of which wa amended in to apply the alternate tax regime established by recently enacted puerto rico legislation starting in all of the unremitted earnings of our foreign subsidiary are considered not to be indefinitely reinvested for continued use in our foreign operation at december and we accrued an immaterial amount of foreign withholding tax and state income tax that would be owed upon future distribution of unremitted earnings of our foreign subsidiary that are not indefinitely reinvested for the amount considered to be indefinitely reinvested it is not practicable to determine the amount of the related deferred income tax liability due to the complexity in the tax law and assumption we would have to make cash payment of federal state and foreign income tax net of refund were follows payment of income tax in december the tax cut and job act tax act wa signed into law the tax act included significant change to the corporate income tax system including one time repatriation transition tax also known the toll tax on unremitted foreign earnings the tax act provided an election to taxpayer subject to the toll tax to make payment over an eight year period beginning in through made this election our future cash payment relating to the toll tax of december are follows totalless than tax act toll tax of december we have additional noncurrent income tax payable of billion unrelated to the toll tax we can not reasonably estimate the timing of future cash outflow associated with these liability following is reconciliation of the consolidated income tax expense applying the federal statutory rate to income before income tax to reported consolidated income tax expense tax at the federal statutory tax rate add deduct international operation including puerto rico general business credit foreign derived intangible income deduction valuation allowance release other income tax includes the impact of puerto rico excise tax gilti tax and other taxation of foreign income reconciliation of the beginning and ending amount of gross unrecognized tax benefit is follows balance at january addition based on tax position related to the current addition for tax position of prior reduction for tax position of prior year settlement lapse of statute of limitation change related to the impact of foreign currency translation ending balance at december the total amount of unrecognized tax benefit that if recognized would affect our effective tax rate wa billion at both december and we file federal foreign and various state and local income tax return we are no longer subject to federal income tax examination for year before in most major foreign and state jurisdiction we are no longer subject to income tax examination for year before examination of tax year began in and remains ongoing while it is reasonably possible that the internal revenue service examination of these tax year could conclude within the next month final resolution of certain matter is dependent upon several factor including the potential for formal administrative proceeding result an estimate of the range of reasonably possible change in unrecognized tax benefit can not be made interest and penalty related to unrecognized tax benefit are recognized in income tax expense and were not material for the year ended december and our accrued interest and penalty related to unrecognized tax benefit were million and million at december and respectively note retirement benefitswe use measurement date of december to develop the change in benefit obligation change in plan asset funded status and amount recognized in the consolidated balance sheet at december for our defined benefit pension and retiree health benefit plan which were follows defined benefitpension plansretiree healthbenefit in benefit obligation benefit obligation at beginning of year service interest actuarial gain loss benefit paid foreign currency exchange rate change and other adjustment benefit obligation at end of change in plan asset fair value of plan asset at beginning of actual return on plan asset employer benefit paid foreign currency exchange rate change and other adjustment fair value of plan asset at end of funded status unrecognized net actuarial gain unrecognized prior service benefit net amount recognized amount recognized in the consolidated balance sheet consisted of other noncurrent asset other current liability accrued retirement benefit accumulated other comprehensive income loss before income net amount recognized the unrecognized net actuarial gain loss and unrecognized prior service benefit cost have not yet been recognized in net periodic pension cost and were included in accumulated other comprehensive loss at december and billion and million decline in benefit obligation in and respectively were both driven primarily by increase in the discount rate the following represents our weighted average assumption of december defined benefitpension plansretiree healthbenefit plan percent rate for benefit discount rate for net benefit rate of compensation increase for benefit rate of compensation increase for net benefit expected return on plan asset for net benefit we annually evaluate the expected return on plan asset in our defined benefit pension and retiree health benefit plan in evaluating the expected rate of return we consider many factor with primary analysis of current and projected market condition asset return and asset allocation and the view of leading financial adviser and economist we may also review our historical assumption compared with actual result well the assumption and trend rate utilized by similar plan where applicable given the design of our retiree health benefit plan healthcare cost trend rate do not have material impact on our financial condition or result of operation the following benefit payment which reflect expected future service appropriate are expected to be paid follows benefit pension plan retiree health benefit amount relating to defined benefit pension plan with projected benefit obligation in excess of plan asset were follows at december benefit obligation fair value of plan amount relating to defined benefit pension plan and retiree health benefit plan with accumulated benefit obligation in excess of plan asset were follows at december defined benefitpension plansretiree health benefit plan benefit obligation fair value of plan the total accumulated benefit obligation for our defined benefit pension plan wa billion and billion at december and respectively pension and retiree health benefit expense included the following component defined benefitpension plansretiree healthbenefit of net periodic benefit cost service cost interest expected return on plan asset amortization of prior service benefit recognized actuarial gain net periodic benefit cost the following represents the amount recognized in other comprehensive income loss for the year ended december and defined benefitpension plansretiree healthbenefit gain loss arising during period plan amendment during period amortization of prior service benefit cost included in net amortization of net actuarial gain loss included in net foreign currency exchange rate change and total other comprehensive income loss during period we have defined contribution saving plan that cover our eligible employee worldwide the purpose of these plan is generally to provide additional financial security during retirement by providing employee with an incentive to save our contribution to the plan are based on employee contribution and the level of our match expense under the plan totaled million million and million for the year ended december and respectively we provide certain other postemployment benefit primarily related to disability benefit and accrue for the related cost over the service life of employee expense associated with these benefit plan for the year ended december and were not material benefit plan investmentsour benefit plan investment policy are set with specific consideration of return and risk requirement in relationship to the respective liability and puerto rico plan represent approximately percent of our global investment given the long term nature of our liability these plan have the flexibility to manage an above average degree of risk in the asset portfolio at the investment policy level there are no specifically prohibited investment however within individual investment manager mandate restriction and limitation are contractually set to align with our investment objective ensure risk control and limit concentration we manage our portfolio to minimize concentration of risk by allocating fund within asset category in addition within category we use different manager with various management objective to eliminate any significant concentration of risk global benefit plan may enter into contractual arrangement derivative to implement the local investment policy or manage particular portfolio risk derivative are principally used to increase or decrease exposure to particular public equity fixed income commodity or currency market more rapidly or le expensively than could be accomplished through the use of the cash market the plan utilize both exchange traded and over the counter instrument the maximum exposure to either market or counterparty credit loss is limited to the carrying value of the receivable and is managed within contractual limit we expect all of our counterparties to meet their obligation the gross value of these derivative receivables and payable are not material to the global asset portfolio and their value are reflected within the table below the defined benefit pension and retiree health benefit plan allocation for the and puerto rico currently comprises approximately percent growth investment and percent fixed income investment the growth investment allocation encompasses and international public equity security hedge fund private equity like investment and real estate these portfolio allocation are intended to reduce overall risk by providing diversification while seeking moderate to high return over the long term public equity security are well diversified and invested in and international small to large company across various asset manager and style the remaining portion of the growth portfolio is invested in private alternative investment fixed income investment primarily consist of fixed income security in treasury and agency emerging market debt obligation corporate bond bank loan mortgage backed security commercial mortgage backed obligation and any related repurchase agreement hedge fund are privately owned institutional investment fund that generally have moderate liquidity hedge fund seek specified level of absolute return regardless of overall market condition and generally have low correlation to public equity and debt market hedge fund often invest substantially in financial market instrument stock bond commodity currency derivative etc using very broad range of trading activity to manage portfolio risk hedge fund strategy focus primarily on security selection and seek to be neutral with respect to market move common grouping of hedge fund strategy include relative value tactical and event driven relative value strategy include arbitrage when the same asset can simultaneously be bought and sold at different price achieving an immediate profit tactical strategy often take long and short position to reduce or eliminate overall market risk while seeking particular investment opportunity event strategy opportunity can evolve from specific company announcement such merger and acquisition and typically have little correlation to overall market directional movement our hedge fund investment are made through limited partnership interest in fund of fund structure and directly into hedge fund plan holding in hedge fund are valued based on net asset value navs calculated by each fund or general partner applicable and we have the ability to redeem these investment at nav private equity like investment fund typically have low liquidity and are made through long term partnership or joint venture that invest in pool of capital invested in primarily non publicly traded entity underlying investment include venture capital early stage investing buyout special situation private debt and private real estate investment private equity management firm typically acquire and then reorganize private company to create increased long term value private equity like fund usually have limited life of approximately year and require minimum investment commitment from their limited partner our private equity like investment are made both directly into fund and through fund of fund structure to ensure broad diversification of management style and asset across the portfolio plan holding in private equity like investment are valued using the value reported by the partnership adjusted for known cash flow and significant event through our reporting date value provided by the partnership are primarily based on analysis of and judgment about the underlying investment input to these valuation include underlying navs discounted cash flow valuation comparable market valuation and may also include adjustment for currency credit liquidity and other risk applicable the vast majority of these private partnership provide with annual audited financial statement including their compliance with fair valuation procedure consistent with applicable accounting standard real estate is composed of public holding real estate investment in registered investment company that trade on an exchange are classified level on the fair value hierarchy real estate investment in fund measured at fair value on the basis of nav provided by the fund manager are classified such these navs are developed with input including discounted cash flow independent appraisal and market comparable analysis other asset include cash and cash equivalent and mark to market value of derivative cash value of the trust owned insurance contract is primarily invested in investment grade publicly traded equity and fixed income security other than hedge fund private equity like investment and portion of the real estate holding which are discussed above we determine fair value based on market approach using quoted market value significant other observable input for identical or comparable asset or liability or discounted cash flow analysis the fair value of our defined benefit pension plan and retiree health plan asset of december by asset category were follows fair value measurement usingasset classtotalquoted price in active market foridentical asset level significantobservable input level significantunobservable input level investment valued at net asset value defined benefit pension planspublic equity security fixed income developed developed market repurchase agreement emerging private alternative investment hedge equity like real total retiree health benefit planspublic equity security fixed income developed emerging private alternative investment hedge equity like cash value of trust owned insurance real total certain investment that are measured at fair value using the nav per share or it equivalent practical expedient have not been classified in the fair value hierarchy no material transfer between level level or level occurred during the year ended december the activity in the level investment during the year ended december wa not material fair value of our defined benefit pension plan and retiree health plan asset of december by asset category were follows fair value measurement usingasset classtotalquoted price in active market for identical asset level significant observable input level significant unobservable input level investment valued at net asset value defined benefit pension planspublic equity security fixed income developed developed market repurchase agreement emerging private alternative investment hedge equity like real total retiree health benefit planspublic equity security fixed income developed emerging private alternative investment hedge equity like cash value of trust owned insurance real total certain investment that are measured at fair value using the nav per share or it equivalent practical expedient have not been classified in the fair value hierarchy no material transfer between level level or level occurred during the year ended december the activity in the level investment during the year ended december wa not material in we expect to contribute approximately million to our defined benefit pension plan to satisfy minimum funding requirement for the year we do not currently expect to make material discretionary contribution in contingencieswe are involved in various lawsuit claim government investigation and other legal proceeding that arise in the ordinary course of business these claim or proceeding can involve various type of party including government competitor customer supplier service provider licensee employee or shareholder among others these matter may involve patent infringement antitrust security pricing sale and marketing practice environmental commercial contractual right licensing obligation health and safety matter consumer fraud employment matter product liability and insurance coverage among others the resolution of these matter often develops over long period of time and expectation can change result of new finding ruling appeal or settlement arrangement legal proceeding that are significant or that we believe could become significant or material are described below we believe the legal proceeding in which we are named defendant are without merit and we are defending against them vigorously it is not possible to determine the final outcome of these matter and we can not reasonably estimate the maximum potential exposure or the range of possible loss in excess of amount accrued for any of these matter however we believe that the resolution of all such matter will not have material adverse effect on our consolidated financial position or liquidity but could possibly be material to our consolidated result of operation in any one accounting period litigation accrual environmental liability and the related estimated insurance recoverables are reflected on gross basis liability and asset respectively on our consolidated balance sheet with respect to the product liability claim currently asserted against we have accrued for our estimated exposure to the extent they are both probable and reasonably estimable based on the information available to we accrue for certain product liability claim incurred but not filed to the extent we can formulate reasonable estimate of their cost we estimate these expense based primarily on historical claim experience and data regarding product usage legal defense cost expected to be incurred in connection with significant product liability loss contingency are accrued when both probable and reasonably estimable because of the nature of pharmaceutical product it is possible that we could become subject to large number of additional product liability and related claim in the future due to very restrictive market for litigation liability insurance we are self insured for litigation liability loss for all our currently and previously marketed product patent litigationalimta european patent litigationin europe alimta pemetrexed wa protected by patent through june number of legal proceeding that were initiated prior to patent expiration are ongoing emgality patent litigationwe are named defendant in litigation filed by teva pharmaceutical international gmbh and teva pharmaceutical usa inc collectively teva in the district court for the district of massachusetts seeking ruling that various claim in three different teva patent would be infringed by our launch and continued sale of emgality for the prevention of migraine in adult following trial in november jury returned verdict in favor of teva the party have filed post trial motion on which the court will rule and then enter final judgment in the case we intend to appeal the jury verdict if necessary pursuant to agreement by the party the award if any will not become due until completion of the appeal process this matter is ongoing in june we were named defendant in second litigation filed by teva in the district court for the district of massachusetts seeking ruling that two of teva patent which are directed toward use of the active ingredient in emgality to treat migraine would be infringed by our continued sale of emgality we challenged these two patent by filing request for inter partes review with the patent trial and appeal board ptab and in october the ptab granted our request the corresponding district court litigation is stayed while this ptab proceeding is ongoing patent litigationin november boehringer ingelheim our partner in marketing and development of jardiance initiated patent litigation in the district court for the district of delaware alleging infringement arising from submission of abbreviated new drug application anda by number of generic company seeking approval to market generic version of jardiance glyxambi and synjardy in accordance with the procedure set out in the drug price competition and patent term restoration act of the hatch waxman act particularly with respect to jardiance the generic company andas seek approval to market generic version of jardiance prior to the expiration of the relevant patent and allege that certain patent including in some allegation the compound patent are invalid or would not be infringed we are not party to this litigation this litigation ha been stayed taltz patent litigationbeginning in may lilly and novartis pharma ag novartis had been litigating the validity and alleged infringement by taltz of certain patent novartis acquired from genentech inc genentech of october we had pending case in ireland italy switzerland and the netherlands where novartis sought injunction to stop taltz commercialization in october we entered into cashless no payment settlement and mutual release agreement with novartis which resolved such dispute without any admission of liability or wrongdoing we and novartis have agreed to mutual release for past claim and mutual covenant not to sue the other in relation to taltz and the patent novartis purchased from genentech this matter is closed zyprexa canada patent litigationbeginning in the mid several generic company in canada challenged the validity of our zyprexa compound patent in the canadian federal court of appeal denied our appeal of lower court decision that certain patent claim were invalid for lack of utility in apotex inc and apotex pharmachem inc collectively apotex brought claim against in the ontario superior court of justice at toronto for damage related to our enforcement of the zyprexa compound patent under canadian regulation governing patented drug apotex seek compensation based on novel legal theory under the statute of monopoly trademark act and common law in march the ontario superior court granted our motion for summary judgment thereby dismissing apotex case apotex appealed that ruling to the court of appeal for ontario in april in august the court dismissed the appeal and in october apotex appealed the decision this matter is ongoing product liability litigationbyetta product liabilitywe have been named defendant in over byetta product liability lawsuit in the that were first initiated in march and involved over plaintiff these lawsuit have been filed in various state and federal jurisdiction including california state court coordinated in los angeles county superior court and various federal court the majority of which are coordinated in multi district litigation mdl in the district court for the southern district of california the majority of these suit contained allegation that byetta caused or contributed to the plaintiff cancer primarily pancreatic cancer or thyroid cancer all of the mdl and state court lawsuit have been dismissed of january and we consider these matter closed environmental proceeding under the comprehensive environmental response compensation and liability act commonly known superfund we have been designated one of several potentially responsible party with respect to the cleanup of fewer than site under superfund each responsible party may be jointly and severally liable for the entire amount of the cleanup litigation and investigationswe are the plaintiff in lawsuit filed in january in the district court for the southern district of indiana against the department of health and human service hhs the secretary of hhs the health resource and service administration hrsa and the administrator of hrsa the lawsuit challenge hhs december advisory opinion stating that drug manufacturer are required to deliver discount under the program to all contract pharmacy and hhs administrative dispute resolution regulation we seek declaratory judgment that the defendant violated the administrative procedure act and the constitution preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendant and with it their application of the advisory opinion and other related relief in march the court entered an order preliminarily enjoining the government enforcement of the administrative dispute resolution process against in may hrsa notified that it determined that our policy wa contrary to the statute in response in may we amended our complaint to bring claim related to hrsa determination and filed motion for preliminary injunction and temporary restraining order requesting that the district court for the southern district of indiana enjoin defendant from taking any action against relating to the drug pricing program until after the court issue final judgment on the aforementioned litigation in may the court denied our motion for temporary restraining order but deferred resolution of our motion for preliminary injunction in june the defendant withdrew the hhs december advisory opinion in july the court held oral argument on the party cross motion for summary judgment the defendant motion to dismiss and our motion for preliminary injunction related to hrsa may enforcement letter in october the court denied the defendant motion to dismiss and granted in part and denied in part the party cross motion for summary judgment both party filed notice of appeal related to the court summary judgment order in october the court of appeal for the seventh circuit held oral argument this matter is ongoing in january we along with other pharmaceutical manufacturer were named defendant in petition currently pending before the hhs administrative dispute resolution panel petitioner seek declaratory and other injunctive relief related to the program described above the district court for the southern district of indiana ha entered preliminary injunction enjoining the government enforcement of this administrative dispute resolution process against in july we along with sanofi aventis llc sanofi novo nordisk inc novo nordisk and astrazeneca pharmaceutical lp were named defendant in purported class action lawsuit filed in the district court for the western district of new york by mosaic health inc alleging antitrust and unjust enrichment claim related to the defendant distribution program we with sanofi and novo nordisk filed motion to dismiss the lawsuit which wa granted in september in october the plaintiff filed motion for leave to amend their complaint this matter is ongoing we received civil investigative subpoena in february from the office of the attorney general for the state of vermont relating to the sale of pharmaceutical product to vermont covered entity under the program we are cooperating with this subpoena branchburg manufacturing facilityin may we received subpoena from the department of justice requesting the production of certain document relating to our manufacturing site in branchburg new jersey we are cooperating with the subpoena litigation cosmopolis facilitylabor attorney litigationfirst initiated in our subsidiary in brazil eli lilly do brasil limitada lilly brasil is named in public civil action brought by the labor public attorney lpa for the region in the labor court of paulinia state of sao paulo brazil the labor court alleging possible harm to employee and former employee caused by alleged exposure to soil and groundwater contaminant at former lilly brasil manufacturing facility in cosmopolis brazil operated by the company between and in may the labor court judge ruled against lilly brasil ordering it to undertake several remedial and compensatory action including health coverage for class of individual and certain of their child in july the appeal court trt generally affirmed our appeal of the labor court ruling which included liquidated award of million brazilian reais which when adjusted for inflation and the addition of pre and post judgment interest using the current central bank of brazil special system of clearance and custody rate is approximately one billion brazilian reais approximately million of december in august lilly brasil filed an appeal to the superior labor court tst and in june the trt published it decision on the admissibility of lilly brasil appeal allowing the majority of the element which were allowed to proceed in june element not proceeding are subject to an interlocutory appeal to the tst that wa filed in june in september the trt stayed number of element of it trial court decision pending the determination of lilly brasil appeal to the tst in june and september the lpa filed application in the labor court for enforcement of certain remedy granted by the trt in it july decision requested restriction on lilly brasil asset in brazil and required lilly brasil and antibiticos do brasil ltda abl to submit list of potential beneficiary of the public civil action in july the labor court issued ruling requiring freeze of lilly brasil immovable property or alternatively security deposit or lien of million brazilian reais which ruling wa subsequently limited in scope and the security wa reduced to million brazilian reais abl and lpa appealed the june labor court ruling to the tst which appeal is under review the labor court is currently assessing the status of lilly brasil and abl compliance with such portion of the july trt decision and an inspection in the industrial plant is expected these matter are ongoing individual former employee litigationlilly brasil is also named in various pending lawsuit filed in the labor court by individual former employee making related claim these individual lawsuit are at various stage in the litigation process puerto rico tax matterin may the municipality of carolina in puerto rico municipality filed lawsuit against alleging noncompliance with respect to contract with the municipality and seeking declaratory judgment in december the puerto rico appellate court ap reversed the summary judgment previously granted by the court of first instance cfi in our favor dismissing the municipality complaint in it entirety the ap remanded the case to the cfi for trial on the merit the trial began in may however the municipality filed new motion requesting the cfi to award damage the request wa denied by the cfi in our favor and the municipality filed for revision at the ap which we opposed staying the case in february the ap denied the municipality motion for revision this matter is ongoing average manufacturer price litigationin november we along with another pharmaceutical manufacturer were named co defendant in united state et al ex rel streck takeda pharm inc et al which wa filed in november and unsealed in the district court for the northern district of illinois the complaint alleges that the defendant should have treated certain credit from distributor retroactive price increase and included such increase in calculating average manufacturer price following trial in august the jury returned verdict in favor of the plaintiff the case is proceeding with post trial motion after which the court will enter final judgment in the case this matter is ongoing choice alliance we are named defendant in two lawsuit filed in texas and new jersey state court in october seeking damage under the texas medicaid fraud prevention act and new jersey medicaid false claim act respectively for certain patient support program related to our product humalog humulin and forteo the texas state court action ha been stayed the new jersey state court action wa dismissed with prejudice pending an ongoing appeal before the appellate division of the new jersey superior court this matter is ongoing pricing litigationwe along with sanofi novo nordisk and in some matter certain pharmacy benefit manager have been named in lawsuit related to insulin pricing that assert various theory including consumer protection fraud false advertising unjust enrichment civil conspiracy federal and state rico statute deceptive trade practice and unfair competition claim these lawsuit include in insulin pricing litigation putative consumer class action district court for the district of new jersey msp recovery claim series llc et al sanofi aventis llc et al district court for the district of new jersey fwk holding llc novo nordisk inc et al putative class action brought by direct purchaser of insulin district court for the district of new jersey and suit brought by the state of minnesota district court for the district of new jersey state of kentucky franklin county circuit court state of mississippi district court for the southern district of mississippi state of arkansas district court for the eastern district of arkansas county of albany new york district court for the northern district of new york state of montana district court for the district of montana state of kansa district court for the district of kansa state of illinois district court for the northern district of illinois state of california los angeles county superior court jackson county missouri in putative class action on behalf of missouri county and municipality jackson county circuit court and the government of puerto rico court of first instance superior court san juan these lawsuit are at various stage in the litigation process investigation subpoena and inquiriesin connection with the pricing and sale of our insulin and other product we have been subject to various investigation and received subpoena civil investigative demand request information request interrogatory and other inquiry from various governmental entity these include subpoena from the new york and vermont attorney general office civil investigative demand from the washington new mexico colorado louisiana texas and ohio attorney general office the department of justice and the federal trade commission well information request from the mississippi washington california florida hawaii and nevada attorney general office in january the michigan attorney general filed petition in michigan state court seeking authorization to investigate lilly for potential violation of the michigan consumer protection act mcpa and complaint seeking declaratory judgment that the attorney general ha authority to investigate lilly sale of insulin under the mcpa the court authorized the proposed investigation and the issuance of civil investigative subpoena in april the party entered into stipulation providing that the state of michigan will not issue any civil investigative subpoena to under the mcpa until the declaratory judgment action is resolved in july the court dismissed the case in it entirety the michigan attorney general filed notice of appeal to the michigan court of appeal which remains pending we received request in january from the house of representative committee on oversight and reform seeking commercial information and business record related to the pricing of insulin product among other issue we also received similar request from the senate finance committee and the senate committee on health education labor and pension and separate request from the house committee on energy and commerce majority and minority member in january the senate finance committee released report summarizing the finding of it investigation in december the house of representative committee on oversight and reform majority and minority staff released separate report with finding from their investigation into drug pricing including of insulin product we are cooperating with all of the aforementioned investigation subpoena and inquiry corporation technology inc in april we were named defendant in litigation filed by research corporation technology inc rct in the district court for the district of arizona rct is seeking damage for breach of contract unjust enrichment and conversion related to process used to manufacture certain product including humalog and humulin in october the court issued summary judgment decision finding in favor of rct on certain issue including with respect to disputed royalty both party filed motion for reconsideration which were denied we filed supplemental summary judgment motion in november the court stayed proceeding so the party can pursue mediation trial date ha not been set potential damage payable under the litigation if finally awarded after an appeal could be material but are not currently reasonably estimable this matter is ongoing note other comprehensive income loss the following table summarizes the activity related to each component of other comprehensive income loss amount presented net of tax foreign currency translation gain loss unrealized net gain loss on securitiesdefined benefit pension and retiree health benefit planseffective portion of cash flow hedgesaccumulated other comprehensive lossbeginning balance at january other comprehensive income loss before net amount reclassified from accumulated other comprehensive loss net other comprehensive income loss balance at december other comprehensive income loss before reclassification net amount reclassified from accumulated other comprehensive loss net other comprehensive income loss balance at december other comprehensive income loss before reclassification net amount reclassified from accumulated other comprehensive net other comprehensive income loss ending balance at december the tax effect on the net activity related to each component of other comprehensive income loss for the year ended december were follows tax benefit expense currency translation gain loss unrealized net gain loss on defined benefit pension and retiree health benefit plan effective portion of cash flow hedge benefit provision for income tax allocated to other comprehensive income loss item except for the tax effect of foreign currency translation gain and loss related to our foreign currency denominated note cross currency interest rate swap and other foreign currency exchange contract designated net investment hedge see note income tax were not provided for foreign currency translation generally the asset and liability of foreign operation are translated into dollar using the current exchange rate for those operation change in exchange rate generally do not affect cash flow therefore resulting translation adjustment are made in shareholder equity rather than in the consolidated statement of operation out of accumulated other comprehensive loss were follows detail about accumulated other comprehensive loss componentsyear ended december affected line item in the consolidated statement of of retirement benefit item prior service benefit net other net income expenseactuarial other net income expensetotal before tax benefit income taxesnet of other net of other net income expensetotal reclassification for the period net of tax note other net income expenseother net income expense consisted of the following expense interest income net investment gain loss on equity security note debt extinguishment loss note retirement benefit plan other income other net income expense reportsmanagement report for financial statement eli lilly and company and subsidiariesmanagement of eli lilly and company and subsidiary is responsible for the accuracy integrity and fair presentation of the financial statement the statement have been prepared in accordance with generally accepted accounting principle in the united state and include amount based on judgment and estimate by management in management opinion the consolidated financial statement present fairly our financial position result of operation and cash flow in addition to the system of internal accounting control we maintain code of conduct known the red book that applies to all employee worldwide requiring proper overall business conduct avoidance of conflict of interest compliance with law and confidentiality of proprietary information all employee must take training annually on the red book and are required to report suspected violation hotline number is available on our lilly com website and on the internal lillynow website to enable reporting of suspected violation anonymously employee who report suspected violation are protected from discrimination or retaliation by the company in addition to the red book the chief executive officer and all financial management must sign financial code of ethic which further reinforces their ethical and fiduciary responsibility the consolidated financial statement have been audited by ernst young llp an independent registered public accounting firm pcaob id their responsibility is to examine our consolidated financial statement in accordance with generally accepted auditing standard of the public company accounting oversight board united state ernst young opinion with respect to the fairness of the presentation of the statement is included in item of our annual report on form ernst young report directly to the audit committee of the board of director our audit committee includes five nonemployee member of the board of director all of whom are independent from our company the committee charter which is available on our website outline the member role and responsibility it is the audit committee responsibility to appoint an independent registered public accounting firm subject to shareholder ratification pre approve both audit and non audit service performed by the independent registered public accounting firm and review the report submitted by the firm the audit committee meet several time during the year with management the internal auditor and the independent public accounting firm to discus audit activity internal control and financial reporting matter including review of our externally published financial result the internal auditor and the independent registered public accounting firm have full and free access to the committee we are dedicated to ensuring that we maintain the high standard of financial accounting and reporting that we have established we are committed to providing financial information that is transparent timely complete relevant and accurate our culture demand integrity and an unyielding commitment to strong internal practice and policy finally we have the highest confidence in our financial reporting our underlying system of internal control and our people who are objective in their responsibility operate under code of conduct and are subject to the highest level of ethical standard management report on internal control over financial reporting eli lilly and company and subsidiariesmanagement of eli lilly and company and subsidiary is responsible for establishing and maintaining adequate internal control over financial reporting defined in rule and under the security exchange act of we have global financial policy that govern critical area including internal control financial accounting and reporting fiduciary accountability and safeguarding of corporate asset our internal accounting control system are designed to provide reasonable assurance that asset are safeguarded that transaction are executed in accordance with management authorization and are properly recorded and that accounting record are adequate for preparation of financial statement and other financial information staff of internal auditor regularly monitor on worldwide basis the adequacy and effectiveness of internal accounting control the general auditor report directly to the audit committee of the board of director we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission on our evaluation under this framework we concluded that our internal control over financial reporting wa effective of december however because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate the effectiveness of internal control over financial reporting of december ha been audited by ernst young llp an independent registered public accounting firm stated in their attestation report which appears herein their responsibility is to evaluate whether internal control over financial reporting wa designed and operating effectively david ricksanat ashkenazichair president and chief executive officerexecutive vice president and chief financial officerfebruary of independent registered public accounting firm to the board of director and shareholder of eli lilly and companyopinion on the financial statementswe have audited the accompanying consolidated balance sheet of eli lilly and company and subsidiary the company of december and the related consolidated statement of operation comprehensive income loss shareholder equity and cash flow for each of the three year in the period ended december and the related note collectively referred to the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company at december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon basis for opinionthese financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit matter the critical audit matter communicated below are matter arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate managed care and medicare sale rebate accrualsdescription of the matteras described in note to the consolidated financial statement under the caption net product revenue the company establishes provision for sale rebate and discount in the same period the related sale occur at december the company had million in sale rebate and discount accrual large portion of these accrual are rebate associated with sale in the united state for which payment for purchase of the product is covered by medicaid managed care and medicare auditing the medicaid managed care and medicare sale rebate and discount liability is challenging because of the subjectivity of certain assumption required to estimate the rebate liability in calculating the appropriate accrual amount the company considers historical medicaid managed care and medicare rebate payment by product percentage of their historical sale well any significant change in sale trend the lag in payment timing an evaluation of the current medicaid and medicare law and interpretation the percentage of product that are sold via medicaid managed care and medicare and product pricing for medicaid there is significant complexity associated with calculating the legislated medicaid rebate management utilizes employee with legislative experience and knowledge in developing assumption used to calculate medicaid rebate similarly for managed care and medicare given variability in prescription drug cost continued historical year over year increase in enrollee and variability in prescription data historical rebate information may not be predictive for management to estimate the rebate accrual and thus management supplement it historical data analysis with qualitative adjustment based upon current utilization how we addressed the matter in our auditwe tested the company control addressing the identified risk of material misstatement related to the valuation of the sale rebate and discount liability this included testing control over management review of the significant assumption used to calculate the medicaid managed care and medicare rebate liability including the significant assumption discussed above this testing also included management control to compare actual activity to forecasted activity and control to ensure the data used to evaluate the significant assumption wa complete and accurate our audit procedure included among others evaluating for reasonableness the significant assumption in light of economic trend product profile and other regulatory factor our testing involved assessing the historical accuracy of management estimate by comparing actual activity to previous estimate and performing analytical procedure based on internal and external data source to evaluate the completeness of the reserve additionally our procedure included reviewing sample of contract testing sample of rebate payment and testing the underlying data used in management evaluation for medicaid we involved our professional with an understanding of the statutory reimbursement requirement to ass the consistency of the company calculation methodology with the applicable government regulation and policy for medicare we evaluated the reasonableness of assumption made by management in estimating the medicare coverage gap liability benefit valuation of alternative investmentsdescription of the matteras described in note to the consolidated financial statement under the caption benefit plan investment the company benefit plan investment policy are set with specific consideration of return and risk requirement in relationship to the respective liability at december the company had million in plan asset related to the defined benefit pension plan and retiree health benefit plan approximately percent of the total pension and retiree health asset are in hedge fund and private equity like investment fund alternative investment these alternative investment are valued using significant unobservable input or are valued at net asset value nav reported by the counterparty adjusted necessary auditing the fair value of these alternative investment is challenging because of the higher estimation uncertainty of the input to the fair value calculation including the underlying net asset value navs discounted cash flow valuation comparable market valuation and adjustment for currency credit liquidity and other risk additionally certain information regarding the fair value of these alternative investment is based on unaudited information available to management at the time of valuation how we addressed the matter in our auditwe tested the company control addressing the risk of material misstatement relating to valuation of alternative investment this included testing management review control over alternative investment valuation which included comparison of return to benchmark and monitoring of investment firm valuation policy and procedure well portfolio performance our audit procedure included among others comparing fund return to selected relevant benchmark and understanding variation obtaining the latest audited financial statement and comparing to the company estimated fair value we also inquired of management about change to the investment portfolio and or related investment strategy and consideration we assessed the historical accuracy of management estimate by comparing actual activity to previous estimate we evaluated for contrary evidence by confirming the fair value of the investment and ownership interest directly with the trustee and sample of manager at year end ernst young llpwe have served the company auditor since indianapolis indianafebruary of independent registered public accounting firmto the board of director and shareholder of eli lilly and companyopinion on internal control over financial reportingwe have audited eli lilly and company and subsidiary internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion eli lilly and company and subsidiary the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of operation comprehensive income loss shareholder equity and cash flow for each of the three year in the period ended december and the related note and our report dated february expressed an unqualified opinion thereon basis for opinionthe company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate ernst young llpindianapolis indianafebruary change in and disagreement with accountant on accounting and financial disclosurenone item control and proceduresevaluation of disclosure control and proceduresunder applicable security and exchange commission sec regulation management of reporting company with the participation of the principal executive officer and principal financial officer must periodically evaluate the company disclosure control and procedure which are defined generally control and other procedure designed to ensure that information required to be disclosed by the reporting company in it periodic report filed with the sec such this form is recorded processed summarized and reported on timely basis our management with the participation of david rick president and chief executive officer and anat ashkenazi executive vice president and chief financial officer evaluated our disclosure control and procedure such term is defined in rule and under the security exchange act of of december and concluded that they were effective management report on internal control over financial reportingmr rick and ashkenazi provided report on behalf of management on our internal control over financial reporting in which management concluded that the company internal control over financial reporting is effective at december based on the framework in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle in the united state due to the inherent limitation no evaluation over internal control can provide absolute assurance that no material misstatement or fraud exist in addition ernst young llp the company independent registered public accounting firm issued an attestation report on the company internal control over financial reporting of december can find the full text of management report and ernst young attestation report in item change in internal control over financial reportingduring the fourth quarter of there were no change in our internal control over financial reporting that materially affected or are reasonably likely to materially affect our internal control over financial reporting item other informationnone item disclosure regarding foreign jurisdiction that prevent inspectionsnot applicable iiiitem director executive officer and corporate governancedirectors and executive officersinformation relating to our board of director is found in our definitive proxy statement to be dated on or about march proxy statement under governance how we build an effective board and is incorporated in this annual report on form by reference information relating to our executive officer is found at item business executive officer of the company and is incorporated by reference herein code of ethicsinformation relating to our code of ethic is found in our proxy statement under governance how we operate an effective board governance practice board oversight key area of oversight by the board and it committee governance code of ethic and is incorporated in this annual report on form by reference corporate governanceinformation about the procedure by which shareholder can recommend nominee to our board of director is found in our proxy statement under governance how we build an effective board director nomination shareholder director candidate and is incorporated in this annual report on form by reference the board of director ha appointed an audit committee consisting entirely of independent director in accordance with applicable security and exchange commission and new york stock exchange requirement for audit committee information about our audit committee is found in our proxy statement under governance how we operate an effective board board structure meeting of the board and it committee committee of the board audit committee and is incorporated in this annual report on form by reference section reporting complianceinformation about our compliance with section is found in our proxy statement under ownership of common stock delinquent section report and is incorporated in this annual report on form by reference item executive compensationinformation on director compensation executive compensation and talent and compensation committee matter can be found in the proxy statement under governance how we operate an effective board board alignment director compensation how we operate an effective board board structure meeting of the board and it committee committee of the board talent and compensation committee compensation compensation discussion and analysis talent and compensation committee matter and executive compensation such information is incorporated in this annual report on form by reference security ownership of certain beneficial owner and management and related stockholder matterssecurity ownership of certain beneficial owner and managementinformation relating to ownership of the company common stock by management and by person known by the company to be the beneficial owner of more than five percent of the outstanding share of common stock is found in the proxy statement under ownership of company stock and incorporated in this annual report on form by reference security authorized for issuance under equity compensation plansthe following table present information of december regarding the company compensation plan under which share of the company common stock have been authorized for issuance plan category number of security to be issued upon exercise of outstanding option warrant and right weighted average exercise price of outstanding option warrant and right number of security remaining available for future issuance under equity compensation plan excluding security reflected in column equity compensation plan approved by security holder equity compensation plan not approved by security holder total share are underlying outstanding equity award other than option item certain relationship and related transaction and director independencerelated person transactionsinformation relating to the policy and procedure for approval of related person transaction by our board of director can be found in the proxy statement under governance how we operate an effective board board alignment conflict of interest and transaction with related person such information is incorporated in this annual report on form by reference director independenceinformation relating to director independence can be found in the proxy statement under governance how we build an effective board director qualification independence and is incorporated in this annual report on form by reference item principal accountant fee and servicesinformation related to the fee and service of our principal independent accountant ernst young llp can be found in the proxy statement under audit matter item ratification of the appointment of the independent auditor service performed by the independent auditor and independent auditor fee such information is incorporated in this annual report on form by reference exhibit and financial statement schedule financial statementsthe following consolidated financial statement of the company and it subsidiary are found at item consolidated statement of operation year ended december and consolidated statement of comprehensive income loss year ended december and consolidated balance sheet december and consolidated statement of shareholder equity year ended december and consolidated statement of cash flow year ended december and note to consolidated financial statement financial statement schedulesthe consolidated financial statement schedule of the company and it subsidiary have been omitted because they are not required are inapplicable or are adequately explained in the financial statement financial statement of interest of percent or le which are accounted for by the equity method have been omitted because they do not considered in the aggregate single subsidiary constitute significant subsidiary exhibitsthe following document are filed part of this report article of incorporation incorporated by reference to exhibit to the company current report on form filed on may amended incorporated by reference to exhibit to the company current report on form filed on may dated february between the company and deutsche bank trust company america successor trustee to citibank trustee incorporated by reference to exhibit to the company registration statement on form registration no agreement dated september appointing deutsche bank trust company america successor trustee under the indenture listed in exhibit incorporated by reference to exhibit to the company annual report on form for the year ended december of the company common stock incorporated by reference to exhibit to the company annual report on form for the year ended december of the company note due and note due incorporated by reference to exhibit to the company annual report on form for the year ended december of the company note due incorporated by reference to exhibit to the company annual report on form for the year ended december of the company note due incorporated by reference to exhibit to the company annual report on form for the year ended december of the company note due and note due incorporated by reference to exhibit to the company annual report on form for the year ended december of the company note due note due and note due incorporated by reference to exhibit to the company annual report on form for the year ended december of the company note due incorporated by reference to exhibit to the company annual report on form for the year ended december and restated lilly stock plan incorporated by reference to exhibit to the company quarterly report on form for the quarter ended june of performance award under the lilly stock plan of shareholder value award under the lilly stock plan of relative value award under the lilly stock plan of non compete payment agreement lilly deferred compensation plan amended incorporated by reference to exhibit to the company annual report on form for the year ended december lilly director deferral plan amended incorporated by reference to exhibit to the company quarterly report on form for the quarter ended june eli lilly and company bonus plan amended incorporated by reference to exhibit to the company annual report on form for the year ended december loxo oncology inc bonus plan incorporated by reference to exhibit to the company annual report on form for the year ended december change in control severance pay plan for select employee amended incorporated by reference to exhibit to the company annual report on form for the year ended december of subsidiary of independent registered public accounting firm certification of david rick chair president and chief executive officer certification of anat ashkenazi executive vice president and chief financial officer certification data file page interactive data file formatted in inline xbrl and contained in exhibit indicates management contract or compensatory plan filed herewith item form summarynot applicable to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized eli lilly and companyby david ricksdavid rickschair president and chief executive officerfebruary to the requirement of the security exchange act of this report ha been signed below on february by the following person on behalf of the registrant and in the capacity indicated signaturetitle david rickschair president and chief executive officer principal executive officer david rick anat ashkenaziexecutive vice president and chief financial officer principal financial officer anat ashkenazi donald zakrowskisenior vice president finance and chief accounting officer principal accounting officer donald zakrowski ralph alvarezdirectorralph alvarez katherine baicker ph directorkatherine baicker ph erik fyrwalddirectorerik fyrwald mary lynne hedley ph directormary lynne hedley ph jamere jacksondirectorjamere jackson kimberly johnsondirectorkimberly johnson william kaelin jr directorwilliam kaelin jr juan lucianodirectorjuan luciano marschall runge ph directormarschall runge ph gabrielle sulzbergerdirectorgabrielle sulzberger jackson taidirectorjackson tai karen walkerdirectorkaren used in this reporttrademarks or service mark owned by eli lilly and company or it affiliate when first used in each item of this report appear with an initial capital and are followed by the symbol or applicable in subsequent us of the mark in the item the symbol may be omitted byetta is trademark of amylin pharmaceutical inc glyxambi jardiance jentadueto synjardy trajenta and trijardy are trademark of boehringer ingelheim international gmbh tyvyt is trademark of innovent biologics suzhou co ltd